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Abstract  
Mutations in FGFR2 are common in a subset of endometrial carcinomas. Given the 
emergence of small molecule inhibitors specific to this receptor tyrosine kinase, 
FGFR2 is an attractive therapeutic target. However, compensatory and adaptation 
mechanisms limit the clinical utility of compounds that target nodes in the receptor 
tyrosine kinase network. Here, we analysed the impact of FGFR inhibition in 
endometrial cancer cells and observed the emergence of a resistant population in an 
FGFR2-mutant cell line. To understand the mechanisms underlying this adaptation 
response, we used a phosphoproteomics approach to measure the kinase network 
in an unbiased manner. These experiments led to the identification of an AKT-related 
compensatory mechanism underpinning this resistance. Further dissection of this 
resistance mechanism utilising gene expression analysis showed PHLDA1, a 
negative regulator of AKT, was significantly down-regulated in resistant cells. This 
was further confirmed at the protein level. siRNA knockdown of PHLDA1 conferred 
immediate drug resistance in the FGFR2-mutant endometrial cancer cell line. 
Therefore, we identified PHLDA1 down-regulation as a mediator of drug resistance 
in FGFR2 mutant cancer cells, the first demonstration of the role of PHLDA1 in the 
acquisition and maintenance of drug resistance. Using a 3D physiomimetic model, 
we demonstrated that AKT inhibition alone also led to generation of a drug-resistant 
population. Most importantly, dual-drug therapy inhibited proliferation and induced 
cell death. Our data highlight how mass spectrometry and microarray gene 
expression analysis can complement each other in the identification of novel 
resistance mechanisms in cancer cells. These data suggest that combination 
treatment of FGFR2-mutant endometrial cancers, targeting both FGFR2 and AKT, 
represents a promising therapeutic approach.  
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1.1 Endometrial cancer  
Endometrial cancer is the most common gynaecological malignancy in the 
developed world and the fourth most common cancer in women (Byron et al., 2008, 
Jemal et al., 2011, Pollock et al., 2007). In 2011, approximately 8500 women were 
diagnosed with endometrial cancer in the UK alone (CRUK, 2014). Patients 
commonly present at an early stage where the tumour is confined to the 
endometrium, the lining of the uterus, with little or no migration into the surrounding 
tissue (Amant et al., 2005) (Figure 1.1 A). In this early stage disease, surgical 
treatment with full hysterectomy is most common and usually curative, with greater 
than 85% of patients surviving for over five years (Amant et al., 2005). However, 
such surgery is associated with the effects of long term oestrogen deprivation, for 
example increased risk of cardiovascular disease (Atsma et al., 2006), as well as the 
additional impact of a loss of fertility in the 14-30% of patients who are pre-
menopausal upon diagnosis (Lau et al., 2014, Wright et al., 2009). In light of this, 
alternative treatments are desirable.  
 
Endometrial cancer is split predominantly into two types, endometrioid and non-
endometrioid, with further subdivision of the latter into serous and clear-cell 
carcinomas. Although only around 20% of all endometrial cancers are non-
endometrioid, these tumours are higher grade by definition (Amant et al., 2005). 
Endometrioid endometrial cancer accounts for the remaining 80% of tumours of the 
uterus. These lesions are generally oestrogen-related and usually associated with 
endometrial hyperplasia, resulting in excessive proliferation of the endometrium 
(Amant et al., 2005). Endometrioid and non-endometrioid cancers present with 
distinct genetic alterations, however, a minority of cases present with mixed features 
(Yeramian et al., 2013).  
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Figure 1.1. Structure of the uterus and localisation of endometrial tumours at surgical 
stages I-IV of the disease.   
(A) Stage Ia endometrial tumours are confined to the endometrium while stage Ib tumours 
commonly penetrate halfway into the muscle wall. (B) Higher grade stage II tumours grow 
into the cervix. (C) Stage III cancer is characterised by spread of the tumour to other parts of 
the pelvis and can be subdivided into tumours spreading to the ovaries (IIIa), into the vagina 
(IIIb) and those which have spread to the lymph nodes (IIIc). (D) The highest grade tumours 
are those which have metastasised to the bladder or bowel (IVa) or to distant organs (IVb). 
The surgical stage of tumours reflects the five year survival rate of approximately 85% for 
stage I, 75% for stage II, 45% for stage III and 25% for stage IV (Amant et al., 2005).  
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Patients presenting with advanced stage and higher grade endometrial cancer 
commonly relapse despite surgery, adjuvant radiotherapy and chemotherapy 
(Chaudhry and Asselin, 2009). Overall patient survival has not improved significantly 
and so endometrial cancer remains among the top ten leading causes of female 
cancer related deaths (Chaudhry and Asselin, 2009). In order to address this, a 
greater understanding of the molecular mechanisms underlying the disease is 
required.  
 
A range of genetic abnormalities are found in endometrial cancer. Microsatellite 
instability is seen in 25-30% of cases (Catasus et al., 1998, Duggan et al., 1994), 
while phosphatase and tensin homologue (PTEN) alterations have been detected in 
37-61% of endometrial cancers, leading to the deregulation of the phosphoinositide 
3-kinase (PI3K) pathway (Yeramian et al., 2013). Other common mutations include 
those in genes encoding phosphoinositide 3-kinase catalytic subunit alpha (PIK3CA) 
and Kirsten-rat sarcoma viral oncogene homologue (K-RAS) (Byron et al., 2008, 
Yeramian et al., 2013).  
 
Mutations in the receptor tyrosine kinase fibroblast growth factor receptor 2 (FGFR2) 
occur in up to 16% of endometrial cancers (Byron et al., 2008, Byron et al., 2012, 
Fearon et al., 2013). Interestingly, many of these somatic oncogenic mutations are 
the same as germline mutations found in developmental disorders, for example 
craniosynostosis dysplasias (Pollock et al., 2007) (Figure 1.2). Such FGFR2 
mutations also give mutant clones of spermatogonia a selective advantage in the 
testes (Wilkie, 2005), suggesting that they are capable of conferring a growth 
advantage at the cellular level and are thus likely driver mutations in endometrial 
cancer (Dutt et al., 2008, Jemal et al., 2011). Thus, this pathway is an attractive 
therapeutic target and so a greater understanding of the role of FGFR2 signalling in 
endometrial cancer is of paramount importance.   
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Figure 1.2. Somatic FGFR2 mutations in endometrial cancer are the same as germline 
mutations found in a range of developmental disorders.  
Schematic representation of FGFR2. In the lower panel, mutations in various regions of the 
receptor (red lines) in both developmental disorders and endometrial cancer are shown 
(boxes). The diseases represented by each colour are detailed in the key. The number of 
FGFR2 mutations found in each region in the various disorders is noted in the corresponding 
box. Mutations were collated from the literature (Freitas et al., 2006, Lajeunie et al., 2006, 
Passos-Bueno et al., 1998) and the catalogue of somatic mutations in cancer (COSMIC). 
Data correct as of September 2014. N, N terminus; C, C terminus. 
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1.2 Fibroblast growth factor (FGF) and FGFR signalling  
1.2.1 FGFs and FGFRs  
FGFs are responsible for a plethora of cellular functions, from embryogenesis to 
metabolism (Bottcher and Niehrs, 2005, Dubrulle and Pourquie, 2004, Feldman et 
al., 1995, Ghabrial et al., 2003, Huang and Stern, 2005, Polanska et al., 2009, Sun 
et al., 1999). FGFs exert their cellular effects by interacting with FGFRs in a complex 
with heparan sulphate (HS) (Yayon et al., 1991). Upon ligand binding, FGFRs 
dimerise and undergo transphosphorylation of their split kinase domain (Coughlin et 
al., 1988) (Figure 1.3 A), leading to the recruitment of adaptor proteins and initiation 
of downstream signalling (Figure 1.3 B). This results in a range of cellular outcomes, 
including proliferation, migration, differentiation and survival (Belov and Mohammadi, 
2013, Carter et al., 2014).  
 
The extended FGF family is composed of 22 members, varying in size from 17-34 
kDa. All members share a conserved 120 amino acid sequence and show 16-65% 
sequence homology (Ornitz and Itoh, 2001). However, only 18 FGFs signal via 
FGFR interactions (FGF1-10 and FGF16-23), while FGF11-14, which lack a signal 
peptide, act in an intracellular manner and do not bind FGFRs (Smallwood et al., 
1996). Thus, many consider the FGF family to comprise only 18 members. 
Furthermore, although they are numbered from 1-23, Fgf15 is the mouse orthologue 
of human FGF19. The 18 true FGFs cluster into six subfamilies; one endocrine 
subfamily, that acts globally in metabolic processes such as glucose metabolism, 
and five paracrine subfamilies acting locally to initiate processes such as 
organogenesis (Belov and Mohammadi, 2013). Each ligand binds to FGFRs with 
varying specificity; some are promiscuous, for example FGF1, and bind to multiple 
receptors, while others, such as FGF7, bind to only one receptor isoform (Ornitz et 
al., 1996).    
 
There are seven signalling receptors, encoded by four FGFR genes, FGFR1-4 
(Johnson and Williams, 1993). Each of the receptors consists of an intracellular split 
tyrosine kinase domain, a transmembrane region and an extracellular domain 
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containing three Immunoglobulin (Ig) loops (IgI-III) (Figure 1.3 A). FGFR1-3 have 
highly conserved intron/exon boundaries (Ornitz et al., 1996). Alternative splicing of 
exons 8 and 9, encoding IgIII of FGFR1-3, results in translation of two distinct 
isoforms capable of signal transduction (Johnson et al., 1991). These isoforms are 
termed IIIb and IIIc, depending on which exons are spliced out.  This third Ig loop 
encodes the ligand binding domain; alternative splicing of this region is responsible 
for ligand binding specificity. A third isoform exists for FGFR1 and 2, termed IIIa. 
This variant results in a truncated, secreted protein, which is unable to transduce a 
signal and may have an auto-inhibitory role in FGF signalling, possibly by 
sequestering ligands (Wheldon et al., 2011). FGFR4 is distinct in that it has only one 
isoform, homologous to the IIIc variant of FGFR1-3 (Vainikka et al., 1992). Receptor 
expression is generally cell type specific, for example IIIb and IIIc isoforms of FGFR1 
and 2 are expressed in epithelial and mesenchymal cells, respectively (Orr-Urtreger 
et al., 1993, Yan et al., 1993). However, this cell type specificity is subject to change 
when FGFRs are associated with diseases such as cancer (Shirakihara et al., 2011, 
Yan et al., 1993).  
 
A fifth member of the FGFR family, fibroblast growth factor receptor like 1 (FGFRL1), 
has also been identified. This protein, which exists as a homodimer consisting of the 
three characteristic extracellular Ig domains, acid box between IgI and IgII and a 
transmembrane helix, differs from the classic receptors in that it has no intracellular 
tyrosine kinase domain (Sleeman et al., 2001, Trueb et al., 2003, Wiedemann and 
Trueb, 2000). Instead, the intracellular portion of FGFRL1 consists of only 100 
residues including a histidine-rich sequence and a tandem tyrosine-based motif 
(Rieckmann et al., 2009, Sleeman et al., 2001, Zhuang et al., 2009). These two 
sequences function as signals for FGFRL1 trafficking from the plasma membrane to 
endosomes and lysosomes. Deletion of these sequences result in inefficient 
FGFRL1 internalisation and prolonged localisation at the plasma membrane 
(Rieckmann et al., 2009).  
 
As FGFRL1 does not contain a tyrosine kinase domain, it is not able to signal in the 
classical FGFR fashion. Its function is yet to be fully determined but a number of 
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theories have been postulated. Firstly, the receptor could have an inhibitory effect on 
FGF signalling, by sequestering ligands and therefore preventing them from binding 
to FGFR1-4 (Sleeman et al., 2001, Steinberg et al., 2010, Trueb et al., 2003). 
However, recent work has suggested FGFRL1 does indeed have some form of 
signalling potential (Silva et al., 2013). Although not itself a receptor tyrosine kinase, 
it is clear that FGFRL1 can play an important role in FGF/FGFR signalling.  
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Figure 1.3. FGFR signalling.  
(A) Schematic representation of FGFR2 depicting the three extracellular Ig loops, the third of 
which is responsible for ligand binding. Alternative splicing of this loop leads to varying 
affinity for different FGF ligands (Ornitz et al., 1996). The acid box (green) between the first 
and second Ig loops is involved in HS binding (Kalinina et al., 2012). The transmembrane 
domain is shown in orange. The intracellular portion of the receptor consists of a split kinase 
domain (blue). Upon ligand binding, dimerisation and subsequent transphosphorylation of 
the receptor occurs on seven tyrosine residues (red spheres) (Furdui et al., 2006, 
Mohammadi et al., 1996). (B) Receptor transphosphorylation induces four key downstream 
pathways: ERK, PI3K/AKT, PLCγ and JAK/STAT. These pathways comprise a series of 
phosphorylation events, culminating in regulation of target genes, which dictate cellular 
processes, for example proliferation and migration (Carter et al., 2014). Figure adapted from 
Carter et al., 2014.  
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1.2.2 FGFR activation   
Heparin, used in vitro as the model HS, is a member of the HS family of 
proteoglycans (HSPGs) and has been used to establish the necessity of HS binding 
in FGFR activation (Lindahl and Hook, 1978). This acidic molecule resembles the 
highly sulfated saccharide chains of HS (Gambarini et al., 1993). The heparin-
binding residues found in the IgII loop and acid box of FGFRs are highly conserved, 
while heparin-binding residues of FGFs are diverse (Kalinina et al., 2012, 
Schlessinger et al., 2000). Because of this, different FGFs require various HS 
sulfation patterns and/or length of chains for their optimum activity. Variability of HS 
sulfation patterns and length across cell types has an effect on FGF-FGFR 
interactions and may be a mediator of the biological activity of FGFRs (Gambarini et 
al., 1993, Guimond and Turnbull, 1999, Ornitz et al., 1992, Ornitz et al., 1995).  
 
The widely accepted model of FGFR activation is of FGF:FGFR:HS complex 
formation in a 2:2:2 ratio (Schlessinger et al., 2000) (Figure 1.4). Two independent 
FGF:FGFR:HS ternary complexes are formed in a 1:1:1 ratio, via HS binding to both 
receptor and ligand. These two complexes bind via receptor interactions, as well as 
interactions between the ligand in one complex and the receptor in another, thus 
forming a stable, symmetrical dimer. Direct ligand-ligand interactions are not 
observed.  
 
However, it has recently been shown that FGFR2 can exist in a dimerised state prior 
to ligand binding, primed to activate downstream signalling upon receiving its 
extracellular ligand (Lin et al., 2012, Ahmed et al., 2013). Growth factor receptor-
bound protein 2 (Grb2), an adapter protein consisting of a Src homology-2 (SH2) and 
two Src homology-3 (SH3) domains, is well known to facilitate activation of 
extracellular signal regulated kinase (ERK – also known as mitogen activated protein 
kinase, MAPK) and PI3K signalling, downstream of receptor-ligand binding (Gotoh, 
2008, Eswarakumar et al., 2005). This protein was found to have a novel function in 
stabilisation of an inactive FGFR2 dimer (Lin et al., 2012). Dimeric Grb2 binds, via an 
SH3 domain, to the C-terminal tail of unstimulated FGFR2 molecules to form a 
34 
 
tetrameric 2:2 complex, in which Grb2 functions to prevent the recruitment of 
downstream signalling proteins. Ligand binding results in Grb2 phosphorylation and 
its subsequent dissociation from the FGFR2 cytoplasmic tail, enabling the activation 
of canonical signalling (Lin et al., 2012). While the 2:2:2 FGF:FGFR:HS model is 
acknowledged as the canonical method of FGFR activation, this work provides 
evidence of alternative mechanisms of FGFR2 stabilisation, and control of activation, 
in basal cellular conditions.  
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Figure 1.4. Canonical FGFR activation.  
The classical model of FGFR activation proposes a symmetrical dimer utilising two HS 
chains, which bind both ligands and receptor monomers, bringing them into close proximity 
and facilitating receptor dimerization (Schlessinger et al., 2000). The binding of the HS 
chains to both ligands and receptors forms a complete, active molecule capable of 
autophosphorylation and subsequent phosphorylation of downstream signalling molecules.  
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1.2.3 FGFR signalling pathways   
Upon FGFR dimerisation and reciprocal phosphorylation of the tyrosine kinase 
domains, the phosphorylated receptors act as docking sites for intracellular proteins, 
leading to activation of signalling cascades (Furdui et al., 2006, Mohammadi et al., 
1992, Mohammadi et al., 1996)  (Figure 1.3 B). This autophosphorylation occurs in a 
specific order; ‘first-phase’ phosphorylation increases the catalytic activity of the 
kinase after ligand binding, while ‘second-phase’ phosphorylation creates 
phosphotyrosine-binding sites for docking molecules containing SH2 and 
phosphotyrosine-binding (PTB) domains (Furdui et al., 2006). From this, four 
signalling pathways can be activated: PI3K, ERK, phospholipase C γ (PLCγ) and 
janus kinase/signal transducer and activator of transcription (JAK/STAT) (Furdui et 
al., 2006). The key difference between FGFRs in signalling is the strength of their 
tyrosine kinase activity; their target proteins are the same (Raffioni et al., 1999). 
However, as will be discussed later, recent work on FGFR2 has highlighted how 
differential ligand binding can result in activation of specific downstream pathways 
and subsequently lead to initiation of distinct cellular processes (Francavilla et al., 
2013).  
 
Lipid-anchored fibroblast growth factor receptor substrate 2 (FRS2) plays an integral 
role in the PI3K and ERK pathways, while PLCγ and JAK/STAT pathways are 
mediated through mechanisms independent of this adapter protein. FRS2 binds to 
the receptor via its PTB domain and undergoes phosphorylation (Dhalluin et al., 
2000, Kouhara et al., 1997, Ong et al., 2000). Grb2 is then recruited to FRS2, from 
which the PI3K and ERK pathways can be activated.  
 
PI3K  
Phosphoinositide lipids are a key component of the plasma membrane (Balla, 2013); 
their phosphorylation status is important in cellular signalling and is therefore tightly 
regulated by kinases and phosphatases. PI3K is one such important regulator of lipid 
phosphorylation status, particularly in response to FGFR activation.  
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PI3K can be divided into three families, class I, II and III, based on their structure and 
substrate specificities. The best understood of these is class I, known to be activated 
downstream of receptor phosphorylation (Vanhaesebroeck et al., 2010).  
 
Class I 
The class I PI3Ks can be further subdivided into class IA and IB. Class IA PI3Ks 
exists as a heterodimer formed of a regulatory subunit coupled to a catalytic subunit. 
The three potential catalytic subunits, p110α (PI3KCA), p110β (PIK3CB) and p110δ 
(PIK3CD) can be associated with any of the following five regulatory subunit 
isoforms: p85α and its splice variants p55α and p50α (PIK3R1), p85β (PIK3R2) and 
p55γ (PIK3R3). The class IB PI3Ks are unique in that the p110γ (PIK3CG) subunit 
can bind one of two regulatory subunits, p101 and p87 (Thorpe et al., 2014). Thus, 
four distinct PI3K class I isoforms exist: PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ. Upon 
FGFR activation, the PI3Kα, β or δ isoforms are activated, as is common in response 
to receptor tyrosine kinase signalling (Ong et al., 2001).  
 
Upon receptor activation, Grb2/FRS2 binds to GAB1 via the SH3 domain of Grb2 
(Gotoh, 2008), whereupon GAB1 is phosphorylated by FGFR2. This 
FRS2/Grb2/GAB1 complex recruits PI3K to the receptor via its regulatory subunit, 
causing a conformational change in the catalytic subunit, rendering it catalytically 
active. PI3K is then able to convert its lipid substrate, phosphatidylinositol (4, 5) 
bisphosphate (PIP2), to  phosphatidylinositol (3, 4, 5) trisphosphate (PIP3).  
 
PIP3 generation leads to recruitment of downstream signalling molecules containing 
a PH domain, for example the serine-threonine kinases protein kinase B (AKT) and 
phosphoinositide-dependent kinase 1 (PDK1). Once engaged at the membrane, AKT 
is phosphorylated, and therefore activated, by PDK1 on the threonine 308 (thr308) 
residue (Alessi et al., 1997, Franke et al., 1995). This in turn affects a number of 
signalling proteins, including tuberous sclerosis complex (TSC), whereupon  
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mammalian target of rapamycin (mTOR) is activated (Inoki et al., 2002, Potter et al., 
2002).  
 
mTOR, a protein complex that functions as a serine/threonine kinase, exists in two 
forms; mTOR complex 1 (mTORC1) and mTORC2. AKT can be further 
phosphorylated at the serine 473 (ser473) residue by mTORC2, resulting in its 
complete activation (Facchinetti et al., 2008, Sarbassov et al., 2005). Indeed, this full 
activation exhibits a fivefold increase in activity over the thr308 phosphorylated 
protein alone (Sarbassov et al., 2005). AKT is then able to promote cell survival 
through regulation of its anti-apoptotic targets, such as B-cell lymphoma 2 (BCL2). 
Cell survival is further promoted by mTORC1 via activation of ribosomal S6 kinase 
(S6K). This protein releases eukaryotic translation initiation factor 4E binding protein 
1 (EIF4EBP1) transcriptional repression and allows for translation of prosurvival 
factors (Wang et al., 2006).  
 
The differential role of PI3K signalling outcomes following FGFR2 activation, in 
response to distinct ligands, has recently been elucidated (Francavilla et al., 2013). 
Interaction between PI3K and phosphorylated residue tyrosine 734 (tyr734) of 
FGFR2IIIb following FGF10 stimulation results in increased cell migration. Here, the 
PI3K p85 subunit binds phospho-tyr734 and recruits the adaptor protein SH3 binding 
protein 4 (SH3BP4), leading to receptor recycling via endosomes. In contrast, FGF7 
stimulation does not result in PI3K/SH3BP4 complex formation, and instead induces 
a more transient stimulation and rapid degradation, resulting in increased 
proliferation rather than migration. This study serves as evidence of the complex role 
of PI3K signalling downstream of FGFR2 and the importance of ligand-receptor 
interactions in dictating cell fate.  
 
Class II and III  
The functional importance of class II and III PI3K subfamilies remains unclear. Two 
of the three class II isoforms, PI3KC2α and β, are widely distributed throughout 
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mammalian tissue; less is known about the third γ isoform. Interestingly, this 
subfamily harbors a catalytic subunit only. The solitary class III PI3K, vacuolar 
protein sorting 34 (Vps34), also known as PIK3C3 in mammals, forms complexes 
with a variety of proteins. Vps34, with intrinsic catalytic activity, binds vacuolar 
protein sorting 15 (Vps15) to form an intracellular membrane bound heterodimer. Its 
function then depends on the multi-protein complex formed, where interaction with 
specific proteins leads to a defined cellular outcome, including autophagy or 
endosomal trafficking (Vanhaesebroeck et al., 2010).  
 
ERK  
In mammals, 14 MAPKs have been described and can be subdivided into 
conventional and unconventional MAPKs (Cargnello and Roux, 2011). Typical 
MAPKs, for example ERK1/2 and p38, are activated via a three-tiered kinase 
cascade culminating in the phosphorylation of the MAPK protein on a threonine and 
tyrosine residue. Whilst unconventional MAPKs are activated via other means, all 
activated MAPKs are proline-directed kinases (Coulombe and Meloche, 2007).  
 
The most extensively studied group of MAPKs are ERK1/2, which are principally 
activated by receptor tyrosine kinases (Cargnello and Roux, 2011) and promote cell 
proliferation and survival (Eswarakumar et al., 2005).  ERK1/2 share 83% amino acid 
homology and are expressed in a wide range of tissues (Bogoyevitch et al., 1994, 
English and Sweatt, 1997). FRS2 is constitutively bound to the juxtamembrane 
region of the FGFR and, upon receptor activation, Grb2 is recruited to the 
FGFR/FRS2 complex (Dhalluin et al., 2000, Kouhara et al., 1997, Ong et al., 2000). 
Son of sevenless (SOS) is subsequently recruited from the cytosol to the plasma 
membrane via interaction with Grb2 (Olivier et al., 1993), whereupon rat sarcoma 
(RAS), a membrane-tethered GTPase, is activated by SOS catalysed dissociation of 
GDP from RAS, which allows GTP binding in its place, rendering RAS active. GTP-
bound RAS is then able to directly interact with its target proteins, including the 
MAPK kinase kinase rapidly accelerated fibrosarcoma (RAF). RAF is recruited to the 
plasma membrane via RAS-GTP, whereupon RAF is phosphorylated and thereby 
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activated. Activated RAF subsequently phosphorylates and activates MAPK or ERK 
kinase (MEK), a dual-specificity kinase. MEK then phosphorylates and activates 
ERK1/2, the final kinase in the core three-tiered cascade. This phosphorylation 
occurs within a conserved threonine-glutamic acid-tyrosine (TEY) motif located in the 
activation loop of ERK1/2 (Marshall, 1995). Phosphorylated ERK is then able to 
activate transcription factors in the nucleus, for example cellular homologue of v-
MYC (c-MYC), and regulate G1-to-S phase cell cycle progression (Chen et al., 1992, 
Lenormand et al., 1993).  
 
PLCγ  
Autophosphorylation of the tyrosine 769 (tyr769) residue in FGFR2 creates a specific 
binding site for the SH2 domain of PLCγ, leading to its tyrosine phosphorylation and 
subsequent catalytic activation (Mohammadi et al., 1991). PLCγ is recruited to the 
membrane by PIP3 and PIP2, where catalytically active PLCγ is able to hydrolyse 
PIP2 into inositol 1, 4, 5 trisphosphate (IP3) and diacylglycerol (DAG) (Carpenter and 
Ji, 1999, Klint and Claesson-Welsh, 1999). IP3 can then release calcium stored in the 
endoplasmic reticulum (ER), which, along with DAG, activate protein kinase C (PKC) 
(Rameh et al., 1998). PKC is then able to relieve inhibition of RAF and activate the 
ERK pathway (Corbit et al., 2003).  
 
As discussed in section 1.2.2, FGFR2 can exist in a dimerised form, primed for 
receptor activation, in the absence of ligand (Lin et al., 2012). In this scenario, Grb2 
binding to the C-terminus of FGFR2 allows low level phosphorylation of the receptor 
but inhibits downstream signalling until ligand is bound and full tyrosine kinase 
phosphorylation of the intracellular portion of the receptor occurs (Lin et al., 2012). 
However, recent investigations have indicated a novel signalling mechanism 
downstream of this pre-dimerised FGFR2 complex, in the absence of ligand binding 
(Timsah et al., 2014). Although recruitment of PLCγ to the membrane is usually 
associated with ligand-dependent receptor activation, Timsah et al., have shown that 
PLCγ1 can also bind to the C terminus of FGFR2 in an SH3-dependent manner, to 
initiate signalling in the absence of FGF ligand. This occurs when the cellular 
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concentrations of PLCγ1 exceeds that of Grb2, thus potentially explaining why 
tumour cells expressing low levels of Grb2 often exhibit enhanced PLCγ1 activity 
and metastatic behaviour (Fearon and Grose, 2014). While ligand-receptor binding is 
acknowledged as the canonical signalling mechanism, this work illustrates the 
presence of alternative mechanisms of FGFR signalling in basal cellular conditions.  
 
JAK/STAT  
The STAT family of cytoplasmic transcription factors can be activated by non-
receptor tyrosine kinases, JAKs, leading to cell proliferation and differentiation 
(Ebong et al., 2004). Upon FGFR dimerisation and autophosphorylation, JAKs are 
phosphorylated by the receptor, forming a FGFR/JAK complex. This acts as a 
docking site for STATs, which are in turn tyrosine phosphorylated in their SH2 
domain (Darnell, 1997). STAT dimers form and translocate to the nucleus, where 
they bind to gamma-activated site (GAS) enhancers to activate or repress gene 
transcription (Darnell, 1997).  
 
1.2.4 Regulation of FGFR signalling    
Regulation of FGF signalling is critical to ensure a balanced response to receptor 
stimulation. This occurs largely through negative feedback mechanisms (Figure 1.5), 
including receptor internalisation, where recruitment of the casitas B-lineage 
lymphoma (CBL) protein to FRS2 leads to ubiquitination of both FGFR and FRS2 
and therefore attenuation of FGFR-mediated signalling (Wang et al., 2002), and 
induction of negative regulators, for example sprouty (SPRY) (Hacohen et al., 1998). 
SPRYs are thought to act through two possible mechanisms. Firstly, via interaction 
with Grb2, interrupting the FRS2/Grb2 complex and therefore decreasing signal 
transduction (Thisse and Thisse, 2005). Secondly, SPRY-RAF interactions can 
occur, preventing RAF phosphorylation and therefore inhibiting ERK signalling 
(Sasaki et al., 2003).  
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ERK signalling can also be inhibited by sprouty-related enabled/vasodilator-
stimulated phosphoprotein homology 1 domain-containing proteins (SPRED1 and 2) 
(Wakioka et al., 2001) . SPRED proteins prevent RAF activation of MEK by forming a 
complex between RAS and RAF. Co-localisation of SPRED2 with the protein 
neighbor of BRCA1 (NBR1) results in sequestration of FGFR and its lysosomal 
degradation (Mardakheh et al., 2009).  
 
 
Similar expression to FGF (SEF) proteins also negatively regulate FGF signalling via 
a number of mechanisms. These include targeted inhibition at, or downstream of, 
MEK (Yang et al., 2003) and inhibition of RAS activation, which also inhibits the PI3K 
pathway (Kovalenko et al., 2003). Direct interaction between SEF and the FGFR 
leads to inhibition of FGFR and FRS2 phosphorylation (Kovalenko et al., 2003, 
Tsang et al., 2002, Xiong et al., 2003), while SEF can also act as a spatial regulator 
of phospho-ERK migration to the nucleus and therefore attenuate ERK signalling 
(Torii et al., 2004).  
 
 
Another mechanism of negative regulation is via direct phosphorylation of ERK 
pathway proteins, for example, the RAS guanine nucleotide exchange factor SOS 
and RAF. Phosphorylation of SOS by ERK disrupts interactions between SOS and 
Grb2, in turn decreasing recruitment of SOS to the membrane and resulting in 
diminished RAS activation (Buday et al., 1995). ERK can also phosphorylate RAF, 
reducing RAF kinase activity and therefore decreasing MEK and ERK 
phosphorylation (Ueki et al., 1994). ERK can also negatively regulate the PI3K 
pathway via direct phosphorylation of GAB1, subsequently decreasing PI3K 
recruitment to GAB1 and in turn reducing AKT pathway activation (Gual et al., 2001). 
The PI3K pathway is also commonly modulated by PTEN, a phosphatase that 
converts PIP3 back to PIP2 (Makker et al., 2014).  
 
 
There is emerging evidence of the importance of the pleckstrin homology like domain 
A (PHLDA) family of proteins in negative regulation of the PI3K pathway (Kawase et 
al., 2009, Ohki et al., 2014). This family, of which there are three known members, 
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contain a PH domain, via which they may be able to bind to phosphoinositide lipids. 
While PHLDA2 seems to be important in embryonic development, PHLDA1 and 3 
are expressed in adult tissue (Frank et al., 1999).  
 
 
PHLDA3 is the most well characterised of the family, with clear evidence of its role 
as a negative regulator of AKT (Kawase et al., 2009). PHLDA3 competes with AKT 
for PIP3 binding and therefore induces apoptosis by inhibiting AKT phosphorylation; 
in this way, PHLDA3 acts as a tumour suppressor (Kawase et al., 2009, Ohki et al., 
2014).  
 
 
PHLDA1 is also known to interact with PIP3 and attenuate AKT signalling (Murata et 
al., 2014). Though the potential role of PHLDA1 in anti-apoptotic signalling has been 
described, the mechanism of this action remains unclear (Toyoshima et al., 2004, 
Neef et al., 2002, Hossain et al., 2003, Murata et al., 2014).  
 
PHLDA3 has also been shown to be a direct target of p53 (Kawase et al., 2009). 
Indeed, a p53-mediated negative feedback loop between AKT and PHLDA3 has 
been illustrated (Liao and Hung, 2010). Here, AKT is recruited to the membrane as a 
result of PI3K activation, as previously described. Following phosphorylation of one 
of its downstream targets, the ubiquitin ligase mouse double minute 2 homologue 
(MDM2), p53 is ubiquitinated and subsequently degraded. This in turn leads to 
decreased expression of PHLDA3 and PTEN and allows for unopposed AKT 
signalling. However, under cell stress, p53 expression is increased, leading to 
upregulation of PHLDA3 and subsequent initiation of apoptotic signalling (Liao and 
Hung, 2010).  
 
 
Alternative internal control mechanisms of FGF signalling exist, including 
autoinhibition of the receptor (Plotnikov et al., 1999, Schlessinger et al., 2000, 
Stauber et al., 2000). The FGFRs exist in ‘closed’ and ‘open’ conformation 
equilibrium (Kalinina et al., 2012). The IgI loop and the IgI/IgII linker region 
containing the acid box, a glutamate, aspartate and serine-rich sequence (Johnson 
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and Williams, 1993), are responsible for formation of the ‘closed’, autoinhibited state. 
Spectroscopic investigations have shown the acid box engages in electrostatic 
interactions with the HS-binding site of the IgII loop, inhibiting receptor-HS 
interactions and, therefore, receptor activation. This then encourages intramolecular 
interactions between IgI and the ligand-binding sites of the IgII and IgIII loops, further 
aiding the acquisition of a closed conformation (Olsen et al., 2004). Alternative 
splicing of exons encoding the IgI and/or acid box region leads to enhanced affinity 
of the receptor for its ligand and HS, increasing downstream signalling (Olsen et al., 
2004). Loss of this region has been implicated in cancer (Kobrin et al., 1993, 
Mansson et al., 1989). This mechanism of autoinhibition supports FGF binding 
specificity of receptors, as only specific ligands with high affinity for the receptors will 
overcome this inhibition and bind to the receptor.  
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Figure 1.5. Negative regulation of FGFR signalling.  
A number of mechanisms exist to negatively regulate FGFR signalling. These include 
recruitment of additional proteins (red boxes) (Hacohen et al., 1998, Wakioka et al., 2001, 
Wang et al., 2002, Yang et al., 2003) as well as downstream elements of, for example, the 
ERK pathway acting upstream to modulate activity (black lines) (Buday et al., 1995, Gual et 
al., 2001, Ueki et al., 1994). Figure adapted from Carter et al., 2014.  
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
1.2.5 FGFR2 and disease  
Developmental disorders  
The importance of the FGF signalling axis in development is well documented, with 
integral functions in, for example, organ morphogenesis and limb function (Pownall 
and Isaacs, 2010). As such, germline mutations in FGFRs are known drivers in a 
range of developmental disorders.  
 
Point mutations in FGFR2 can manifest in skeletal malformations and dwarfism 
(Hatch, 2010). FGFR2 mutations common in the craniosynostosis dysplasias 
Crouzon, Jackson-Weiss, Pfieffer and Apert syndromes cluster in the linker region 
between the IgII and IgIII loops, which alter the ligand binding specificity of the 
receptor (Eswarakumar et al., 2004, Chen et al., 2003, Ibrahimi et al., 2001, Yu et 
al., 2000). Mutations in two conserved cysteine residues within IgIII of FGFR2 are 
also common. In normal receptor signalling, these cysteine residues form 
intramolecular bonds, preventing receptor dimerisation until ligand binding. In mutant 
FGFR2, substitution of one of these cysteine residues creates an unpaired cysteine 
able to form an intermolecular disulphide bridge, leading to receptor dimerisation and 
activation (Eswarakumar et al., 2005).  
 
 
Mouse models of the most common of these gain-of-function mutations, S252W 
(Oldridge et al., 1997, Webster and Donoghue, 1997), show phenotypic traits of 
Apert syndrome, including impaired bone growth (Wang et al., 2005). Additional 
studies have suggested this mutation enhances FGFR2IIIb expression, as well as 
one of its ligands, FGF10, which may be responsible for the premature fusion of the 
cranial plates characteristic of this disorder (Yokota et al., 2014). It is also postulated 
that the S252W mutation leads to the modified receptor remaining on the cell surface 
for an extended period of time, rather than undergoing rapid recycling like its wild 
type counterpart. Downstream signalling pathways are affected, leading to increased 
ERK phosphorylation and therefore increased cell proliferation and migration 
capabilities, as well as premature differentiation (Ahmed et al., 2008).  
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Cancer  
In 2000, Hanahan and Weinberg first proposed six hallmarks of cancer: sustainment 
of proliferative signalling, evasion of growth suppressors, activation of invasion and 
metastasis, establishment of replicative immortality, induction of angiogenesis and 
evasion of cell death (Hanahan and Weinberg, 2000). This notion has recently been 
revised and two additional hallmarks added; deregulation of energetics, i.e. the 
reprogramming of metabolic processes to enhance cellular proliferation, and evasion 
of immune destruction (Hanahan and Weinberg, 2011). The tumour 
microenvironment is also known to be of particular importance in maintaining tumour 
growth and progression (Gligorijevic et al., 2014, Langley and Fidler, 2011, Onuigbo, 
1975, Suh et al., 2014, Witz and Levy-Nissenbaum, 2006). For example, pancreatic 
cancer is known to have a dense stromal cell component, which communicates with 
tumour cells and subsequently aids tumour growth (Froeling et al., 2009). Another 
characteristic of cancer progression elucidated over recent years is that of infiltration 
of tumours by the immune system, causing an inflammatory response (Hanahan and 
Weinberg, 2011). Rather than eradicating tumour growth, it appears such 
inflammation is capable of promoting tumour progression by supplying growth factors 
and enzymes that facilitate angiogenesis and metastasis (DeNardo et al., 2010, 
Grivennikov et al., 2010, Qian and Pollard, 2010).  
 
Whilst it is generally accepted that the evolution of normal cells to a malignant state 
involves acquisition of these hallmarks in a multistep process, genomic instability is 
also known to be an important feature in enabling neoplastic progression (Hanahan 
and Weinberg, 2011). Such instability can confer a selective advantage in a 
subpopulation of cells in a polyclonal environment, eventually leading to dominance 
in the population. Indeed, such selective advantage can lead to clonal expansions 
over the evolution of the tumour, resulting in a malignant phenotype (Vogelstein et 
al., 2013).  
 
An important facet of this idea of clonal expansion of cells within a tumour is that of 
driver and passenger mutations (McFarland et al., 2014). Tumour progression is now 
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known to be driven by a relatively small selection of mutations and chromosomal 
abnormalities (Lawrence et al., 2014, Zack et al., 2013). Acquisition of a mutation in 
an oncogene or tumour suppressor can provide a cell with a distinct advantage over 
others in the population, allowing for outgrowth and, potentially, dominance in the 
tumour (Hanahan and Weinberg, 2011). Due to the rapid rate of cell division in 
tumours, additional mutations also arise that do not confer a selective advantage to 
the tumour but are inherited alongside advantageous mutations, and are thus known 
as passenger mutations (Lawrence et al., 2014).  
 
Whilst tumours often contain multiple subpopulations of clonal expansions, resulting 
from a small number of driver mutations, tumour cells can become dependent on a 
particular driver mutation (McFarland et al., 2014). One hypothesis for such addiction 
is genetic streamlining, whereby cancer cells dismiss signalling pathways that do not 
provide a fitness advantage. This can provide a therapeutic window, where inhibition 
of this dominant signalling pathway can lead to tumour eradication (Torti and 
Trusolino, 2011).  
 
Given the ability of the FGF signalling pathway to facilitate cell survival and 
proliferation, amongst other cellular responses, it is not surprising this pathway is 
hijacked in cancer cells. According to the catalogue of somatic mutations in cancer 
(COSMIC), FGFR2 aberrations have been identified in 23 tissue types (COSMIC, 
2014) (Figure 1.6). The majority of these mutations are activating, resulting in 
increased proliferation, migration and angiogenesis and are generally indicative of a 
more malignant phenotype (Turner and Grose, 2010). This deregulation in FGFR2 
signalling is known to occur via a range of mechanisms (Figure 1.7):   
 
Receptor amplification  
Amplification of FGFR2 correlates with poor survival in a range of different cancers 
(Figure 1.6). However, patients who present with FGFR2 amplified tumours respond 
favourably to FGFR targeted therapies, compared to those harbouring non-amplified 
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tumours (Andre et al., 2013, Cheng and Alper, 2014, Soria et al., 2014). 
Interestingly, recent work investigating the use of the EGFR-targeted monoclonal 
antibody cetuximab found that while patients responded initially, they quickly 
acquired resistance to the treatment (Zhang et al., 2014). Through use of xenograft 
models, this was shown to be the result of concomitant FGFR2 amplification. Drug 
therapy directed against FGFR2 led to re-sensitisation to cetuximab, highlighting the 
complex role of receptor tyrosine kinases in cell signalling. FGFR1, 3 and 4 
amplifications are also found in a range of cancers, including lung and breast, and 
show enhanced sensitivity to FGFR-directed therapies (Carter et al., 2014).  
 
Isoform switching/autocrine stimulation  
Epithelial cells commonly express FGFR2IIIb, while mesenchymal cells express the 
IIIc isoform. However, a change in isoform expression is frequently seen in cancer 
and is indicative of a more malignant phenotype (Ishiwata et al., 2012, Kawase et al., 
2010, Peng et al., 2014, Turner and Grose, 2010) . In breast cancer, epithelial cell 
lines expressing the FGFR2IIIc isoform displayed a more invasive phenotype 
(Shirakihara et al., 2011), while pancreatic cells over-expressing FGFR2IIIc in in vivo 
models display enhanced tumour growth (Ishiwata et al., 2012).  
 
Induction of autocrine signalling is common in cancer and such a method of 
enhanced signalling via FGFR2 has been noted in epithelial ovarian cancer (Steele 
et al., 2001). Here, over-expression of FGFR2IIIb, as well as its cognate ligand, 
FGF7, was observed in cancer cells of epithelial origin. As such, it was suggested 
that induction of this autocrine signalling axis may play a role in development of 
ovarian carcinoma.  
 
Fusion proteins  
A number of novel FGFR2 fusion proteins have recently been described (Wu et al., 
2013). One such fusion protein, FGFR2-bicaudal C homolog 1 (BICC1) found in 
cholangiocarcinoma, was shown to consist of full length FGFR2 fused to BICC1, an 
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RNA binding protein known to regulate gene expression. Such fusion proteins are 
proposed to lead to enhanced receptor activity by mediating oligomerisation (Wu et 
al., 2013). Importantly, inclusion of the kinase domain makes such fusion proteins 
potential therapeutic targets (Arai et al., 2014).  
 
One fusion protein of particular interest was identified in prostate cancer (Wu et al., 
2013). This protein, solute carrier family 45, member 3 (SLC45A3)-FGFR2, consists 
of the entire FGFR2 gene fused to, and under the control of, an androgen-regulated 
promoter, SLC45A3, resulting in over-expression of FGFR2. One would postulate 
that patients harbouring this fusion should respond to both anti-androgens and 
FGFR inhibition.  
 
Another fusion protein of interest involving an FGFR family member is FGFR3-
transforming acidic coiled coil 3 (TACC3), described in bladder and lung carcinomas 
(Wang et al., 2014b, Williams et al., 2013). FGFR3-TACC3 promotes constitutive 
kinase activity, enhancing cellular proliferation (Singh et al., 2012, Williams et al., 
2013).  
 
Activating mutations  
A number of cancers have been found to contain somatic mutations identical to germ 
line mutations in FGFRs associated with developmental disorders. FGFR2 mutations 
commonly seen in Apert and Pfeiffer Syndromes are frequently identified in 
endometrial cancer (Pollock et al., 2007), for example S252W and N550K, both of 
which result in receptor activation (Greulich and Pollock, 2011a). Other FGFR2 
mutations in endometrial cancer include S373C and Y376C, which result in gain of a 
cysteine residue, allowing formation of intermolecular disulphide bonds, leading to 
constitutive receptor dimerisation and therefore downstream signalling (Wilkie, 
2005).  
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Other FGFR2 mutations of note include those in breast cancer, which have been 
shown to enhance kinase activity (Reintjes et al., 2013). The functionality of these 
mutations in tumour development, and their potential to be targeted therapeutically, 
has been demonstrated in mouse models (Tchaicha et al., 2014).  
 
Receptor mutation is particularly important in non-muscle invasive bladder cancer, 
where approximately 70% of tumours harbour FGFR3 mutations, which correlate 
with enhanced PI3K signalling (Juanpere et al., 2012, Liu et al., 2014). In vivo 
studies have shown the functional role of FGFR3 mutations in bladder cancer, 
whereby FGFR3-mutant mice exhibit enhanced urothelial cell proliferation and 
hypertrophy (Foth et al., 2014).  
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Figure 1.6. Frequency of FGFR2 point mutations, copy number and gene expression 
variations in cancer.  
FGFR2 mutations are found in a range of tumour types and their proportions differ 
depending on the tissue of origin. Here, we show all tissue types and number of tumours 
screened (A and B, top panels), as well as the proportion of these tumours harbouring an 
FGFR2 point mutation (A, bottom panel) and copy number or gene expression variations (B, 
bottom panels), as listed in COSMIC. All dots in the plot are in proportion within the same 
panel. BT, biliary tract; CNS, central nervous system; H&L, haematopoietic and lymphoid; LI, 
large intestine; NS, not specified; SG, salivary gland; SI, small intestine; ST, soft tissue; 
UAT, upper aerodigestive tract; UT, urinary tract. Gain and loss indicate increased and 
decreased copy number respectively; over and under indicate increased and decreased 
gene expression respectively. Data correct as of September 2014. Figure adapted from 
Carter et al., 2014. 
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Figure 1.7. Mechanisms of aberrant FGFR signalling in disease.  
Increased signalling downstream of FGFRs, in both developmental disorders and cancer, 
occurs via four main mechanisms: (i) gene amplification, where overexpression of the 
receptor leads to augmented intracellular signalling (Turner and Grose, 2010); (ii) autocrine 
stimulation by release of ligands with high affinity for the receptor expressed on the cell 
(Ishiwata et al., 2012, Kawase et al., 2010, Peng et al., 2014, Shirakihara et al., 2011, Steele 
et al., 2001); (iii) fusion proteins, whereby the kinase domain is fused to, for example, BICC1 
(Wu et al., 2013); (iv) activating mutations, for example in the kinase domain, which lead to 
constitutive activation of the receptor (Greulich and Pollock, 2011b, Pollock et al., 2007, 
Wilkie, 2005). Figure adapted from Carter et al., 2014. 
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1.3 Targeted drug therapy  
Historically, tumour burden has been relieved by surgical and radiotherapeutic 
measures. Whilst classic systemic treatment of malignant lesions using 
chemotherapy is still a common treatment option, continuing research into the 
molecular mechanisms underpinning cancer has led to the advent of a range of 
drugs targeting a variety of pathways, for example small molecule inhibitors towards 
receptor tyrosine kinases (Hojjat-Farsangi, 2014). An emerging therapeutic option is 
that of immunotherapy, which aims to utilise and augment the ability of the immune 
system to eradicate cancer cells (Perica et al., 2015). One key aspect of this 
emerging treatment strategy relies on tumour-associated T-cells. As T-cell 
responses are specific and can potentially distinguish between healthy and 
cancerous tissue, their utility in cancer treatment is particularly promising (Perica et 
al., 2015).  
 
One immunotherapy option is the use of cancer vaccines, whereby delivery of 
tumour-associated antigens expands and activates the tumour-specific T-cell 
population (Finn, 2014). However, the current treatment choice that seems to offer a 
paradigm shift in harnessing the power of the immune system is the use of immune 
checkpoint antagonists. Immune checkpoints negatively regulate T-cells, therefore 
decreasing T-cell function (Emens and Middleton, 2015). Using antagonists of these 
checkpoints, the negative signals that diminish T-cell activity at the tumour site can 
be abrogated, resulting in increased tumour-associated T-cell activity (Pardoll, 2012). 
For example, the immune checkpoint molecule cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4) down-regulates T-cell activation (Melero et al., 2007). The 
monoclonal antibody Ipilimumab blocks CTLA-4, thereby promoting anti-tumour 
immunity (Fong and Small, 2008, O'Day et al., 2007, Robert and Ghiringhelli, 2009, 
Weber, 2009). Indeed, Ipilimumab monotherapy in metastatic melanoma has proven 
successful in phase 2 clinical trials (O'Day et al., 2010, Weber et al., 2009, Wolchok 
et al., 2010). The ultimate aim of this emerging treatment option is to establish a 
population of tumour-specific T-cells with the ability to lyse tumour cells and to 
combine such measures with existing systemic therapies to achieve the greatest 
clinical benefit to patients (Emens and Middleton, 2015).  
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The high rate of FGFR mutations in a range of diseases makes this family of proteins 
an attractive therapeutic target. Numerous studies have shown the benefits of FGFR 
knockdown and inhibition in cancer cell lines where the result is, for example, a 
decrease in cell proliferation (Byron et al., 2008, Chioni and Grose, 2012, Coleman 
et al., 2014). However, translating this into a therapy for patients has proven difficult, 
due to even specific FGFR inhibitors having off-target effects (Mohammadi et al., 
1998). However, given the importance of these receptors in a range of pathologies, 
numerous drugs have been, and currently are, under development. A number of 
different approaches to develop therapeutics to target this pathway have been 
employed (Figure 1.8).  
 
Kinase inhibitors  
The most clinically advanced FGFR inhibitors to date are multi-kinase inhibitors, 
targeting the kinase domain of receptors to prevent downstream signalling (Figure 
1.8 (iv)) and include Dovitinib (Trudel et al., 2006) and SU6668 (Fabbro and Manley, 
2001). While these compounds are known to be promiscuous, hitting receptor 
tyrosine kinases outside of the FGFR family, recent analysis has shown that 
Dovitinib and Lucitanib have better responses in clinical trials in patients with 
cancers harbouring FGFR amplifications than those that do not (Andre et al., 2013, 
Soria et al., 2014). However, broad-reaching tyrosine kinase inhibitors have shown 
dismal toxicity profiles, evidenced in Ponatinib’s recent temporary withdrawal from 
the treatment of chronic myeloid leukaemia (CML) due to a high proportion of 
patients exhibiting arterial and venous thromboses (Report, 2014). As such, work in 
recent years has focused on development of more potent, FGFR-selective inhibitors.  
 
One inhibitor, PD173074, a pyrazoloamide derivative targeting the intracellular ATP 
binding pocket of FGFRs, preferentially binds to FGFRs, with weak activity against 
other receptor tyrosine kinases (Mohammadi et al., 1998). However, due to toxicity 
issues, this drug can only be used as a laboratory tool in the investigation of the 
effects of FGFR inhibition (Knights and Cook, 2010). More success has been 
achieved with an alternative FGFR kinase inhibitor, AZD4547, which is currently in 
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phase II clinical trials for solid tumours (Clinicaltrials.gov, 2014, Gavine et al., 2012). 
This ATP-competitive small molecule inhibitor targets FGFR1, 2 and 3 and results in 
both inhibition of growth and induction of apoptosis, specifically in cancer cell lines 
with known FGFR mutations or amplifications. While selectivity for FGFRs is high 
with this compound, at high concentrations this inhibitor too has off-target effects, for 
example activity against vascular endothelial growth factor receptor 2 (VEGFR2). 
However, the potency of this off-target inhibition is much lower than that versus 
FGFRs.   
 
Orthosteric receptor binding  
While small molecule kinase inhibitors remain the most clinically advanced method 
of FGFR-targeted therapeutics, alternative methods, in the form of antibody-based 
approaches, allow for more direct action against FGFRs by targeting specific 
receptor isoforms (Figure 1.8 (i)). For example, an anti-FGFR2IIIb antibody, GP369, 
has demonstrated promising results in animal models where FGFR2-mutant 
xenograft tumours have shown reduced growth in GP369-treated mice (Bai et al., 
2010). Moreover, an FGFR3 antibody, MGFR1877S, is currently in phase I clinical 
trials for multiple myeloma and solid tumours (Clinicaltrials.gov, 2014).  
 
In an alternative approach, FGF-ligand trap antibodies have been developed, for 
example FP-1039, to prevent ligand-receptor binding (Harding et al., 2013) (Figure 
1.8 (iii)). FP-1039 is currently in phase I clinical trials for solid tumours. However, 
while this form of inhibition may temper FGF-stimulated activation of FGFRs, such 
therapeutics provide little benefit against tumours with kinase mutations which lead 
to constitutive activation of the receptor.  
 
Allosteric receptor binding  
Recently, the potential use of allosteric inhibitors has been described (Figure 1.8 (ii)). 
Interestingly, initial in vivo investigations of one such drug, SSR128129E, have 
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shown no evidence of vascular side effects, suggesting this may be a preferable 
alternative to use of receptor tyrosine kinase inhibitors (Herbert et al., 2013).  
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Figure 1.8. Mechanisms of FGFR inhibition.  
Given the importance of FGFR signalling in a range of pathologies, numerous drugs have 
been, and currently are, under development to target this pathway. These therapeutics fall in 
to one of four categories: (i) orthosteric inhibitors, where inhibitors target the ligand binding 
domain of the receptor, therefore preventing FGF attachment and induction of downstream 
signals (Bai et al., 2010, Clinicaltrials.gov, 2014); (ii) allosteric inhibitors, which bind to the 
extracellular portion of the receptor, preventing it being internalised and transducing a signal, 
even when ligand is bound (Herbert et al., 2013); (iii) ligand trap, consisting of the ligand 
binding domain of, for example, FGFR1 bound to the Fc portion of IgG1, resulting in 
sequestration of ligand and therefore prevention of receptor stimulation (Harding et al., 
2013); (iv) small molecule kinase inhibitors, the most common therapeutic option, targeting 
the ATP-binding pocket of the intracellular kinase domain of the receptor (Fabbro and 
Manley, 2001, Gavine et al., 2012, Mohammadi et al., 1998, Trudel et al., 2006). Figure 
adapted from Carter et al., 2014. 
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1.4 Drug resistance in cancer  
Continuing research into the molecular mechanisms underpinning cancer has led to 
the advent of a range of drugs targeting a variety of pathways. Whilst this has led to 
the beginnings of personalised medicine, where therapeutics are prescribed on the 
basis of the molecular aberrations present in the tumour, resistance to these new 
drugs, as well as to classic chemotherapeutics, continues to be one of the major 
barriers in successfully treating cancer patients (Holohan et al., 2013). This is of 
particular importance in endometrial cancer, where patients with advanced disease 
often relapse due to drug resistance (Chaudhry and Asselin, 2009). To overcome 
this, a thorough understanding of the mechanisms implemented by cancer cells to 
circumvent drug treatment is necessary.  
 
One common mechanism of multidrug resistance is up-regulation of efflux proteins, 
resulting in removal of drugs from cells and therefore preventing them reaching their 
targets (Ambudkar et al., 1999, Gottesman et al., 2002). Alterations in signalling, 
leading to activation of pro-survival or inactivation of pro-apoptotic pathways, are 
also common. For example, deregulation of the PI3K/AKT pathway is seen in a 
variety of cancer types (Faratian et al., 2009, Goltsov et al., 2011, Goltsov et al., 
2012). Indeed, this pathway has been postulated as a potential therapeutic target in 
chemoresistant endometrial cancer, where administration of doxorubicin in 
combination with PTEN over-expression in resistant cells led to cell death (Wan et 
al., 2007).  
 
A particularly striking example of resistance to targeted therapies is that of 
vemurafenib-treated melanoma (Flaherty et al., 2010, Wagle et al., 2011). 
Approximately 50% of melanomas carry a mutation in the serine-threonine protein 
kinase b-raf (BRAF); of these 90% harbour the V600E mutation, leading to 
constitutive activation of the protein and therefore its downstream ERK signalling 
pathway (Davies et al., 2002, Flaherty et al., 2010). The prevalence of this mutation 
makes it an attractive therapeutic target, and led to the development of Vemurafenib, 
a small molecule inhibitor that preferentially binds to the V600E mutant form of BRAF 
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(Tsai et al., 2008). Initial clinical trials showed excellent results, with complete or 
partial regression in approximately 80% of patients (Flaherty et al., 2010). However, 
resistance to the drug occurred and the duration of response lasted only two to 18 
months (Flaherty et al., 2010).  
 
Dissection of this resistance by mutation profiling revealed several mechanisms of 
importance. Activating mutations in MEK1 were seen in vemurafenib resistant 
populations (Wagle et al., 2011), as well as increased expression of MAP3K8 
(Johannessen et al., 2010). Activation of CRAF has been noted in resistant cells 
(Montagut et al., 2008), as has up-regulation of platelet derived growth factor 
receptor β (PDGFRβ) (Nazarian et al., 2010). All of these aberrations ultimately lead 
to activation of the ERK pathway, therefore circumventing BRAF inhibition. Together, 
these data show the multitude of mechanisms cancer cells can employ to elude 
death in response to drug treatment.  
 
Modelling of resistance to vemurafenib in mice has indicated that cyclical 
administration of the drug could delay acquisition of resistance and therefore 
potentially prolong patient life (Das Thakur et al., 2013). In vivo studies have shown 
that mice implanted with BRAF mutant tumour cells and sequentially treated with the 
drug for four weeks followed by removal for two weeks did not develop tumours, 
while control mice continuously dosed did. Tumour heterogeneity can give rise to 
drug resistance through positive selection of a resistant subpopulation; these data 
indicate that some drug resistant cells confer a fitness deficit in the tumour 
environment, in the absence of drug. Understanding the balance between molecular 
subtypes within tumours and utilising this knowledge, not only in drug choice but also 
in how drugs are administered, may prove crucial in overcoming drug resistance.  
 
Although current clinical trials of FGFR-targeted therapies have reported favourable 
results, based on knowledge of other small molecule inhibitors, it is possible that 
treatment of FGFR-mutant tumours with such drugs will result in resistance in a 
subpopulation of patients. Recent work in FGFR2-mutant gastric cancer aimed to 
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pre-empt possible resistance mechanisms and alluded to potential combination 
therapies that may overcome such issues (Grygielewicz et al., 2014). The authors 
noted a compensatory signalling mechanism in FGFR-inhibitor resistant cells that 
could be overcome by blockade of human epidermal growth factor 2 (HER2) and 
attributed this change in signalling to induction of epithelial to mesenchymal 
transition (EMT). Acquired resistance to FGFR-inhibition in FGFR3-dependent 
bladder cancer cells has also been ascribed to EMT and a change in signalling from 
FGFR3 to HER2/3 (Wang et al., 2014a). In another study, investigation of small 
molecule inhibition of FGFR3 mutant cell lines revealed a secondary gatekeeper 
mutation critical for acquired resistance to a selection of FGFR inhibitors, including 
the AZD4547 compound currently in clinical trials (Chell et al., 2013). Such work is 
important in the anticipation of drug resistance mechanisms that may affect the utility 
of drugs in the clinic.  
 
High throughput technologies, such as mass spectrometry (MS), gene microarray 
profiling and next generation sequencing, afford greater insight into the processes 
employed by drug resistant cells and therefore offer opportunities to overcome 
resistance using rational drug combinations (Holohan et al., 2013). Ultimately, to 
overcome the hurdle of drug resistance in the treatment of cancer, we require a 
greater understanding of how resistance is acquired and to view cell signalling as an 
interconnected network, capable of rewiring upon inhibition of the dominant 
signalling pathways.  
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1.5  Screening of signalling networks  
As discussed in section 1.4, a common mechanism of drug resistance is via 
reprogramming of signalling networks upon inhibition of a mutant receptor (Holohan 
et al., 2013). This ‘kinome reprogramming’ is the product of pathway redundancy in 
cancer cells, where blockade of one receptor tyrosine kinase is compensated for by 
re-wiring of the signalling network either downstream of the receptor or via up-
regulation of a different receptor tyrosine kinase. To dissect an intracellular signalling 
network, it is essential to use an unbiased, quantitative and well-validated assay.  
Microarray and MS provide two effective ways to assess gene and protein levels, 
respectively, and can be used to complement each other in the dissection of 
signalling networks.  
 
1.5.1 Microarray gene expression analysis  
Advances in genome sequencing have facilitated high resolution gene expression 
studies. Microarray technology has increased hugely the efficiency of gene 
expression analysis, as well as measuring gene expression in a global, unbiased 
fashion. Using this technology, the levels of thousands of gene transcripts can be 
measured simultaneously from one RNA sample. While the specifics vary between 
providers, the format is generally one of a chip composed of DNA probes specific to 
a gene. For example the Illumina platform provides probes for over 47000 gene 
transcripts. RNA is extracted from tissue or cells, reverse transcribed and labelled 
with a fluorescent dye. Upon hybridisation, fluorescent imaging provides a measure 
of relative gene expression across and, in the case of chips whereby multiple 
samples can be analysed in tandem, between samples (Tarca et al., 2006). Whilst 
this approach has been used to great effect to garner a wealth of transcriptomic 
data, it is being superseded by direct RNA sequencing, which offers greater 
resolution and also encompasses analysis of mRNA splice variants (Qian et al., 
2014).  
 
Although transcriptome investigation omits information about the posttranslational 
modifications proteins undergo to perform their various functions, expression arrays 
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have been crucial in identifying important players in a range of cellular processes, as 
well as aiding identification of therapeutic targets in disease states (Aguan et al., 
2000, Banwait and Bastola, 2014, Critchley et al., 2006, Ohgino et al., 2014, Olivera-
Martinez et al., 2014).  
 
1.5.2 Mass spectrometry   
Microarray transcriptomics represents an important breakthrough in the global 
identification and quantification of gene expression in distinct cell populations. While 
this has often been used as a proxy for protein expression, it is important to assess 
cellular activity at the protein level in a similar global, unbiased fashion. MS provides 
the ideal tool for such analysis.  
 
The initial step of all proteomic experiments is sample preparation, which is typically 
performed in one of two ways: labelled or label-free. While these terms denote 
sample preparation methods, ultimately they determine how proteins in the samples 
are identified and quantified. The labelled system can be further subdivided into two 
distinct processes: chemical labelling using isobaric tag for relative and absolute 
quantification (iTRAQ) and metabolic stable isotope labelling with amino acids in cell 
culture (SILAC) (Ong et al., 2002, Ross et al., 2004).  
 
The iTRAQ system utilises isotope-containing tags, which react with primary amine 
groups of peptides and act as reporter molecules. These tags are fragmented in the 
mass spectrometer and the difference in the intensity of the various reporters is 
employed to derive the relative abundance of the proteins in the starting cell 
population (Ross et al., 2004). The SILAC method involves incorporation of ‘heavy’ 
isotope-containing amino acids (Ong et al., 2002). Arginine and lysine labelled with 
13C and/or 15N are fed to cells as a medium supplement, leading to the incorporation 
of these heavy labels into newly synthesised proteins in the cell. At the end of 
experimental treatment, differentially labelled cell populations can be mixed and, 
because the heavy and light proteins can be distinguished from each other, run 
64 
 
through the mass spectrometer together. The ability to run all sample conditions 
through the spectrometer at once is advantageous, as the influence of differences in 
MS runs between samples on peptide quantification is minimised. However, 
experimental conditions are limited to the number of labels available, both in iTRAQ 
and SILAC systems, and sample preparation is both costly and time consuming.  
  
The label-free approach of sample preparation is advantageous in that it allows for 
analysis of an unlimited number of samples and removes cumbersome culturing 
techniques. In this system, cells are grown in their normal culture medium and run 
through the mass spectrometer separately. Historically, this has been associated 
with difficulty in normalising between samples. However, advances in computational 
methods have allowed for internal normalisation controls, minimising this problem 
(Cutillas and Vanhaesebroeck, 2007).  
 
MS identifies proteins based on their weight, or mass-to-charge (m/z) ratio. In the 
‘bottom-up’ MS approach, sample proteins are identified based on their constituent 
peptides. Peptide fragments are obtained by digestion of whole proteins, commonly 
using trypsin. This method is generally considered more sensitive than the ‘top-
down’ alternative, where whole proteins are detected; therefore the fragmentation 
approach allows identification of a more complete protein network (Moradian et al., 
2014).  
 
In liquid chromatography (LC)-MS, solid phase extraction of peptides typically follows 
tryptic digest, after which peptides are run through high performance-LC (HPLC), 
separating peptides based on their hydrophobicity. Peptides are then transferred 
from liquid to gas phase by passing through an electrospray ionisation unit, 
producing multiply charged ions. The ions then pass into the vacuum of the mass 
spectrometer, where an electromagnetic field is applied and peptides are separated 
based on their m/z ratio, which is recorded by the detector. From these data, the 
isotopic distribution and charge of the peptides in the sample can be deduced, as 
well as its retention time, i.e. the time taken for the analyte to pass from the HPLC 
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inlet to the detector (Ens and Standing, 2005). To garner information about the 
peptide sequence from the MS spectra, the peptide must be fragmented along its 
backbone, giving an MS/MS, or ‘tandem MS’, spectrum. This is performed on a 
number of top multiply charged ions, the number of which is defined by the user, 
typically in the range of 5-7 ions. The resulting MS/MS spectra is essentially a list of 
m/z ratios of the various fragments (Walther and Mann, 2010).  
 
From comparison of tandem mass spectra, peptide molecular weights or mass data 
and amino acid sequence data with an annotated database, for example Mascot, 
peptide identification can be achieved (Perkins et al., 1999). Reference values of 
peptides listed in the database are calculated by applying appropriate cleavage rules 
to known proteins. Experimental data can be compared to those listed in the 
database and given a score based on the likelihood of each peptide belonging to a 
particular protein. The peptide match with the highest score, with this score 
representing the probability that the pairing is not a chance event, is reported as the 
best match and the peptide assigned accordingly.   
 
Following identification of the proteins present in the experimental sample, 
quantification of these peptides can be performed. Label-free MS can be quantified 
by using an internal control such as inclusion of yeast extracts spiked with standard 
proteins in the experimental sample (Old et al., 2005). One method developed for 
accurate quantification of peptides from label-fee MS is the peak statistical calculator 
(Pescal) programme (Cutillas and Vanhaesebroeck, 2007). Here, the retention time 
and m/z ratio of a given peptide is used to generate an extracted ion chromatogram. 
These ion intensities are then normalised by subtracting the intensities of the 
particular ion in a blank sample from the experimental peptide intensity and 
subsequently dividing this by the peptide intensities of the internal standard (Cutillas 
and Vanhaesebroeck, 2007). The relative quantity of peptide is calculated relative to 
the mean of normalised ion intensities of the peptide of interest across the samples 
being compared. Further calculations are employed to garner intensity values of 
peptides matching each protein and are ultimately reported as fold expression 
relative to the mean expression (Cutillas and Vanhaesebroeck, 2007). Other 
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methods of quantitation of label-free proteomics have been described (Ishihama et 
al., 2005, Mallick et al., 2007). However, as these methods only allow for 
approximation of protein abundance from spectral count, they lack the precision of 
Pescal (Cutillas and Vanhaesebroeck, 2007).  
 
As well as identifying total protein levels in cells, MS can be used to identify post-
translationally modified proteins, for example those which have been 
phosphorylated. Protein kinase signalling plays an essential role in mediating cell 
behaviour, and changes in signalling via phosphorylation status of proteins provide 
valuable information in both normal and disease states. The phosphoprotein 
signature of cells is a reflection of kinase pathways active in the population, and 
allows us to acquire greater understanding of the complexity of cellular signalling 
(Choudhary and Mann, 2010).  
 
The phosphoproteome can be deduced using MS by including an enrichment step. 
Following proteolytic digest of the sample proteins, phosphopeptides are selected 
using, for example, TiO2 chromatography or incubation with phospho-selective 
antibodies (Boersema et al., 2009). The resulting fraction can then be run through 
the mass spectrometer as described, as can the total protein fraction, therefore 
providing a wealth of information regarding both the phospho- and total proteome. 
This fully quantitative method is capable of identifying at least 2000 phosphopeptides 
(Casado et al., 2013a).   
 
Although the changes in phosphoprotein levels have routinely been assessed using 
antibody-based methods, such as western blotting, such methods only shed light on 
pre-selected signalling pathways and are limited to the number of proteins that can 
be investigated at one time. As such, only hints of the myriad signalling changes 
which occur between cell populations are identified. The ability of MS to identify 
changes in thousands of phosphoproteins in one run gives a much broader, 
quantifiable and unbiased insight into multiple signalling pathways. From such data, 
a detailed model can be built and an assessment of the networks involved in discreet 
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populations can be made. Indeed, MS-based phosphoproteomics has been reported 
as a tool capable of identifying signalling pathways that contribute to intrinsic drug 
resistance to targeted therapies (Alcolea et al., 2012, Casado and Cutillas, 2011, 
Casado et al., 2013a, Casado et al., 2013b).   
 
As noted previously, MS/MS spectra are produced by fragmentation of peptides 
along their amino acid backbone. The most popular method of gas phase 
fragmentation is collision induced dissociation (CID) (Boersema et al., 2009). In CID, 
ionised peptides are accelerated by an electric potential in a vacuum and allowed to 
collide with an inert gas, such as helium or nitrogen. These collisions convert the 
kinetic energy of the peptide ion to internal energy distributed throughout the 
molecule. This causes disruption of the peptide bonds and leads to their 
fragmentation, typically at the amide bond, producing b- and y-ions, from which the 
amino acid sequence can be deduced (Biemann, 1988, Boersema et al., 2009, 
Roepstorff and Fohlman, 1984). However, when fragmenting phosphorylated 
peptides, CID can cause the phosphate group to break away from the peptide, an 
energetically more favourable process than backbone fragmentation. This is termed 
‘neutral loss’ and results in a dominant peak in the MS/MS spectrum that can hinder 
identification of the rest of the fragments and therefore prevent accurate peptide 
sequence information being obtained (DeGnore and Qin, 1998, Tholey et al., 1999).  
 
To overcome this, an additional step can be added to the MS process. The standard 
LC-MS/MS process involves the initial MS scan to determine peptide masses and 
charge state, after which ions are selected and fragmented for MS/MS (MS2) scans. 
A third step is then introduced, isolating the neutral loss fragment ion and 
fragmenting the precursor ion again so as to achieve more efficient backbone 
fragmentation (MS3) (Schroeder et al., 2004). However, this additional step 
increases analysis time and so MS2 and MS3 steps can be combined in a process 
known as ‘multistage activation’ (MSA) (Schroeder et al., 2004). Therefore, CID-MSA 
gives more accurate identification of phosphopeptides than its CID predecessor 
(Boersema et al., 2009).  
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Additional advances in peptide fragmentation have been achieved in recent years, 
for example electron capture dissociation (ECD) and electron transfer dissociation 
(ETD) methods, which are ideal for post-translationally modified peptides, as neutral 
loss is not observed (Syka et al., 2004, Zubarev, 2004). Higher energy C-trap 
dissociation (HCD) can also be used to identify peptide modification with very high 
confidence (Olsen et al., 2007).  
 
MS presents a valuable tool in assessing protein activity within cells. As well as 
looking at global proteomes, signatures of post-translationally modified proteins can 
be assessed and modification of the technique can allow for investigation of discreet 
protein complexes, for example RNA polymerases (Melnik et al., 2011). Indeed, this 
technique represents an opportunity to assess both cell line and human tissue 
proteomes and use these data to identify therapeutic targets and subsequently guide 
both pre-clinical and clinical research.  
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1.6 Cell culture models  
Whilst in vitro 2D culture of cells allows dissection of molecular events, it is important 
to assess cellular behaviour in a more physiological environment, where interactions 
between different cell types can be taken into consideration. This is particularly 
important in the investigation of cancer, where the tumour microenvironment is 
known to play a critical part in cancer cell signalling and therefore tumour 
progression (Gligorijevic et al., 2014, Langley and Fidler, 2011, Onuigbo, 1975, Suh 
et al., 2014, Witz and Levy-Nissenbaum, 2006). One useful pre-clinical investigative 
model is the genetically modified mouse, where the impact of tumour 
microenvironment, vasculature and immune response can be taken into account. 
However, such models are expensive and time consuming and are not readily 
available for all cancer and molecular aberrations, as is the case for FGFR2 mutant 
endometrial cancer. As such, an intermediary model is required where cell-cell 
interactions in a 3D environment, as well as the effects of targeted drugs, can be 
assessed in a cost- and time-effective manner.  
 
3D cell culture models are particularly important in assessing and visualising cancer 
cell invasion. Transwell assays, where cells invade through a membrane towards a 
chemoattractant, have been used to this effect and allow for quantification of cell 
invasion (Nystrom et al., 2005). However, this system fails to incorporate a stromal 
population of mesenchymal cells and therefore omits the effect of paracrine 
signalling between the two cell types (De Wever and Mareel, 2003, Liotta and Kohn, 
2001, Mueller and Fusenig, 2002). Incorporation of such a layer allows for 
recapitulation of physiologically-relevant cancer cell-stroma interactions and 
assessment of their effect on growth and migration.  
 
To address this issue, the organotypic culture model was created (Fusenig et al., 
1983). This system has since been modified and used to assess the 3D culture 
properties of a range of cancer types (Chioni and Grose, 2012, Coleman et al., 2014, 
Froeling et al., 2009, Mauchamp et al., 1998, Nystrom et al., 2005, Sakamoto et al., 
2001, Sanderson et al., 1996, Vukicevic et al., 1990). In general, this system 
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consists of fibroblasts mixed with collagen and Matrigel, acting as the extracellular 
matrix, to form a stromal equivalent, and cancer cells are seeded on top of this layer. 
These cultures are then raised to an air-liquid interface and fed from underneath. 
After a given time course, cultures are formalin-fixed and stained for various markers 
(Figure 1.9 A). While this method lacks insight into the role of the full range of 
physiological factors, it is arguably as clinically relevant as mouse xenograft models 
using nude mice, which also lack infiltrating immune responses and clinically 
accurate in situ tumour phenotypes (Kahn et al., 2012). 
 
The optimal 3D cell culture would consist of either primary or immortalised stromal 
cells from the tissue of origin of the cancer under investigation (Coleman et al., 
2014). However, the successful use of these cells in such cultures is influenced by 
the amenability of the primary cells to tissue culture, as well as access to adequate 
amounts of primary tissue. To overcome such obstacles, immortalised primary 
mesenchymal cells from another tissue may be used as a substitute (Nystrom et al., 
2005). In scenarios where primary cells are available, a ‘mini’ organotypic model has 
been established to accommodate small quantities of cells (Coleman et al., 2014) 
(Figure 1.9 B).  
 
An attractive feature of this model is its amenability for investigation of a range of 
cancer types and as a tool in aiding the answer of an array of molecular questions. 
For example, in addition to quantification of invasion, this system can be used to 
assess the effects of drug compounds on cell growth of both cancer and stromal 
cells, and immunofluorescence can be performed on sections to quantify proliferative 
cells and localisation of proteins (Chioni and Grose, 2012, Coleman et al., 2014). In 
short, this 3D physiomimetic system serves as a relatively high throughput, 
preclinical model in the analysis of cell-cell interactions and the evaluation of the 
effects of pharmacological agents.  
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Figure 1.9. Schematic representation of the 3D organotypic cell culture model.  
(A) The standard organotypic model consists of a collagen/Matrigel stromal equivalent 
containing embedded fibroblasts, upon which cancer cells are seeded. This culture is raised 
onto a collagen-coated membrane placed on a metal grid in a 6-well plate. Cultures are fed 
from underneath. This model can be used to assess the effects of pharmacological agents 
by inclusion of such drugs in the medium (Chioni and Grose, 2012, Coleman et al., 2014, 
Froeling et al., 2009). (B) An alternative method of organotypic culture has been developed, 
where fibroblasts and cancer cells are seeded in the same ratios as shown in A but in a 
smaller total volume (Coleman et al., 2014). In this method, the organotypic is created as 
before, this time using a Transwell insert placed inside the well of a 24-well plate. In both 
systems, cells are fed every 2-3 days for the duration of the experiment, after which they are 
formalin fixed, sectioned and stained for a range of cellular markers.  
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1.7 Aims and objectives  
FGFR2 is mutated in approximately 16% of endometrial cancers and, while these 
aberrations are known to be the driver mutations in a range of developmental 
disorders, little is known about their relevance in endometrial cancer (Byron et al., 
2008, Byron et al., 2012, Pollock et al., 2007). Small molecule inhibition of FGFR 
signalling in FGFR2 mutant endometrial cancer has been postulated as a viable 
therapeutic target (Byron et al., 2008, Dutt et al., 2008, Konecny et al., 2013). 
However, as resistance to both chemotherapy and hormone therapy is common in 
recurrent endometrial cancer, and acquired and intrinsic resistance to small molecule 
inhibitors have been documented in other carcinomas (Goltsov et al., 2011, Goltsov 
et al., 2012, Lito et al., 2013, Wagle et al., 2011, Zhang et al., 2009), the efficacy of 
prolonged FGFR-targeted therapy is an important area of study.  
 
To ascertain the role of mutant FGFR2 in endometrial cancer, and to decipher the 
susceptibility of various cell populations to acquisition of FGFR inhibitor resistance, 
the first aim of this project was to establish a 3D cell culture model to interrogate 
these populations using pharmacological agents.  
 
The second objective was to use phosphoproteomics to analyse differential 
signalling behaviour in cells prior to and post FGFR-targeted drug resistance 
acquisition and use these data to identify viable therapeutic targets to abrogate 
resistance pathways.  
 
The third objective was to determine the mechanism of drug resistance in FGFR2 
mutant cell lines using a combination of microarray gene expression analysis and 
biochemical techniques.  
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Chapter 2 
Materials and methods   
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2.1 Cell culture   
MFE-296 cells (Health Protection Agency, HPA) were grown in Modified Eagle’s 
Medium (MEM) (Sigma-Aldrich) supplemented with 10% foetal bovine serum (FBS) 
(GE Healthcare). AN3CA (American Type Culture Collection, ATCC) and HFF2 cells 
(ATCC) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-Aldrich) 
supplemented with 10% FBS and 1% L-glutamine (GE Healthcare). Ishikawa cells 
(Sigma-Aldrich) were grown in MEM supplemented with 5% FBS, 1% L-glutamine 
and 1% Non-Essential Amino Acids (Sigma-Aldrich). All cells were incubated at 
37oC, 8% CO2 and 100% relative humidity.  
 
When cells reached approximately 80-90% confluence, medium was removed and 
trypsin/ethylenediaminetetraacetic acid (EDTA) (GE Healthcare) was added for 5-7 
min at 37oC, 8% CO2 in order to detach cells from the flask surface. Once cells were 
detached, trypsin was inactivated with the relevant medium. Cell suspensions were 
centrifuged at 240 x g for 3 min at room temperature. Following centrifugation, 
supernatant was removed and the cell pellet re-suspended in standard medium. If 
counting of cells was required, 10 μL of cell suspension was added to a 
haemocytometer and cells counted manually under a light microscope. Cells were 
sub-cultured at a 1:3 ratio.  
 
For storage of cells, cell pellets were re-suspended in 2 mL of a 90% FBS and 10% 
dimethyl sulphoxide (DMSO) (Sigma-Aldrich) solution. Aliquots were frozen slowly at 
-80oC and then transferred to liquid nitrogen for long-term storage.  
 
When recovering cells from liquid nitrogen stocks, cell suspensions were thawed at 
37oC and transferred to a 15 mL Falcon tube containing standard medium. To 
remove DMSO, the cell suspension was centrifuged at 240 x g for 3 min. The 
supernatant was removed and cells were re-suspended in standard medium and 
plated into a tissue culture flask.  
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2.2 Cell line sequencing  
To ensure each cell line contained the FGFR2, PIK3CA, PIK3R1 and PTEN 
mutations detailed in the literature, PCR-based cell line sequencing was performed. 
Primers were designed using Primer3Plus (Primer3Plus, 2015) to amplify an 
approximately 200 base pairs (bp) region around the mutation site (Table 2.1). PCR 
using HotStarTaq Plus DNA Polymerase (QIAGEN) was then performed according 
to the manufacturer’s instructions and using the PCR conditions detailed in Table 
2.2.  
 
The PCR product was subsequently run on a 1.5% agarose gel, containing Gel Red 
(Biotium), and visualised under UV light to ensure a single, strong band was 
produced from the PCR. The PCR product was then sent to Barts Genome Centre 
for cycle sequencing and the resulting data analysed using BioEdit and CLC 
Sequence Viewer (v6) software.   
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Table 2.1. Primers used to sequence endometrial cancer cell point mutations 
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Table 2.2. HotStarTaq Plus DNA Polymerase PCR programme 
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2.3 PCR  
To establish the FGFR expression status of each cell line, primers for each FGFR 
(Table 2.3) were used and the PCR cycle in Table 2.4 followed. PCR products were 
then run on an agarose gel containing Gel Red and visualised under UV light. All 
experiments were performed in duplicate.  
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Table 2.3. FGFR PCR primers  
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Table 2.4. PCR cycle for amplification of FGF and FGFR sequences 
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2.4 Serum starvation assay  
Cells were seeded in six well plates in standard medium and incubated at 37oC, 8% 
CO2. After 16 h, medium was removed and cells were serum starved in FBS-free 
medium for 1, 2, 4, 8 or 16 h. Control cells were treated with full serum for 16 h, after 
which all cells were lysed and protein isolated as outlined in section 2.6. All 
experiments were performed in duplicate.  
 
2.5 Stimulation assay  
Cells were seeded in six well plates in standard medium and incubated at 37oC, 8% 
CO2. After 16 h, medium was removed and cells were serum starved in FBS-free 
medium for 4-6 h. Medium was removed and cells were treated with FBS-free 
medium supplemented with PD173074 (Sigma-Aldrich) at a final concentration of 2 
μM, 1 µM AZD4547 (AstraZeneca, UK) or the equivalent volume of DMSO for control 
wells, for 1 h. 300 ng/mL heparin (Sigma-Aldrich) was added to each well and cells 
were stimulated with 100 ng/mL FGF2 (PeproTech) for 15 and 60 min. After 1 h, 
cells were lysed and protein isolated as outlined in section 2.6. All experiments were 
performed in triplicate.  
 
2.6 Western blotting  
Cell lysates were prepared using radioimmunoprecipitation assay (RIPA) buffer 
(Millipore) supplemented with protease inhibitor (Millipore) and phosphatase inhibitor 
(Millipore) at a dilution of 1:100. Protein concentration was then determined with a 
BioRad DC protein assay (BIORAD, Reagent A; Reagent B; Reagent S) according to 
the manufacturer’s instructions. Equal concentrations of denatured protein at 20-40 
μg were loaded onto 4-12% NuPage Bis-Tris pre-cast gels (Invitrogen). After protein 
separation by electrophoresis, proteins were transferred to a nitrocellulose 
membrane (GE Healthcare) for 4 h at 4oC, run at 44 V. Membranes were blocked in 
5% milk in phosphate buffered saline (PBS) (Fisher Scientific) at room temperature 
for 30 min and then incubated with primary antibody in 3% BSA/PBS overnight at 
4oC. All antibodies were rabbit polyclonal at a dilution of 1:1000 unless otherwise 
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stated: anti-Actin (goat polyclonal; Santa Cruz, sc-1615), anti-AKT (Cell Signalling 
Technology, 9272S), anti-Calnexin (Cell Signalling Technology, 2433S), anti-
Cyclophilin A (Abcam, ab58144), anti-ERK (Millipore, 06-182), anti-FGFR1 (rabbit 
monoclonal; Cell Signalling Technology, 9740S), anti-FGFR2 (Santa Cruz, sc-122), 
anti-FRS2 (Santa Cruz, sc-8318), anti-HSC70 (mouse monoclonal; Santa Cruz, sc-
7298), anti-P-AKT (Ser473) (Cell Signalling Technology, 9271S), anti-P-ERK 
(Thr202/Tyr204) (Cell Signalling Technology, 9101S), anti-P-RFS2 (Cell Signalling 
Technology, 3861), anti-PHLDA1 (Sigma-Aldrich, HPA019000-100UL).  
 
Membranes were incubated with HRP-conjugated secondary antibodies for 1 h at 
room temperature. All secondary antibodies were obtained from Dako. Specific 
protein bands were visualised using Amersham Enhanced chemiluminescence 
(ECL) Western Blotting Detection Kit (GE Healthcare) and photographic film (Super 
RX).   
 
All washes after primary and secondary antibody incubations were performed in 
0.1% Tween20-TBS (TBST) (Applichem) for 3 x 5 min. Densitometric analysis was 
performed using ImageJ 1.429 software (National Institutes of Health), Microsoft 
Excel (2007) and Prism (v5.03). Where phospho-antibodies were used, signal 
density was normalised to the total protein level, unless otherwise stated. Signal 
density was normalised to the anti-actin, anti-HSC70, anti-calnexin or anti-cyclophilin 
A level as a loading control/reference in all other western blots.  
 
2.7 2D cell survival assay and generation of FGFR-inhibitor resistant cell lines  
Cells were seeded in their respective culture medium, as detailed previously, in 12 
well plates at the following densities: MFE-296 9 x 103, AN3CA 1 x 104 and Ishikawa 
9 x 103. After 24 h, the relevant concentration of inhibitor or DMSO control was 
added. Medium was changed every 2-3 d. After 7 or 14 d, cells were detached from 
the well using trypsin/EDTA and cells counted manually under a light microscope 
using a haemocytometer. All experiments were performed in triplicate. The MFE-
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296PDR cell line was generated by treating MFE-296 cells with 5 µM PD173074 
continuously. MFE-296AZR cells were generated by treating MFE-296 cells with 2.5 
µM AZD4547.  
 
2.8 3D physiomimetic model  
This was modified from previously published protocols (Chioni and Grose, 2012, 
Coleman et al., 2014). Organotypic cultures were prepared as shown in Figure 1.9 A. 
The stromal extracellular matrix (ECM) equivalent was composed of 70% 3.48 
mg/mL collagen type I (BD Bioscience) and 30% Matrigel (BD Bioscience), (80% of 
the final volume of the ECM). 10x Hanks buffer (Sigma-Aldrich) was added to the 
mix (10% of the final volume) and the pH adjusted to 7.4 using 2 M NaOH. HFF2 
cells were re-suspended in FBS (10% of the final volume), at 5 x 105 cells/mL and 
added to the mix. The final mixture was added to a 24-well plate (1 mL/well) and 
incubated at 30oC, 8% CO2 for 4 h to polymerise. The gels were equilibrated by 
immersion in DMEM for 16 h, whereupon the medium was replaced by 1 mL culture 
medium containing 1 x 106 endometrial cancer cells/mL. Cells were left to adhere to 
the gel at 37oC, 8% CO2 for 16 h.  
 
250 μL collagen mix (7 vol collagen type I, 1 vol each of 10x Hanks buffer, FBS and 
culture medium neutralized with 2 M NaOH) was added drop-wise onto 400 mm2 
Nylon membranes (100 μm pore; Tetko, Inc.). Membranes were incubated at 37oC 
for 15 min, fixed in 1% glutaraldehyde (Sigma-Aldrich) in PBS and incubated at 4oC 
for 1 h. After fixation, the membranes were washed 3 x for 5 min with PBS and 
incubated for 16 h in culture medium at 4oC. The coated membranes were placed on 
25 mm2 sterile stainless steel grids in 6 well plates. Gels were lifted from the 24 well 
plate and laid on top of the coated membranes. An appropriate amount of culture 
medium supplemented with either 2 μM PD173074, 1 μM AKTVIII (Sigma-Aldrich), 1 
μM MK2206 (Selleckchem), 2 μM PD173074 in combination with 1 μM AKTVIII or 
MK2206 or the equivalent volume of DMSO, for control wells, was added to each 
well until it reached the lower part of the gel, so that cultures were maintained at the 
air-liquid interface. 5 µM PD173074 was used for MFE-296PDR cell cultures. Fresh 
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inhibitor or DMSO was added to the medium at each medium change. In all cases, 
medium was changed every 2-3 d. At the relevant time point, gels were fixed in 10% 
neutral buffered formalin (CellPath) for 16 h at 4oC. After fixation, gels were washed 
thoroughly in PBS, bisected and dehydrated in 70% ethanol before paraffin 
embedding. Each treatment was performed in biological duplicates or triplicates with 
one to three technical replicates of each.  
 
The mini organotypic model was prepared as shown in Figure 1.9 B. All reagents 
and cells were used in the same ratio but in a total volume of 120 µL. 200 µl of the 
Matrigel/collagen mix containing 6.25 x 104 HFF2 cells was added to the insert of a 
Transwell in a 24 well plate. Gels were equilibrated by immersion in DMEM for 2 h, 
after which the medium was replaced with 200 µL medium containing 1.25 x 105 
endometrial cancer cells. Cells were left to adhere to the gel at 37oC, 8% CO2 for 16 
h, upon which medium was removed and the inserts placed into a new 24 well plate. 
350 µL medium containing the relevant drug or vehicle control was added to the 
base of the well. Medium was changed every 2-3 d and gels removed, formalin fixed, 
paraffin embedded and sectioned as previously described.  
 
The mini organotypic procedure was modified where stated by fully submerging the 
Transwell insert throughout drug treatment. All other parameters were kept constant.  
 
2.9 Immunofluorescence  
Four μm paraffin sections of organotypic cultures were dewaxed in xylene, 
rehydrated through a graded ethanol series and transferred to PBS. Antigens were 
retrieved by microwaving in 10 mM citrate buffer (pH 6) for 20 min. Sections were 
washed 3 x with PBS, blocked for 1 h at room temperature with 6% BSA/PBS and 
incubated with anti-Ki67 primary antibody (rabbit, 1:200; AbCam, ab15580) diluted in 
6% BSA/PBS for 1 h at room temperature.  
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After incubation with primary antibody, cells were washed 3 x for 5 min in PBS and 
incubated with a secondary antibody conjugated with FITC (goat anti-rabbit IgG 
(H+L)-FITC; 1:200; Invitrogen, A11008) diluted in 6% BSA/PBS for 1 h at room 
temperature. Cells were washed 3 x in PBS for 5 min and a final wash of H2O was 
performed. Finally, slides were mounted using aqueous mounting medium 
supplemented with 4’, 6-diamidino-2-phenylindole (DAPI) (Life Technologies). 
Hematoxylin-eosin (H&E) staining was performed by the BCI Pathology service, 
according to standard procedures.  
 
2.10 Microscope image acquisition  
Confocal images were acquired at room temperature using a confocal microscope 
(LSM510 Axio; Carl Zeiss). Images were taken using a Plan Apochromat 40x 
objective, 1.3 oil differential interference contrast M27. Immersol 518 F (Carl Zeiss) 
was used as an imaging medium. The acquisition software used was ZEN 2011 
(Carl Zeiss). Thresholds were set per slide and kept constant for all images 
analysed.  
 
Bright-field images were acquired at room temperature using a light microscope 
(Axiophot; Carl Zeiss) connected to a camera (AxioCam HRz; Carl Zeiss). The 
objective used was Plan Neofluar with 10x magnification and 0.3 aperture. The 
acquisition software used was AxioVision Release 4.8 (Carl Zeiss).  
 
2.11 Data analysis  
In all experiments, excluding those using MS, all quantitative data are presented as 
means ± standard errors. Statistical significance was determined with Student’s t 
test.  
 
Cell number and percentage Ki67 staining in the confocal images of organotypic 
cultures were analysed using ImageJ 1.429 software. Six random fields of each 
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organotypic culture, and three fields of each mini organotypic culture, were analysed. 
Percentage Ki67 staining was calculated as Ki67 positive cells as a percentage of 
the total number of cells (DAPI stained nuclei) per field of view. An average was 
taken from the multiple fields per slide. 
 
2.12 Isolation, purification, growth and maintenance of primary cells, and cell 
immortalisation  
Endometrial tissue was collected from a healthy uterus after hysterectomy (collaboration with 
Dr Michelle Lockley, Barts Cancer Institute, Barts Gynae Tissue Bank ethics number 
10/H0304/14). Tissue was transported on ice, washed in 70% ethanol for 20 s and 
subsequently washed three times in RPMI-1640 medium (RPMI; Sigma-Aldrich) 
supplemented with 5% FBS. Tissue was dissected into 1mm3 pieces and added to 15 mL 
RPMI supplemented with 1% FBS. Tissue was digested in a final volume of 0.05% trypsin 
and 0.01% EDTA in PBS, incubated at 37oC for 1 hour with rotation at 200 rpm. Digestion 
was stopped by dilution with RPMI + 1% FBS. The cell suspension was then centrifuged at 
380 x g for 5 min. The supernatant was removed and the remaining tissue/cell pellet was re-
suspended in RPMI + 1% FBS and passed through a 40 μm cell strainer (BD Biosciences) to 
remove undigested tissue. The supernatant was collected and centrifuged at 380 x g for 5-
10 min at room temperature. The pellet was re-suspended in RPMI + 1% FBS and cells 
were counted as described in section 2.1.  
 
Epithelial cell isolation was achieved using Epcam-coated magnetic beads (Invitrogen). 
Beads were washed in 10 mL RPMI + 1% FBS and placed on a magnet for 2 min. The 
supernatant was removed and the process repeated using 5 mL and 2 mL of medium, 
respectively. Finally, supernatant was removed and beads re-suspended in 100 μL of RPMI 
+ 1% FBS.  
 
Based on personal recommendation (collaboration with Dr Jenny Gomm, Barts Cancer 
Institute), it was assumed 50% of these cells were epithelial. Bead solution was added in a 
1:1 ratio of beads:target cells where 2.5 μL of bead solution is equivalent to 1x106 beads. 
Beads:target cell suspension was incubated at 4oC for 20 min. The suspension was then 
placed on a magnet for 2 min. The supernatant, containing non-epithelial cells, was removed 
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and stored in freezing medium containing RPMI supplemented with 40% FBS and 6% 
DMSO at -80˚C for one day, then transferred to liquid nitrogen for long term storage. The 
bead:target cell mixture was then re-suspended in RPMI + 1% FBS in a final volume of 1 
mL. The suspension was centrifuged at 380 x g for 5 min and the pellet re-suspended in 
freezing medium and stored as per the epithelial fraction.  
 
Isolated cells were then cultured as an adherent monolayer in sterile tissue culture 
flasks at 37oC and 8% CO2. Cells were grown in DMEM:F12 (50:50) (Sigma-Aldrich) 
supplemented with 10% FBS, 10% Pen Strep (Invitrogen), 0.25 μg/mL fungizone 
(Invitrogen), 0.5 ng/mL hydrocortisone (Sigma-Aldrich), 2.5 ng/mL insulin (Sigma-
Aldrich), 0.1 ng/mL epidermal growth factor (EGF) (Sigma-Aldrich) and 10 ng/mL 
Apo-transferrin (Sigma-Aldrich).  
 
HEK293T cells were seeded in a T175 flask and allowed to reach 90% confluence. 
50 μg vector construct, 17.5 μg pMD.G2 envelope plasmid (Addgene 12259) and 
32.5 μg pCMVΔ8.74 packaging plasmid (Addgene 22036) were added to 6 mL 
OptiMEM and mixed with a further 6 mL OptiMEM plus 1 μL 10 mM Polyethylenimine 
(PEI). The solution was incubated for 20 min at room temperature. Medium was 
removed from cells and 12 mL of the PEI/DNA complex was added. Cells were 
incubated at 37oC, 5% CO2 for 3 h, after which medium was removed and replaced 
with 15 mL DMEM and 10% FBS. Medium change was repeated after 24 h. Cell 
supernatant was harvested at 48 and 72 h and centrifuged at 3400 x g for 10 min at 
room temperature. The supernatant was removed and passed through a 0.22 μm 
filter (Millex). Virus was concentrated by centrifugation at 23000 x g for 2 h at 4oC. 
Supernatant was removed and tubes inverted for 2 min, after which 50 μL OptiMEM 
was added. The suspension was incubated on ice for 1 h under intermittent agitation. 
Concentrated virus was stored at -80oC.  
 
Primary cells, isolated from endometrial tissue, were seeded in a six well plate in 1 
mL media and 20 μL of concentrated virus. Cells were incubated at 37oC, 5% CO2 
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for 3 d. Cells were transferred to a T25 flask and medium was changed every 5-7 d. 
Cells were split as per section 2.1.              
 
2.13 Mass spectrometry  
2.13.1 Cell culture  
MFE-296 cells were plated at 7 x 105 per 10cm plate in their appropriate culture 
medium, as previously outlined earlier in this chapter. After 16 h, an appropriate 
amount of fresh culture medium was added to untreated (UT) control plates, 
supplemented with DMSO as a vehicle control, or 2 μM PD173074 (PD). Medium 
was changed every 2-3 d. Cells were lysed at 1, 7 or 14 d. Experiments were 
performed in duplicate.  
 
2.13.2 Cell lysis, digestion and solid-phase extraction  
Cells were washed with PBS supplemented with 1 mM Na3VO4 (Sigma-Aldrich) and 
0.5 mM NaF (Sigma-Aldrich) on ice. Cells were lysed in 8 M urea in 20 mM HEPES 
(Sigma-Aldrich) (pH 8.0) supplemented with 100 mM Na3VO4, 0.5 M NaF, 1 M β-
Glycerol Phosphate (Sigma-Aldrich) and 0.25 M Na2H2P2O7 (Sigma-Aldrich). Lysates 
were sonicated on ice at 50% intensity 3 x for 15 s followed by centrifugation for 10 
min at 4oC. Protein concentration in the supernatant was determined using Bradford 
assay reagent (Sigma-Aldrich) according to the manufacturer’s instructions. 
Cysteines were reduced using 1 M dithiothreitol (DTT) (Sigma-Aldrich) with 30 min 
incubation at room temperature in darkness. Samples were subsequently alkylated 
by addition of 415 mM iodoacetamide (IAM) (Sigma-Aldrich) and incubated at room 
temperature for 30 min in darkness. Samples were diluted 1:4 with 20 mM HEPES to 
a final volume of 4 mL. Proteins were digested using immobilized trypsin beads (GL 
Sciences) re-suspended in 20 mM HEPES. Samples were incubated at 37oC for 16 
h with constant agitation. Trypsin was removed by centrifugation and the resultant 
peptide solutions desalted by reversed solid-phase extraction with OASIS HLB 
cartridges (Waters Corp.) using a vacuum manifold (P = 5.0 inHg, ± 0.5). Digested 
sample peptides were kept on ice during desalting but were allowed to equilibrate to 
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room temperature prior to loading into the OASIS cartridge.  Cartridges were 
conditioned with 1 mL 100% acetonitrile (ACN) (Sigma-Aldrich) and columns 
equilibrated by purging of 1 mL 1% ACN + 0.1% TFA followed by 0.5 mL of 1% ACN 
+ 0.1% trifluoroacetic acid (TFA) (Sigma-Aldrich). Samples were loaded into the 
corresponding cartridge and purged at a low flow rate. Columns were subsequently 
washed with 1 mL 1% ACN + 0.1% TFA and desalted peptides then eluted 0.5 mL 1 
M glycolic acid (50% ACN, 5% TFA).  
 
2.13.3 TiO2 Metal Oxide Affinity Chromatography (MOAC)  
Phosphopeptides were enriched using MOAC by TiO2. Desalted peptides were 
normalised to 1 mL with 1 M glycolic acid and incubated with 50 μL TiO2 beads, re-
suspended in 1% TFA, at room temperature with constant agitation for 5 min. TiO2 
beads were re-suspended in 4 x 200 μL supernatant and loaded into Glygen TopTips 
(Glygen) previously washed with 100% ACN. The samples in spin tips were 
centrifuged. Unbound peptides were discarded and beads were sequentially washed 
with 1M glycolic acid, 100 mM ACN and 2 x 10% ACN, centrifuging between each 
wash. Bound peptides were eluted from the beads, washing with 4 x 5% NH4OH 
(10% ACN) followed by centrifugation. Samples were snap-frozen on dry ice, 
vacuum dried overnight and stored at -80oC.  
 
2.13.4 Nanoflow-liquid chromatography tandem mass spectrometry (LC-
MS/MS)  
Immediately prior to LC-MS analysis, samples were reconstituted with 20 μL 50 nM 
enolase peptide digest and dissolved in 5% ACN + 0.1% TFA, followed by bath 
sonication for 15 min at room temperature and centrifugation for 5 min at 5oC. The 
supernatant was recovered for LC-MS analysis.  
 
Phosphopeptide LC separations were carried out on a Dionex Ultimate 3000 nRSLC 
system with an Acclaim PepMap RLSC C18 Analytical Column (75 μm x 25 cm, 
2μm, 100Å) (Thermo Scientific) and an Acclaim PepMap 100 C18 Trap Column (100 
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μm x 2 cm, 5 μm, 100Å) (Thermo Scientific). Solvent A consisted of 2% ACN + 0.1% 
formic acid (FA). Solvent B was made up of 80% ACN + 0.1% FA. Sample injections 
of 3 μL were loaded onto the trap column at a flow rate of 8 μL.min-1 for 5 min. Once 
loaded, samples were eluted over an 85 min gradient from 6.3% to 43.8% solvent A. 
Following elution, the column was cleaned with 90% solvent B for 10 min, and 
subsequently equilibrated with 6.3% solvent A for 10 min.  
 
All analyses were completed on a Thermo Scientific LTQ Orbitrap-Velos hybrid 
instrument, operated in data-dependent acquisition (DDA) mode. In the DDA method 
used, a full MS1 survey scan (m/z 350-1500) was performed at a resolution of 30000 
FWHM (at m/z 400) and the ions analysed in the Orbitrap. The top seven most 
intense multiply charged precursor ions present in the MS1 scan were automatically 
mass-selected and fragmented by collision-induced dissociation (CID – normalised 
collision energy = 35%) with multi-stage activation enabled, and analysed in the 
LTQ-Velos linear ion trap (m/z 190-2000). Neutral losses of 98, 49, 32.7 and 24.5 
were accounted for (representing differentially charged phosphate losses) and 
dynamic exclusion was enabled (avoiding repeat analysis of identical precursor ions 
within a 60 min window). Samples were run in duplicate.  
 
2.13.5 Identification and quantification of phosphopeptides  
Mascot Daemon and Distiller (v2.3.0.0 and v2.4.2.0 respectively, Matrix Science) 
were used in conjunction to automate the conversion of Thermo Scientific .raw files 
to MS2 smoothed and centroided peak lists (.mgf files) and to search the peak lists 
against the Uniprot/Swissprot human database. LTQ Orbitrap-Velos data were 
searched using the following criteria: ±10 ppm precursor and ±600 mmu fragment 
ion m/z tolerances; enzyme = trypsin (2 missed cleavages tolerated); fixed 
modification: carbamidomethyl (C); variable modifications: gln→pyro-glu (N-term Q), 
oxidation (M), phospho (ST), and phospho (Y). 
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Phosphopeptide identification data produced by Mascot search engine results were 
collated using a combination of a Perl script (Barts Cancer Institute, London) and 
Peptide ANalysis and Database Assembly (PANDA) software (v1.1), (Barts Cancer 
Institute, London). The data were algorithmically curated to include only unique 
phosphopeptide ions with a q-value ≤ 0.05 (calculated via comparison to searches 
against a randomised database). All phosphopeptides with a Mascot delta score < 
10 were reported as ‘Protein (residues), charge, modification(s)’. All those with a 
score ≥ 10 were reported as the specific phosphorylation site.  
 
Phosphopeptides were quantified using PEak Statistical CALculator (PESCAL) Barts 
Cancer Institute, London) (Cutillas and Vanhaesebroeck, 2007). This automatically 
generates extracted ion chromatograms (XIC) for the first three isotopes of each 
phosphopeptide ion within the created database (± 7 ppm m/z tolerance, ± 1.5 min 
retention time tolerance, isotope correlation > 0.8), subsequently calculating the peak 
heights of each constructed XIC. Peak heights for each phosphopeptide ion were 
log2-transformed and quantile normalised. Each of the phosphopeptide ions was 
then fitted to a linear model, and the difference in magnitude and statistical 
significance between conditions calculated using an empirical Bayes shrinkage of 
standard deviations (Smyth, 2004). The resulting p-values were then multiple-testing 
corrected using the Benjamini-Hochberg procedure. All of the described analysis 
was performed using the limma package (v3.16.2) within the R statistical computing 
environment (v3.0.0). Data were processed further and analysed within Microsoft 
Excel (2007/2010) and R (v3.1.2). Kinase Substrate Enrichment Analysis (KSEA) 
was performed as previously described (Casado et al., 2013b).  
 
2.14 Cell tracker  
Cells were seeded in T175 tissue culture flasks at 40% confluence and incubated for 
16 h at 37oC, 8% CO2. Medium was removed and cells were washed with sterile 
PBS. Medium was replaced with standard culture medium supplemented with 1 
µL/mL of the relevant CellTracker fluorescent dye (Invitrogen). Cells were incubated 
at 37oC for 30 min, after which cells were detached from the surface of the flask and 
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counted using a haemocytometer, as outlined in section 2.1. MFE-296 and MFE-
296PDR cells were re-seeded at a 1:1 ratio (4.5 x 104 cells each) on 35 x10 mm glass 
bottomed plates (SPL Life Sciences) and were incubated at 37oC, 8% CO2 for 16 h. 
Following incubation, cells were treated with 5 µM PD173074, 1 µm MK2206, 
PD173074 in combination with MK2206, or DMSO as a vehicle control. Cells were 
monitored on a Confocal microscope every day for four days. Confocal images were 
acquired at room temperature using a confocal microscope (LSM510 Axio; Carl 
Zeiss). Images were taken using a Plan Apochromat 40x objective, 1.3 oil differential 
interference contrast M27. Immersol 518 F (Carl Zeiss) was used as an imaging 
medium. The acquisition software used was ZEN 2011 (Carl Zeiss). Thresholds were 
set per slide and kept constant for all images analysed. Images of six random fields 
were taken. Cell number of each population was quantified using ImageJ, Microsoft 
Excel and Prism. Experiments were performed in duplicate or triplicate.  
 
2.15 Receptor tyrosine kinase (RTK) and signalling node phosphoprotein 
immunofluorescence assay 
Cells were seeded on 10cm plates to be 70% confluent the following day. Cells were 
lysed and a slide-based Immunofluorescence assay performed using the PathScan 
RTK Signalling Antibody Array Kit (Cell Signalling Technology) according to the 
manufacturer’s instructions. Slides were read using an ODYSSEY SA Infrared 
Imaging System (Li-COR) with excitation at 680 nm and detection at 700 nm. Spot 
intensities were quantified using ImageJ software and data analysed in Microsoft 
Excel and Prism.  
 
2.16 Microarray  
MFE-296, MFE-296PDR and MFE-296AZR cells were seeded on T75 tissue culture 
flasks at 40% confluence. After 16 h incubation at 37oC, 8% CO2, total RNA was 
extracted using the RNeasy Plus RNA extraction kit (QIAGEN) according to the 
manufacturers instructions. From this, cDNA was synthesised using the first-strand 
cDNA synthesis using SuperScript II reverse trascriptase  kit (Invitrogen) according 
to the manufacturer’s instructions. cDNA of two biological replicates of each cell line 
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was then sent for microarry gene expression analysis using the Illumina platform at 
Barts Genome Centre. Each sample was run on the array in duplicate. The resulting 
data were analysed using Genome Studio, Microsoft Excel and Prism software.  
 
2.17 Fractionation  
Cells were seeded in 10 cm dishes and incubated at 37oC, 8% CO2 for 16 hr. Cells 
were then washed in PBS and lysed in hypotonic buffer consisting of 20 mM Tris-HCl 
(pH 7.5) (Sigma-Aldrich), 10 mM MgCl2 (Sigma-Aldrich), 5 mM (EDTA) (Sigma-
Aldrich), 250 μM sucrose (Sigma-Aldrich) and 200 μM phenylmethylsulphonyl 
fluoride (PMSF) (Sigma-Aldrich). Cells were incubated on ice for 15 min. Lysates 
were then centrifuged at 100000 x g for 1 h at 4oC. Supernatants (cytosolic fraction) 
were transferred to a fresh tube and pellets (membrane fraction) were re-suspended 
in hypertonic buffer. Western blot analysis with the relevant antibodies was then 
performed as described in section 2.6.  
 
2.18 Short interferring RNA (siRNA) knockdown  
Cells were seeded in six well plates in standard medium. The following day, at 
approximately 40% confluence, the medium was removed and replaced with 1 mL of 
standard medium. Cells were transfected with either a pool of four siRNA 
oligonucleotides targeting FGFR2 or PHLDA1 (GE Healthcare) at a final 
concentration of 10 nM. Control cells were transfected with a pool of non-targeting 
siRNA at the same concentration. Transfection was achieved using INTERFERin 
(Polyplus). INTERFERin and siRNA complexes were prepared in OptiMEM (Gibco 
By Life Technologies), vortexed and incubated at room temperature for 20 min 
before the total mixture was added to cells in culture medium. Cells were incubated 
for 48 or 120 h before cell lysis and confirmation of knockdown by western blot 
(section 2.6).  
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2.19 PHLDA1 over expression  
Cells were seeded in a T75 flask at 40% confluence in standard medium. The 
following day, medium was removed and cells were washed with PBS. OptiMEM 
was warmed to 37oC and 5 mL added to each flask. For transfection control wells, 1 
μg/μL pmaxGFP (pGFP) (Lonza)  was added to 1.25 mL OptiMEM in a Falcon tube. 
A second Eppendorf tube containing 25 μL Lipofectamine 2000 (Invitrogen) with 1.25 
mL OptiMEM was prepared and both solutions incubated at room temperature for 5 
min. The contents of both tubes were then mixed and incubated at room temperature 
for 20 min. The total volume was then added to control flasks and incubated at 37oC 
for 4 hours. Medium was then removed and replaced with standard culture medium 
and cells incubated at 37oC for 16 h.   
 
The PHLDA1 plasmid with GFP fluorescent tag was a gift from Richard C. Austin 
(Addgene 32699). For pPHLDA1 transfection, 1 μg/μL of plasmid was added to 1.25 
mL OptiMEM and mixed with the Lipofectamine 2000 preparation as above and 
added to the cells. After 16 h, flasks were inspected under UV light for GFP 
expression. Cells were lysed and PHLDA1 levels analysed via western blot, as 
outline in section 2.6.  
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Chapter 3 
Results: Endometrial cancer cell line 
characterisation and model development 
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3.1 Introduction  
Whilst approximately 16% of endometrial cancers harbour FGFR2 mutations, little is 
known about their importance in driving progression of this tumour type (Byron et al., 
2008, Byron et al., 2012, COSMIC, 2014). As these same FGFR2 mutations are 
known to be integral to the aetiology of a range of developmental syndromes, for 
example craniosynostoses, their characterisation in endometrial cancer is of utmost 
importance (Dutt et al., 2008, Jemal et al., 2011, Pollock et al., 2007). The effect of 
targeting FGFR2 mutant tumours with small molecule inhibitors is of particular 
interest, given the abundance of such drugs currently in clinical trials for other cancer 
types (Clinicaltrials.gov, 2014). A thorough investigation of the phenotypic and 
mechanistic effects of these mutations, and the effects of targeted drug treatment, 
should be considered in the context of other cell types and compared to FGFR2 wild 
type endometrial cells. Of particular importance is the characterisation of the effects 
of these drugs over a prolonged period, given the prevalence of acquired resistance 
to these inhibitors seen in carcinomas of other tissues (Flaherty et al., 2010, Holohan 
et al., 2013, Wagle et al., 2011).  
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3.2 Endometrial cancer cell line characterisation  
To establish the role of mutant FGFR2 in endometrial cancer, three endometrial 
cancer cell lines were selected (Table 3.1). Two cell lines, MFE-296 and AN3CA, 
harbour the N550K FGFR2 mutation (COSMIC, 2014), which results in constitutive 
activation of kinase activity (Byron et al., 2008). Both of these cell lines also display 
the FGFR2 IgIII loop mutation K310R (COSMIC, 2014), suggested in previous 
studies to be a passenger mutation with no obvious phenotype (Dutt et al., 2008). 
Both cell lines are heterozygous for the N550K and K310R mutations (Pollock et al., 
2007) 
 
The MFE-296 cell line also possesses one copy of the activating PIK3CA mutation 
P539R (COSMIC, 2014, Gymnopoulos et al., 2007, Konstantinova et al., 2010, 
Weigelt et al., 2013), and is heterozygous for the I20M PIK3CA mutation of unknown 
consequence (COSMIC, 2014, Weigelt et al., 2013). The inactivating R130Q and 
N323 frameshift (fs) PTEN mutations are also expressed in MFE-296 cells 
(COSMIC, 2014, Han et al., 2000, Weigelt et al., 2013).  
 
Whilst the AN3CA cell line is R130fs*1 PTEN mutant, the PIK3CA locus is wild type 
(Byron et al., 2008, COSMIC, 2014). The AN3CA cell line is, however, heterozygous 
for the PI3K regulatory subunit R557_D560del mutation, which can interfere with 
PTEN binding (Cheung et al., 2011, COSMIC, 2014, Van Allen et al., 2014).  
 
The Ishikawa cell line, which expresses wild type FGFR2 (Byron et al., 2013, 
COSMIC, 2014), multiple inactivating PTEN mutations (COSMIC, 2014, Weigelt et 
al., 2013) and a PI3K regulatory subunit mutation (COSMIC, 2014, Weigelt et al., 
2013) was used as a control. The mutation status of FGFR2, PTEN and PIK3CA in 
each cell line was confirmed by Sanger sequencing (Table 3.1, Appendix Figures 
1.1-1.4).  
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Table 3.1. FGFR2, PTEN, PIK3CA and PIK3R1 mutation status of endometrial cancer 
cell lines 
 
Mutations listed in COSMIC as of January 2015.  
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To establish the levels and activation of various proteins under basal conditions, it is 
common to serum starve cells overnight. However, serum starvation can induce 
cellular stress responses, consequently leading to changes in protein abundance 
(Pirkmajer and Chibalin, 2011). Because of this, the effect of serum starvation on 
MFE-296 and AN3CA cells was assessed via western blot (Figure 3.1). ERK 
phosphorylation (P-ERK) returned to levels seen in full serum culture conditions after 
16 hours serum starvation in both MFE-296 and AN3CA cells. P-ERK levels reached 
basal levels between four and six hours starvation. On this basis, all further 
experiments requiring serum starvation were performed after culturing for four to six 
hours in serum-free medium.  
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Figure 3.1. Effect of serum starvation on basal signalling in FGFR2 mutant 
endometrial cancer cell lines.  
Cells were cultured in serum free medium for one to 16 hours, or full serum for 16 hours as a 
control. A decrease in ERK phosphorylation was observed up to eight hours in MFE-296 
cells. Minimum P-ERK levels of AN3CA cells were reached at between two and four hours. 
P-ERK levels increased to full serum levels after 16 hours in both cell lines. As a result, all 
subsequent experiments requiring serum starvation were performed after four to six hours of 
serum starvation. 20 µg protein was used for each lane. Protein bands are representative of 
two independent experiments.  
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Expression levels of all isoforms of FGFR1-4 in MFE-296 and AN3CA cell lines were 
established via PCR (Table 3.2, Appendix Figure 1.5). Expression of FGFR1 
isoforms IIIa, IIIb and IIIc was apparent in both cell lines, while only isoforms IIIa and 
IIIc of FGFR2 were expressed. Neither MFE-296 nor AN3CA cells expressed either 
isoform of FGFR3. FGFR4 was expressed in both cell lines.  
 
FGFR1 and FGFR2 expression in all endometrial cancer cell lines was also 
established at the protein level (Figure 3.2). The efficacy of the FGFR2 antibody was 
validated via siRNA knockdown of FGFR2 (Appendix Figure 1.6). There was no 
significant difference in FGFR1 levels between the three cell lines (Figure 3.2 A and 
B, left panel). AN3CA cells expressed the highest levels of FGFR2, followed by the 
MFE-296 and Ishikawa cell lines, respectively (Figure 3.2 A and B, left panel). There 
was no significant difference in FGFR2 levels between MFE-296 and Ishikawa cells 
(Figure 3.2 A and B, right panel).  
 
Basal levels of various important signalling nodes downstream of FGFR2 activation 
were also evaluated. FRS2 phosphorylation (P-FRS2) was lower in Ishikawa cells 
than in FGFR2 mutant cell lines, as was the total FRS2 protein level (Figure 3.2 A 
and C, left panel). Basal ERK phosphorylation was significantly higher in AN3CA 
cells than the MFE-296 and Ishikawa cell lines (Figure 3.2 A and C, middle panel). 
Baseline AKT phosphorylation (P-AKT) was equivalent across all three cell lines 
(Figure 3.2 A and C, right panel).  
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Table 3.2. FGFR isoform expression profile 
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Figure 3.2. Baseline expression of FGFR1, FGFR2 and downstream signalling 
molecules in endometrial cancer cell lines. 
Cells were starved in serum free medium for six hours. There was no significant difference in 
FGFR1 levels between the three cell lines (A and B, left panel). AN3CA cells expressed 
significantly higher levels of FGFR2 than both MFE-296 and Ishikawa cells; there was no 
significant difference in FGFR2 expression between MFE-296 and Ishikawa cell lines (A and 
B, right panel). FRS2 phosphorylation was lower in Ishikawa cells than in MFE-296 and 
AN3CA cell lines, as was total FRS2 protein level (A and C, left panel). ERK phosphorylation 
was significantly higher in the ANC3A cell line than in MFE-296 and Ishikawa cells (A and C, 
middle panel). There was no significant difference in AKT phosphorylation between any of 
the endometrial cancer cell lines (A and C, right panel). *, P ≤0.05; **, P ≤0.01; ***, P ≤0.001 
(Student’s t test). 20 µg protein was used for each lane. Error bars show means ± SEM of 
three replicates. 
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3.3 Differential signalling in the presence and absence of FGFR inhibition in 
endometrial cancer cell lines  
Given that FGFR inhibitors are currently in clinical trials for a range of cancer types 
(Clinicaltrials.gov, 2014), we sought to establish the differential effects of FGFR 
inhibition in endometrial cancer cells. Two FGFR inhibitors were used: PD173074, 
an FGFR-targeted small molecule inhibitor tool compound (Knights and Cook, 2010) 
and AZD4547, another ATP-competitive inhibitor currently in clinical trials for 
FGFR2-mutant solid tumours (Clinicaltrials.gov, 2014, Gavine et al., 2012).  
 
The effect of increasing concentration of PD173074 (10-10000 nM) on cell number in 
2D culture over seven days was assessed in all three cell lines (Figure 3.3 A). Cell 
number decreased with increasing inhibitor concentration in both FGFR2 mutant cell 
lines (Figure 3.3 A, left and middle panels ). The AN3CA cell line was more sensitive 
to PD173074 treatment than the MFE-296 cell line, with cell number reduced to 50% 
of the DMSO control at approximately 100 nM PD173074 in AN3CA cells compared 
to approximately 5000 nM in MFE-296 cells. 50 nM to 500 nM PD173074 increased 
Ishikawa cell number, after which cell number remained broadly constant, regardless 
of increasing PD173074 concentration (Figure 3.3 A, right panel).  
 
MFE-296 cells were further interrogated with 5 nM to 5000 nM of the more potent 
AZD4547 (Figure 3.3 B). The effect of this drug on cell number was comparable to 
that observed with PD173074 (Figure 3.3 A, left panel and B).  
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Figure 3.3. Effect of FGFR inhibition on endometrial cancer cell number in 2D culture.  
MFE-296, AN3CA and Ishikawa cells were treated with increasing concentrations of 
PD173074 (10-10000 nM) for seven days, after which cells were counted using a 
haemocytometer and cell number as a percentage of the DMSO control calculated. (A and 
B) Cell number was decreased with increasing PD173074 concentration in both FGFR2 
mutant cell lines. The AN3CA cell line was more sensitive to FGFR inhibition with a 50% 
reduction in DMSO control-normalised cell number at 100 nM compared to 5000 nM in MFE-
296 cell. Cell number was increased at 500 nM PD173074 compared to 50 nM in Ishikawa 
cells, after which cell number remained broadly constant, irrespective of treatment with 
PD173074 concentration. (B) Treatment of MFE-296 cells with increasing concentration of 
AZD4547 (5-5000 nM) recapitulates PD173074 treatment. Arrows indicate the concentration 
of inhibitor used in subsequent 2D and 3D experiments (2 µM PD173074, 1 µM AZD4547). 
Error bars show means ± SEM of three replicates. 
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To assess the effect of FGFR2 stimulation and inhibition on cell signalling, cells were 
treated with 100 ng/ml FGF2 for 15 or 60 minutes, either in the presence of 
PD173074 or AZD4547, or DMSO as a vehicle control (Figure 3.4 A and B 
respectively). FGF2 was chosen since it efficiently activates the IIIc variants of 
FGFR1 and FGFR2, which are expressed by the tumour cells (Table 3.2).  
 
FGF2 stimulation activated the ERK pathway in all cell lines, indicated by increased 
ERK phosphorylation on threonine and tyrosine residues; this was inhibited upon 
FGFR inhibition (Figure 3.4 A and B, top panels). The extent of inhibition varied 
between cell lines, with near complete abolition of ERK phosphorylation in AN3CA 
cells (Figure 3.4 A and B, top and middle panels).  
 
FGF2 treatment also increased AKT signalling in MFE-296 cells; whilst this was 
decreased following FGFR inhibition, the effect was not significant (Figure 3.4 A and 
B, top and bottom panels). However, in AN3CA and Ishikawa cells, the AKT pathway 
was unaffected by FGF2 stimulation. AKT phosphorylation (P-AKT) on serine 473 
(ser473) was decreased in AN3CA cells upon PD173074 treatment, while AKT 
signalling in Ishikawa cells was unaffected by FGFR inhibition. Overall, comparable 
data were observed between PD173074 and AZD4547 treated cells across all cell 
lines.  
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Figure 3.4. Effect of FGF2 stimulation and FGFR2 inhibition on cell signalling.  
Cells were serum-starved for six hours and stimulated with 100 ng/mL FGF2 in the presence 
of 300 ng/mL heparin in serum-free medium for 15 and 60 min. Where indicated, cells were 
pre-treated with 2 μM PD173074 or 1 μM AZD4547 (one hour). Stimulation of all cell lines 
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activated the ERK pathway; this was inhibited by PD173074 and AZD4547. FGF2 
stimulation also increased AKT phosphorylation in MFE-296 cells; AKT signalling was 
unaffected by stimulation in the AN3CA and Ishikawa cell lines. FGFR inhibition decreased 
AKT phosphorylation in the MFE-296 and AN3CA cell lines; AKT phosphorylation was 
unaffected by PD173074 or AZD4547 treatment in Ishikawa cells. 20 µg protein was used 
for each lane. Error bars show means ± SEM of three replicates. *, P≤0.05; **, P ≤0.01 
(Student’s t test). 
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3.4 Primary cell line immortalisation  
Whilst all analysis of the effect of FGFR inhibition in endometrial cancer cell lines has 
been performed on FGFR2 mutant cells and wild type cells as a control, another 
important consideration is the effect of such drug treatment on normal epithelial cells. 
However, such endometrial cells are not commercially available, so benign primary 
tissue was obtained and primary cell culture attempted.  
 
Endometrial tissue was taken from a 46 year old pre-menopausal patient after 
abdominal hysterectomy and bilateral salpingo-oophorectomy due to the presence of 
fibroids and menorrhagia. Pathological investigation showed the tissue to be benign 
(Figure 3.5 A).  
 
Cell culture of non-malignant primary cells is often hindered by the limited 
proliferative capabilities of diploid cells (Hayflick and Moorhead, 1961). As such, their 
culture often leads to immediate cell death or senescence after only a few of rounds 
of the cell cycle (Condon et al., 2002). Because of this, an attempt to immortalise the 
primary endometrial cells was undertaken using lentiviral infection with polycomb 
group RING finger protein 4 (BMI-1), a polycomb protein that suppresses cyclin-
dependent kinase inhibitor 2A (p16), thereby preventing cellular senescence (Guney 
et al., 2006, Silva et al., 2006).  
 
Epithelial and stromal cells were extracted from the endometrial tissue using an 
affinity bead-based method (Gomm et al., 1995). Both primary cell fractions were 
then cultured separately on plastic. The BMI-1 lentivirus was prepared by 
transfection of the lentivirus plasmid (pFCRu), with BMI-1 and a puromycin 
resistance cassette under control of a ubiquitous promoter (Feng et al., 2010), into 
HEK293T cells alongside pMD.G2 envelope and pCMVΔ8.74 packaging plasmids. 
The supernatant was harvested after 48 and 72 hours, from which the fully packaged 
BMI-1 lentivirus was isolated. Primary cells were then transduced using this 
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concentrated virus. A sub fraction of epithelial and stromal cells were not infected 
with the lentivirus and were cultured on plastic as a control.  
 
After approximately one week, these slow growing non-transduced primary cells 
began lifting off the culture plate. BMI-1 lentivirus infected cells remained adhered to 
the plate; however, the morphology of the epithelial cell fraction became more 
mesenchymal-like (Figure 3.5 B). To assess whether these cells had undergone 
epithelial to mesenchymal transition (EMT), epithelial cells were stained for the 
mesenchymal marker vimentin, as were stromal primary cells as a control (Figure 
3.5 C). Cells from both fractions stained positive for vimentin, indicating a transition 
to a mesenchymal phenotype in the epithelial cell fraction. As EMT subsequently 
changes the signalling characteristics of cells (Lamouille et al., 2014), these cells 
could not be used in the comparison of non-malignant epithelial cells and FGFR2 
mutant endometrial cancer cells.  
 
Cells from the stromal fraction were cultured for potential use in the analysis of 
endometrial cancer cells in a 3D environment (Section 3.5). However, these slow 
growing cells stopped proliferating after approximately two weeks of culture and 
were therefore unavailable for use.  
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Figure 3.5. Immortalisation of non-malignant primary endometrial tissue.  
Tissue was taken from a pre-menopausal patient following abdominal hysterectomy and 
bilateral salpingo-oophorectomy due to fibroids and menorrhagia. (A) Pathological 
investigation showed the tissue to be benign. (B) Tissue was homogenised and epithelial 
and stromal cells were separated. The resulting cell fractions were cultured separately. To 
immortalise these non-malignant cells, cells were infected with fully packaged BMI-1 
lentivirus. Primary epithelial cells showed mesenchymal morphology approximately one 
week post infection with BMI-1 lentivirus. (C) Cells from both the epithelial and stromal 
fractions were stained for the mesenchymal marker, vimentin. Epithelial cells stained positive 
for vimentin expression, indicating EMT had taken place. Original magnification of H&E 
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image, 10X objective; bar, 100 µm. Original magnification of bright field image, 10X 
objective; bar 100 µm. Original magnification of confocal images, 40X objective; bar, 25 µm. 
Confocal images representative of three images acquired from imaging of one biological 
replicate.  
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3.5 Development of a 3D organotypic model to investigate endometrial cancer 
cell behaviour   
To investigate the effect of FGFR inhibition in a more physiologically relevant form, a 
3D organotypic model was developed. This consisted of a collagen/Matrigel mix with 
human foreskin fibroblasts (HFF2) embedded, acting as a stromal equivalent in the 
absence of immortalised non-malignant endometrial stromal cells. Gels were 
overlaid with MFE-296, AN3CA or Ishikawa cells and raised to an air-liquid interface. 
Cultures were treated for seven or 14 days in the presence of PD173074 or DMSO 
vehicle control (Figure 1.9 A).  
 
Preliminary investigations showed the optimum ratio of HFF2:endometrial cancer 
cells to be 1:2 and so this ratio was used throughout (Appendix Figure 1.7). Analysis 
of the effect of FGFR inhibition on HFF2 cell number in 2D culture showed there was 
no significant change with increasing PD173074 concentration (Figure 3.6). Previous 
work has also successfully used this cell line in stromal matrices of breast cancer cell 
models (Chioni and Grose, 2012).  
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Figure 3.6. Effect of PD173074 on fibroblasts in 2D culture.  
HFF2 cells were treated with increasing concentrations of PD173074 for seven days, after 
which cells were counted using a haemocytometer and cell number as a percentage of the 
DMSO control calculated. FGFR inhibition did not induce cell death in FGFR2 wild type 
HFF2 cells. Arrow indicates the concentration of inhibitor used in subsequent 2D and 3D 
experiments. Error bars show means ± SEM of three replicates. 
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Hematoxylin and eosin (H&E) staining showed that endometrial cancer cells did not 
invade into the stroma in either control or PD173074 treated cultures (Figure 3.7 A-
C, top panels). Ki67 staining (green) was used to assess proliferation in all cultures 
(Figure 3.7 A-C, middle panels). MFE-296 cell number and proliferation decreased 
significantly in PD173074 treated cells compared to the DMSO control after seven 
days (Figure 3.7 A, left panels). However, while cell number in PD173074 treated 
cultures remained lower relative to the control, there was no significant difference in 
the percentage of cells capable of proliferation after 14 days, as indicated by Ki67 
staining (Figure 3.7 A, right panels). Thus, after 14 days, a potentially inhibitor 
resistant population of cells was established. In contrast, treatment of AN3CA cells 
with PD173074 led to cell death after seven days (Figure 3.7 B). To ensure this 
effect was due to induction of cell death upon FGFR signalling inhibition, and not the 
result of the inability of this cell line to adhere to the stromal equivalent layer in the 
presence of the drug, cultures were assessed after three days (Figure 3.8). These 
data showed adhesion of AN3CA cells to the stromal layer, as well as decreased cell 
number upon drug treatment.  
 
There was no significant difference between PD173074 and control treated Ishikawa 
cell number or proliferation rate after either seven or 14 days (Figure 3.7 C), 
suggesting that FGFR inhibition specifically affects FGFR2 mutant cell lines.  
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Figure 3.7. Effect of FGFR2 inhibition on endometrial cancer cells in a 3D 
physiomimetic model.  
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An endometrial cancer cell model was designed using a collagen/Matrigel mix, containing 
HFF2 cells as a stromal equivalent, overlaid with either MFE-296, AN3CA or Ishikawa cells. 
Organotypic cultures were raised to an air-liquid interface and cultured for seven or 14 days 
in the presence of 2 μM PD173074 or DMSO control. (A) After seven days PD173074 
treatment of MFE-296 cells, cell number was decreased (left panels). H&E staining showed 
endometrial cancer cells did not invade into the stroma (top panel). Sections were stained 
with Ki67 (green) to identify cell proliferation. Proliferation decreased following seven days 
treatment with PD173074. Cell number in PD173074 treated cells also decreased compared 
to the DMSO vehicle control at 14 days, however, there was no significant difference in 
proliferation. An inhibitor-resistant population of MFE-296 cells was apparent. (B) Treatment 
of AN3CA cells with PD173074 led to cell death after seven days. (C) FGFR2 inhibitor 
treatment did not affect cell number or proliferation of Ishikawa cells after either seven or 14 
days. n.s., not significant (P >0.05); ***, P ≤0.001 (Student’s t test). Nuclei were stained with 
DAPI (blue). Original magnification of H&E images, 10X objective; bar, 100 µm. Original 
magnification of confocal images, 40X objective; bar, 25 µm. Error bars show means ± SEM. 
Data points represent the average cell number/percentage of Ki67 positive cells of six fields 
of view of one to three technical replicates of three biological replicates. Cell number and 
percent Ki67 positive cells represents average values per field of view.  
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Figure 3.8. AN3CA cells adhere to the stromal equivalent layer in a 3D organotypic 
model in the presence of PD173074.  
Cultures were prepared as in Figure 3.7. AN3CA cells adhered to the stromal equivalent in 
the 3D endometrial cancer model in the presence of PD173074. Cell number was decreased 
in the presence of the FGFR inhibitor. Nuclei were stained with DAPI (blue). Proliferating 
cells were visualised using the Ki67 marker (green). Original magnification of H&E images, 
10X objective; bar, 100 µm. Original magnification of confocal images, 40X objective; bar, 25 
µm. Images representative of three technical repeats of one biological replicate. Six fields of 
view per replicate were analysed.   
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These data, showing the emergence of an FGFR inhibitor resistant population of 
MFE-296 cells, were further interrogated using a mini organotypic model (Figure 1.9 
B). Firstly, the validity of this alternative mini model was assessed by repetition of the 
experiment outlined in Figure 3.7 using MFE-296 cells (Figure 3.9). In this model, 
cell number was decreased compared to the DMSO control after both seven and 14 
days (Figure 3.9 A). There was no significant difference in the percentage of cells 
positive for Ki67 staining after 14 days, recapitulating the data obtained in the 
original model, where an inhibitor resistant population of MFE-296 cells was 
apparent.  
 
The effect of the AZD4547 inhibitor in this mini 3D model was then assessed (Figure 
3.9 B). Treatment of MFE-296 cells with AZD4547 gave strikingly similar results to 
those seen in the PD173074-treated cultures (Figures 3.7 A and 3.9 A), thereby 
demonstrating the emergence of an FGFR inhibitor resistant population using two 
independent FGFR-targeted small molecule inhibitors.  
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Figure 3.9. The emergence of a drug resistant population in FGFR inhibitor treated 
MFE-296 cells.  
An endometrial cancer cell model was designed using a collagen/Matrigel mix containing 
HFF2 cells as a stromal equivalent, overlaid with MFE-296 cells in a Transwell insert, 
respecting the cell ratios previously outlined. Cells were cultured at an air-liquid interface for 
seven or 14 days in the presence of an FGFR inhibitor or DMSO control. (A) Cell number 
was significantly decreased in cultures treated with 2 µM PD173074 for seven and 14 days. 
There was no significant difference in the percentage of cells positive for Ki67 staining 
(green) in PD173074 treated cells compared to the DMSO control at either seven or 14 
days. (B) Whilst cell number was decreased in cultures treated with 1 µM AZD4547, there 
was no significant difference in the percentage of cells positive for the Ki67 proliferation 
marker. In both PD173074 and AZD4547 treated cultures, an inhibitor resistant population 
was identified. n.s., not significant (P >0.05); *, P ≤ 0.05; ***, P ≤0.001 (Student’s t test). 
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Nuclei were stained with DAPI (blue). Original magnification of H&E images, 10X objective; 
bar, 100 µm. Original magnification of confocal images, 40X objective; bar, 25 µm. Error 
bars show means ± SEM. Data points represent the average cell number/percentage of Ki67 
positive cells of three fields of view of one to three technical replicates of three biological 
replicates. Cell number and percent Ki67 positive cells represents average values per field of 
view.  
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Further investigation of the validity of this model and the resulting data were 
assessed via modification of the culture conditions. It is well established that 
endometrial cancer metastasis to the ovaries can occur through endometrial cancer 
cell implantation as a result of retrograde menstruation (Kurman and Shih Ie, 2011). 
In our organotypic model, cancer cell invasion is not observed. However, as this 
cancer type can spread via the budding off of malignant cells from the endometrium 
into the menstrual fluid, from where cell implantation on the ovaries can occur, the 
propensity of these cancer cells to behave in this way, and the effect of FGFR 
inhibition on this, was assessed.  
 
Using the mini organotypic model, MFE-296 cell cultures were set up as outlined 
previously (Figure 1.9 B). However, medium was also added to the Transwell insert 
so the organotypic culture was fully immersed. Cells were treated with PD173074 or 
DMSO as a control and cell number and proliferating cells assessed using H&E and 
Ki67 staining (Figure 3.10 A). In this model, the viability of cells collected from the 
medium and found adhered to the bottom of the plate was also assessed, using 
trypan blue staining (Figure 3.10 B).  
 
These cultures showed the same trend as previous data with regards to cell number 
and percentage of  Ki67 positive cells after 14 days, where an inhibitor resistant 
population of cells was established upon PD173074 treatment (Figure 3.10 A). 
Trypan blue staining showed that, while there was no significant difference in the 
number of cells either free in the medium or adhered to the well of the plate after 
seven days, the viability of these cells was significantly decreased upon FGFR 
inhibitor treatment (Figure 3.10 B, left panels). However, while the number of free 
cells in the media and adhered to the plate was decreased after 14 days inhibitor 
treatment, there was no significant difference in the percentage of viable cells 
between those which were control and PD173074 treated, indicating the emergence 
of an inhibitor resistant population of free cells in the media and adhered to plastic 
outside of the organotypic culture (Figure 3.10 B, right panels).  
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Figure 3.10. Effect of FGFR inhibitor treatment on free circulating cells in a 3D model.   
Cultures were prepared as outlined in Figure 3.9 using MFE-296 cells. However, the 
experimental conditions were modified so that the cultures were fully submerged in medium 
containing either 2 µM PD173074 or DMSO as a control. After either seven or 14 days, 
cultures were assessed for cell number and Ki67 staining as previously detailed. Culture 
medium was also collected, as were cells adhered to the plate, via trypsinisation. These two 
populations were then pooled and the number of cells counted using a haemocytometer. 
Trypan blue staining was used to assess viability of these cells. (A) Cell number was 
significantly decreased upon PD173074 treatment compared to the DMSO control at both 
seven and 14 days. However, a resistant population of MFE-296 cells emerged that retained 
their proliferative capability, as shown by Ki67 staining (green). (B) There was no significant 
difference in the number of free cells in the culture medium or adhered to the plate between 
drug or control treated cultures after seven days. However, free cells from PD173074 treated 
cultures were less viable than DMSO treated cells (left panels). After 14 days, this trend was 
reversed, whereby free cell number was decreased in FGFR inhibitor treated cultures 
compared to the control; the viability of these free cells was the same regardless of drug 
treatment. An inhibitor population of free cells was identified. n.s., not significant (P >0.05); *, 
P ≤0.05; **, P ≤0.01; ***, P ≤0.001 (Student’s t test). Nuclei were stained with DAPI (blue). 
Original magnification of H&E images, 10X objective; bar, 100 µm. Original magnification of 
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confocal images, 40X objective; bar, 25 µm. Error bars show means ± SEM. Data points 
represent the average cell number/percentage of Ki67 positive cells of three fields of view of 
one to three technical replicates of three biological replicates. Cell number and percent Ki67 
positive cells represents average values per field of view.  
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3.6 Summary of results  
o The MFE-296 cell line harbours FGFR2, PTEN and PIK3CA mutations; the 
AN3CA cell line harbours FGFR2, PTEN and PIK3R1 mutations; the Ishikawa 
cell line harbours PTEN and PIK3R1 mutations  
o Minimal signalling levels in MFE-296 and AN3CA cells are achieved by four to 
six hours of serum starvation  
o Both MFE-296 and AN3CA cell lines express the FGFR2IIIc isoform  
o AN3CA cells have higher baseline expression levels of FGFR2 and P-ERK 
than MFE-296 and Ishikawa cells; MFE-296 and AN3CA cells have higher P-
FRS2 levels than Ishikawa cells  
o AN3CA cells are more sensitive to FGFR inhibition than MFE-296 cells in 2D 
culture; FGFR inhibition does not decrease cell number in Ishikawa cell 
cultures  
o The AZD4547 small molecule inhibitor has a similar effect on cell number of 
MFE-296 cells as PD173074  
o ERK and AKT pathways are stimulated in response to FGF2 in FGFR2 
mutant cell lines; the inhibitory effect of FGFR targeted drug treatment on 
these pathways is greater in AN3CA cells  
o Primary epithelial cell immortalisation using BMI-1 lentivirus infection leads to 
EMT  
o Development of a 3D organotypic model of endometrial cancer allowed 
analysis of the effects of prolonged drug treatment on cell number and 
proliferation  
o 3D modelling confirmed the sensitivity of AN3CA cells to FGFR inhibition  
o Ishikawa cell proliferation was unaffected by FGFR inhibition  
o Treatment of MFE-296 cells with an FGFR inhibitor led to the selection of an 
inhibitor resistant population  
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 3.7 Discussion  
In these initial investigations, we provide new insight into the significance of FGFR2 
mutations in endometrial cancer. We have established differences in oncogene 
addiction between FGFR2 mutant cell lines using two small molecule inhibitors, 
providing evidence that in some cases, as seen in AN3CA cells, FGFR2 inhibition 
alone was sufficient to induce cell death throughout the cancer cell population. 
However, a drug resistant population was established in another FGFR2 mutant cell 
line, MFE-296, after prolonged FGFR inhibitor treatment. Importantly, the effects of 
small molecule inhibition outlined in these data were FGFR2 mutation status 
dependent, as shown by the absence of growth inhibition of the FGFR2 wild-type 
Ishikawa cell line.  
 
Differential signalling of endometrial cancer cells  
Previous studies have used PD173074 treatment to investigate the effect of FGFR 
inhibition on endometrial cancer cell lines (Dutt et al., 2008, Byron et al., 2008, Byron 
et al., 2013). Where 2D cell proliferation was measured, the findings were consistent 
with our data, showing that AN3CA cells are more sensitive to FGFR inhibition than 
MFE-296 cells (Dutt et al., 2008, Byron et al., 2008). Similarly, a recent study has 
shown that the IC50 of PD173074 was higher in MFE-296 cells than the AN3CA cell 
line (Byron et al., 2013), further validating their differential response to FGFR 
inhibition.  
 
As both MFE-296 and AN3CA cell lines harbour the same FGFR2 mutation, N550K, 
it is interesting that differences in signalling response are invoked upon FGFR 
inhibition (Byron et al., 2008, Byron et al., 2013). Recent work has debated the 
status of N550K as a gatekeeper mutation (Byron et al., 2013). However, as cell 
lines harbouring this mutation have varying responses to FGFR inhibition, it is 
possible that, rather than N550K conferring innate resistance to receptor inhibition, 
the effect of drug treatment in mutant cell lines varies depending on relative addiction 
to oncogenic FGFR2 signalling (Sharma and Settleman, 2007). For example, our 
initial signalling data show that baseline FGFR2 and P-ERK levels are higher in the 
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AN3CA cell line compared to those observed in MFE-296 cells, suggesting that the 
AN3CA cell line has evolved to preferentially depend on the effects of this particular 
mutation.  
 
Cell line immortalisation  
Ideally, the effects of tumourigenic mutations would be compared to non-malignant 
cells arising from the same tissue of origin. However, primary cell culture of such 
tissue is difficult and so induced immortalisation is particularly useful. One method 
commonly used is transfection of human telomerase reverse transcriptase (hTERT) 
expression vectors, whereby hTERT transfection of primary cells maintains telomere 
length and thereby extends their cell culture lifespan (Bodnar et al., 1998, Condon et 
al., 2002, Dickson et al., 2000, Fanning, 1992, Farwell et al., 2000, Morales et al., 
1999, Vaziri et al., 1999). However, this method has limitations, for example over-
expression of hTERT can compromise regulation of cell differentiation 
(Georgopoulos et al., 2011). While such epithelial cells of endometrial origin are not 
commercially available, one laboratory has reported successful generation of such 
cells via transfection of hTERT alongside human papilloma virus (HPV) E7 to 
overcome telomere-independent senescence (Kyo et al., 2003). Collaboration was 
attempted with the only laboratory still in possession of these cells. However, upon 
their receipt, they were found to have undergone EMT. For this reason, we began 
attempts to generate our own immortalised non-malignant endometrial cell lines.  
 
A potential alternative to hTERT transfection is induction of BMI-1 expression in 
primary cells (Douillard-Guilloux et al., 2009, Fulcher et al., 2009). BMI-1 is a 
polycomb protein that suppresses p16 and therefore enhances cell survival (Guney 
et al., 2006, Silva et al., 2006). This protein has been shown to be required for self-
renewal of stem cells in a range of tissues, such as lung epithelial stem cells 
(Zacharek et al., 2011). As such, it is an attractive candidate for use in 
immortalisation of non-malignant primary cells. Early work using lentiviral induced 
expression of a combination of both hTERT and BMI-1 showed a normal diploid 
karyotype over 15 passages (Fulcher et al., 2009). Indeed, BMI-1 expression via 
128 
 
lentivirus infection has been observed by other members of Barts Cancer Institute to 
result in immortalised cells with superior karyotypic stability over 20 passages 
compared to those transfected with hTERT (personal communication – Dr Tyson 
Sharp). Lentiviral technology is particularly useful in this context as it is a robust 
method of achieving long-term expression of a transgene in vitro (Kumar and Woon-
Khiong, 2011).  
 
Non-malignant endometrial tissue was obtained following hysterectomy and both 
epithelial and stromal cells were isolated and prepared for lentiviral transfection of 
BMI-1. After approximately one week of cell culture post-infection, the epithelial cells 
began displaying a mesenchymal morphology and EMT was confirmed by vimentin 
staining. The propensity of BMI-1 to induce EMT has recently been documented (Li 
et al., 2014) and so it is possible that this process was induced as a result of the 
immortalisation method employed. Whilst immortalised stromal cells behaved as 
expected, they did not adhere to the plastic culture dish for longer than two weeks. 
Due to limitations on the availability of non-malignant endometrial tissue, repetition of 
primary cell immortalisation was not possible. However, future attempts of stromal 
cell immortalisation should assess the effect of coating culture plates with collagen 
prior to cell culture to increase efficiency of cell attachment and proliferation.  
 
Identification of an FGFR-inhibitor resistant population of MFE-296 cells using 
a 3D organotypic model  
The use of 3D cell culture models has been used to great effect in delineating cell-
cell interactions as well as the phenotypic consequences of drug treatment in a 
range of cancer types (Chioni and Grose, 2012, Coleman et al., 2014, Froeling et al., 
2009, Mauchamp et al., 1998, Nystrom et al., 2005, Sakamoto et al., 2001, 
Sanderson et al., 1996, Vukicevic et al., 1990). An in vitro model of endometrial 
cancer has been lacking and so we set out to establish such organotypic cultures.  
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One advantage of the organotypic model is the ability to assess the effect of drug 
treatment over prolonged time periods. Our 3D culture model identified the 
differential effects of FGFR inhibitor treatment on two FGFR2 mutant cell lines, which 
were consistent with our previous 2D culture data. The importance of mutant FGFR2 
in the AN3CA cell line was demonstrated by induction of cell death upon FGFR 
inhibition after seven days.  
 
The reduced sensitivity of MFE-296 cells to FGFR inhibition, demonstrated in 2D 
culture, was recapitulated in the organotypic model. Most interestingly, while cell 
number was decreased upon PD173074 and AZD4547 treatment, compared to the 
DMSO control, the beginnings of an inhibitor resistant population remained after 14 
days and retained its ability to proliferate. The specificity of these data to FGFR2 
mutant cell lines was demonstrated using the FGFR2 wild type Ishikawa cell line. 
The absence of cell growth and proliferation inhibition in Ishikawa cells suggests the 
effects observed in the FGFR2 mutant cell lines are due to blockade of aberrant 
FGFR2 signalling rather than off target effects of the inhibitor.  However, further 
validation using additional cell lines should be performed in the future to confirm the 
specificity of the effect to FGFR2 mutant cells.  
 
Similar organotypic models have been used to evaluate the invasive capacity of a 
range of cancer cell types (Chioni and Grose, 2012, Coleman et al., 2014). Our 
model did not show invasion of endometrial cancer cells into the stromal equivalent 
layer. However, endometrial cancer cell metastasis can occur through retrograde 
menstruation and subsequent implantation of endometrial cells in, for example, the 
ovaries (Kurman and Shih Ie, 2011). Therefore, the model was modified to 
encompass this possibility and to assess the effect of FGFR inhibition on this mode 
of migration.  
 
Full submersion of the organotypic cultures in medium showed the ability of MFE-
296 cells to bud from the organotypic culture and either remain free in the medium or 
re-adhere to the culture plate. After 14 days of FGFR inhibition, free and re-adhered 
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cell number was decreased; however, the viability of these cells, relative to the 
DMSO treated control cultures, was demonstrated using trypan blue staining. These 
data, as with those from the supporting organotypic models of MFE-296 cells, show 
the establishment of an FGFR inhibitor resistant population.  
 
Whilst the 3D culture was useful in assessing the effects of drug treatment on 
endometrial cancer cells and could be modified to answer a range of questions, the 
model was time consuming. As such, it may be of more value to proceed with 2D 
culture experiments in the future, especially as we have shown the results thus far 
can be recapitulated in both systems. This would allow for analysis of more cell lines 
and use of more small molecule inhibitors in a similar timeframe.  
 
Emergence of drug resistant clones of cancer cells in a population can be acquired 
through a number of mechanisms, from up-regulation of efflux proteins to rewiring of 
signalling cascades to compensate for inhibition of an important pathway (Ambudkar 
et al., 1999, Faratian et al., 2009, Flaherty et al., 2010, Goltsov et al., 2011, Goltsov 
et al., 2012, Gottesman et al., 2002, Wagle et al., 2011). To fully understand the 
potential of FGFR inhibitors in treatment of FGFR2 mutant endometrial cancer, as 
well as assess viable strategies to overcome this observed resistance, the 
mechanism underlying the development of this population was subsequently 
explored (Chapters 4 and 5).  
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Chapter 4 
Results: Investigation of FGFR inhibitor 
resistance in MFE-296 cells   
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4.1 Introduction  
Small molecule inhibition of FGFR signalling in FGFR2 mutant endometrial cancer 
has been postulated as a viable therapeutic target (Byron et al., 2008, Dutt et al., 
2008, Konecny et al., 2013). However, as resistance to both chemotherapy and 
hormone therapy is common in recurrent endometrial cancer, and acquired and 
intrinsic resistance to small molecule inhibitors have been documented in other 
carcinomas (Chell et al., 2013, Goltsov et al., 2012, Goltsov et al., 2011, Lito et al., 
2013, Wagle et al., 2011, Zhang et al., 2009), the efficacy of prolonged FGFR-
targeted therapy is an important area of study.  
 
Drug resistance remains one of the biggest challenges in cancer therapeutics 
(Holohan et al., 2013). To overcome this, we require a greater understanding of how 
resistance is acquired and need to view cell signalling as an interconnected network, 
capable of rewiring upon inhibition of the dominant signalling pathways. To dissect 
the changes in an intracellular signalling network, it is essential to have an unbiased, 
quantitative and well-validated assay. MS-based phosphoproteomics has previously 
been reported as a tool capable of identifying signalling pathways that contribute to 
intrinsic resistance to targeted therapies (Alcolea et al., 2012, Casado et al., 2013a, 
Casado and Cutillas, 2011, Casado et al., 2013b). This technique could also, in 
principle, be used to define potential compensatory pathways that could be targeted 
alongside FGFR inhibition.  
 
Initial data assessing the effect of FGFR inhibition in FGFR2 mutant endometrial 
cancer showed one cell line acquired resistance to drug treatment over 14 days 
exposure to an FGFR-targeted small molecule inhibitor. To investigate the 
mechanism of this resistance, MS was employed. Measuring signalling networks 
using global phosphoproteomics should allow us to: (i) further understand the 
plasticity of signalling networks upon perturbation of one of their components and (ii) 
define compensatory pathways in drug resistant cell lines.  
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4.2 Phosphoproteomic investigation of resistance acquisition in MFE-296 cells  
An unbiased phosphoproteomic approach was adopted to investigate the mode of 
resistance to FGFR inhibition in MFE-296 cells. Cells were treated with PD173074 
(PD), DMSO vehicle control (DMSO) or left untreated (UT) for one, seven or 14 days 
in 2D culture, after which MS was used to assess changes in the global 
phosphoproteome (Figure 4.1).  
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Figure 4.1. Workflow of MS employed to detect changes in the phosphoproteome of 
MFE-296 cells upon inhibition of FGFR signalling.   
Cells were cultured for one, seven and 14 days in the presence of PD173074, DMSO as a 
vehicle control, or were left untreated. Cells were then lysed and digested into their 
constituent peptides by trypsinisation. The resulting peptide mixture was enriched for 
phosphopeptides via MOAC using TiO2 affinity beads. The phosphopeptide fraction was 
then run through the MS. A full MS1 survey scan was performed; the top seven most intense 
multiply charged precursor ions were automatically mass selected and fragmented by CID-
MSA and analysed in the LTQ-Velos linear ion trap. Two biological replicates of each 
condition were run through the MS in duplicate. Phosphopeptides were identified using the 
Mascot search engine and quantified using PESCAL.  
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We identified a total of 6706 unique phosphopeptide ions (i.e. phosphorylation sites) 
across four replicates (two biological and two technical). The false discovery rate 
(FDR) was <1% for 95% of identifications and <5% for the remainder (Appendix 
Figure 1.8 A). A previously described, well established, label-free methodology was 
used to identify (Mascot) and quantify (PESCAL) the phosphorylation sites (Alcolea 
et al., 2012, Casado et al., 2013a). After quantile normalisation (Appendix Figure 1.8 
B and C), statistical analysis was performed.  
 
Hierarchical clustering of the average intensities of the resulting phosphorylation 
motifs was used to assess the similarity of the phosphoproteome across the time 
points and treatments (Figure 4.2 A). The resulting dendrogram showed all 
treatments at one day (blue) and 14 days (orange) clustered together, indicating a 
high degree of similarity between the intensities of phosphopeptides identified in 
these samples. However, the seven day PD173074 treatment (green) clustered 
away from the DMSO and UT controls at the same time point, as well as from all 
samples at one and 14 days. This indicated that the seven day treatment of MFE-
296 cells with PD173074 induced a change in the global phosphoproteome of this 
cell line that was distinct from the DMSO or UT samples.  
 
Of the 6706 phosphopeptides identified, 525 were significantly up- or down-regulated 
in the PD samples compared to the DMSO control for at least one time point 
(adjusted P <0.05). These phosphopeptides were grouped according to their 
temporal profile (Figure 4.2 B, left panel), with 412 down-regulated at seven days, 
but returning to baseline levels after 14 days of exposure to PD173074 (Figure 4.2 B, 
clusters 1 and 2). An increase in the log2 fold-ratio of 104 phosphopeptides was 
induced after seven days, which returned to baseline levels after 14 days PD173074 
treatment (Figure 4.2 B, cluster 3). Clustering analysis also identified nine 
phosphopeptides whose abundance was stable at one and seven days, but 
increased after 14 days PD173074 treatment compared to the DMSO control (Figure 
4.2 B, cluster 4, Figure 4.3).  
137 
 
Interestingly, FGFR inhibition did not induce a significant change in the 
phosphoproteome compared to the DMSO control after one day of exposure to 
inhibitor (Figure 4.2 B). This lack of phenotypic change upon one day of FGFR 
inhibition in MFE-296 cells was confirmed in our 3D organotypic model (Figure 4.4). 
Cultures were prepared as detailed in Figure 1.9 A and treated with 2 µM PD173074 
or a DMSO control for one day, upon which cultures were formalin fixed and 
sectioned for histochemical and immunohistochemical analysis. There was no 
significant difference in cell number or proliferation (Ki67 staining, green) in MFE-296 
cells after seven days of drug treatment.  
 
To determine kinase activity from these data, the 525 significantly changed 
phosphopeptides were analysed using Kinase Substrate Enrichment Analysis 
(KSEA) (Casado et al., 2013b) (Figure 4.2 B, middle panel). This analysis allows 
phosphopeptides to be grouped according to their upstream kinase, based on 
annotated kinase-substrate relationships from three, independent databases 
(PhosphoPoint, Phospho.ELM and PhosphoSite). KSEA thus allows inference of the 
activities of kinases active in the system. Analysis of the KSEA output demonstrated 
that phosphopeptides known to be downstream of AKT and AKT-related pathways 
were significantly enriched (according to a hypergeometric t-test) in clusters 1 and 2 
(Figure 4.2 B and C). For example, as well as direct AKT targets, mTOR, 
serine/threonine protein kinase Pim-2 (PIM2) and PIM3 substrates were significantly 
down-regulated at seven days and returned to basal levels at 14 days. All of these 
moecules are associated with AKT signalling (Facchinetti et al., 2008, Inoki et al., 
2002, Meja et al., 2014, Narlik-Grassow et al., 2013, Potter et al., 2002, Sarbassov 
et al., 2005, Wang et al., 2006).  The down-regulation and subsequent re-
establishment of AKT signalling in FGFR inhibitor treated MFE-296 cells indicates 
this pathway may be critical to acquisition of drug resistance in this cell line.  
 
The potential importance of AKT related signalling in establishment of an FGFR 
inhibitor resistant cell line is highlighted further by the nine phosphopeptides that are 
up-regulated at 14 days drug exposure, compared to the DMSO control (Figure 4.2 
B, Figure 4.3). The phosphorylation sites of these peptides could not be identified 
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with absolute certainty, owing to their inadequate fragmentation, i.e. multiple 
potential phosphorylation sites exist closely together within the peptide. Because of 
this, these peptides could not be clustered using KSEA. However, whilst their exact 
phosphorylation site could not be determined, peptide identification could be 
achieved from the MS1 spectra. Of these nine peptides, four of them, poly(rC)-
binding protein 1 (PCBP1), eukaryotic translation initiation factor 4E binding protein 2 
(EIF4EBP2) (two phosphopeptides identified) and Yes-associated protein 1 (YAP1), 
are implicated in AKT signalling (Chaudhury et al., 2010, Hussey et al., 2011, Ma et 
al., 2014, Morita et al., 2013, Roux and Topisirovic, 2012, Song et al., 2014, Zhang 
and Dou, 2014). This further reinforced the potential importance of the AKT pathway 
in FGFR inhibitor resistance acquisition. This was subsequently investigated using 
the 3D organotypic model.  
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Figure 4.2. Phosphoproteomic analysis of FGFR-inhibitor resistance acquisition in 
MFE-296 cells.  
MFE-296 cells were treated with DMSO vehicle control (DMSO), 2 μM PD173074 (PD) or 
untreated (UT) for one, seven or 14 days, after which lysates were collected, tryptic digest 
performed and the resulting peptides enriched for phosphopeptides. MS was employed to 
analyse differences in phosphorylation patterns of peptides upon FGFR inhibition. (A) To 
determine the similarity of phosphorylation patterns across the various treatments and time 
points, hierarchical clustering (Pearson Correlation distance metric) of the average 
intensities of the resulting phosphorylation motifs represented in the phosphopeptides 
identified was employed. The dendrogram shows all treatments at one (blue) and 14 days 
(orange) clustered together, indicating a high degree of similarity between the intensities of 
the phosphopeptides identified in these samples. At seven days (green) the PD sample 
clustered away from the DMSO and UT controls, as well as from all samples at one and 14 
days. Treatment of MFE-296 cells with PD173074 for seven days induced a change in the 
global phosphoproteome of this cell line. (B) MS identified 6706 unique phosphopeptides in 
total across all samples. Of these, 525 were significantly up- or down-regulated in the PD 
samples compared to the DMSO control for at least one time point, and were grouped 
according to their phosphorylation pattern using unsupervised clustering (clusters 1-4; left 
panel). The resulting phosphopeptides were analysed using Kinase Substrate Enrichment 
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Analysis (KSEA) and grouped in a heatmap according to their upstream kinases (middle 
panel). P values of each group are shown as bars (right panel). pPoint, pSite and pELM in 
the heatmap represent the database employed by KSEA to cluster substrates into their 
kinase groups (phosphoPoint, phosphoSite and phospho.ELM respectively). Blue lines in the 
clusters represent individual phosphopeptides; the red lines represent the line of best fit. (C) 
Heatmap of phosphopeptides downstream of AKT which were significantly down-regulated 
at seven days PD173074 treatment, compared to the DMSO control. z indicates number of 
potential phosphorylation sites identified on each peptide; 2 phospho indicates two 
phosphorylation sites were identified on the proceeding residues (S, serine; T, threonine; Y, 
tyrosine); pS118 etc indicates phosphorylation on S or T at the residue indicated by the 
number; Oxi indicates the phosphopeptide was oxidised; numbers preceding protein name 
indicate phosphopeptide length. Data represent average of two technical replicates of two 
biological replicates, i.e. each replicate was run through the MS twice. *, P ≤0.05, **, P 
≤0.01.  
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Figure 4.3. Phosphopeptides showing significant up-regulation after 14 days 
PD173074 treatment.  
Significantly up- or down-regulated phosphopeptides, identified via MS, were clustered 
according to their upstream kinases (Figure. 4.2 B); KSEA analysis was unable to identify 
the upstream kinases of phosphopeptides identified in cluster 4. These phosphopeptides, 
and their up-regulation compared to the DMSO control, are shown in the heatmap. Four of 
these are implicated in AKT signalling (PCBP1, EIF4EBP2 - two phosphopeptides identified, 
YAP). z indicates number of potential phosphorylation sites identified on each peptide; 2 
phospho indicates two phosphorylation sites were identified on the proceeding residues (S, 
serine; T, threonine; Y, tyrosine); M, methionine; N-term Q indicates the N terminus of the 
peptide was a glutamine residue; numbers preceding protein name indicate phosphopeptide 
length.  *, P < 0.05, **, P < 0.01, ***, P < 0.001.  
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Figure 4.4. Effect of FGFR inhibition on MFE-296 cells after one day PD173074 
treatment.  
The 3D organotypic model was prepared as detailed in Figure 1.9 A. MFE-296 cells were 
treated with of 2 μM PD173074 or DMSO control for one day. There was no difference in cell 
number or proliferation, indicated by Ki67 staining (green), between FGFR inhibitor treated 
and control treated cultures. Original magnification of H&E images, 10X objective; bar, 100 
µm. Original magnification of confocal images, 40X objective; bar, 25 µm. Error bars show 
means ± SEM. Data points represent the average cell number/percentage of Ki67 positive 
cells of six fields of view of two to three technical replicates of two biological replicates. Cell 
number and percent Ki67 positive cells represents average values per field of view.  
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4.3 Effect of AKT inhibition alone and in combination with FGFR inhibition in 
MFE-296 cells  
To explore the significance of AKT signalling in FGFR inhibitor resistance, MFE-296 
cells were treated with one of two AKT inhibitors, alone or in combination with 
PD173074, in the 3D organotypic model (Figure 4.5). The AKT inhibitors used were 
AKTVIII, an allosteric AKT1 and 2 inhibitor (Lindsley et al., 2005), and MK2206, 
which allosterically targets AKT1, 2 and 3 (Hirai et al., 2010). Ishikawa cells were 
treated in an identical fashion as a control (Figure 4.6).  
 
Treatment with AKTVIII alone for seven days did not significantly change either cell 
number or the percentage of proliferating cells (Figure 4.5 A). MK2206, alone and in 
combination with PD173074, did significantly reduce cell number over seven days. 
However, only AKTVIII/PD173074 and MK2206/PD173074 treatments led to a 
reduction in the percentage of proliferating cells.  
 
Over 14 days, cell number was decreased upon all drug treatments compared to the 
control (Figure 4.5. B). However, only MK2206, MK2206/PD173074 and 
AKTVIII/PD173074 combination treatments led to a significant reduction in the 
number of cells capable of proliferation compared to the DMSO control. In MK2206 
treated cultures, a distinct cell population remained. In MK2206/PD173074 treated 
cells, few cells remained and thus FGFR and AKT1, 2 and 3 inhibition was sufficient 
to overcome FGFR inhibitor resistance in MFE-296 cells.  
 
Ishikawa cells were largely unaffected by drug treatments, indicating the effects seen 
in MFE-296 cells were potentially FGFR mutation status dependent (Figure 4.6).  
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Figure 4.5. Effect of AKT inhibition, alone and in combination with FGFR inhibition, in 
MFE-296 cells in a 3D physiomimetic model. 
Cultures were prepared as outlined in Figure 1.9 A. (A) MFE-296 cells were treated with 2 
μM PD173074, 1 μM AKTVIII, 1 μM MK2206, 2 μM PD173074 in combination with 1 μM of 
either AKTVIII or MK2206 or DMSO as a control for seven days. Cell number was 
significantly decreased in PD173074, MK2206 and MK2206/PD173074 treated cells 
compared to the DMSO control. Proliferation (Ki67 staining, green) was significantly reduced 
in cultures treated with AKTVIII/PD173074 and MK2206/PD173074 compared to the DMSO 
control. (B) MFE-296 cells were treated as in A for 14 days. Cell number was significantly 
decreased in all cultures compared to the DMSO control. However, cell number was 
significantly higher in cultures treated with AKTVIII compared to all other small molecule 
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inhibitor treated cultures. Cell proliferation was only decreased in MK2206, 
MK2206/PD173074 and AKTVIII/PD173074 treated cultures compared to the DMSO control. 
*, P ≤0.05; **, P ≤0.01; ***, P ≤0.001 (one-way ANOVA). Nuclei were stained with DAPI 
(blue). Original magnification of H&E images, 10X objective; bar, 100 µm. Original 
magnification of confocal images, 40X objective; bar, 25 µm.  Error bars show means ± 
SEM. Data points represent the average cell number/percentage of Ki67 positive cells of six 
fields of view of one to three technical replicates of three biological replicates. Cell number 
and percent Ki67 positive cells represents average values per field of view.  
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Figure 4.6. Effect of AKT inhibition, alone and in combination with FGFR inhibition, in 
Ishikawa cells in a 3D physiomimetic model. 
Cultures were prepared as described in Figure 1.9 A. (A) Ishikawa cells were treated with 2 
μM PD173074, 1 μM AKTVIII, 1 μM MK2206, 2 μM PD173074 in combination with 1 μM of 
either AKTVIII or MK2206 or DMSO as a control for seven days. Cell number was 
significantly decreased in MK2206 cultures compared to AKTVIII/PD173074 treated cells 
only. There was no significant effect on the percentage of cells positive for Ki67 in any 
treatment. (B) Ishikawa cells were treated as in A for 14 days. Cell number was unaffected 
by any of the small molecule inhibitor treatments. There was, however, a significant increase 
in the percentage of cells positive for Ki67 between AKTVIII and MK2206 treated cultures. *, 
P ≤0.05; **, P ≤0.01; ***, P ≤0.001 (one-way ANOVA). Nuclei were stained with DAPI (blue). 
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Original magnification of H&E images, 10X objective; bar, 100 µm. Original magnification of 
confocal images, 40X objective; bar, 25 µm. Error bars show means ± SEM. Data points 
represent the average cell number/percentage of Ki67 positive cells of six fields of view of 
one to three technical replicates of three biological replicates. Cell number and percent Ki67 
positive cells represents average values per field of view.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
148 
 
The reproducibility of these data was examined by seven day treatment of 
organotypic cultures with AKTVIII and MK2206 in combination with 1 µM of the 
FGFR inhibitor AZD4547 (Figure 4.7). In both treatments, cell number and 
proliferation was significantly decreased compared to the control, recapitulating the 
effect of seven day combination treatment with PD173074 (Figure 4.5 A).  
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Figure 4.7. AKT inhibition in combination with the FGFR inhibitor AZD4547, for seven 
days, overcomes FGFR inhibitor resistance in MFE-296 cells.  
Cultures were prepared as outlined in Figure 1.9 B and treated with 1 µM AZD4547 in 
combination with 1 µM AKTVIII (A) or 1 µM MK2206 (B). (A) AKT1 and 2 inhibition, in 
combination with FGFR inhibitor treatment, significantly decreased both cell number and 
proliferation (Ki67 staining, green) after seven days. (B) Inhibition of AKT1, 2 and 3 in 
combination with FGFR signalling significantly reduced both cell number and proliferation. 
These data recapitulate those seen with another FGFR inhibitor, PD173074 (Figure 4.5 B 
and 4.6 B). ***, P ≤0.001 (Student’s t test). Nuclei were stained with DAPI (blue). Original 
magnification of H&E images, 10X objective; bar, 100 µm. Original magnification of confocal 
images, 40X objective; bar, 25 µm. Error bars show means ± SEM. Data points represent 
the average cell number/percentage of Ki67 positive cells of three fields of view of one to 
three technical replicates of three biological replicates. Cell number and percent Ki67 
positive cells represents average values per field of view.  
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4.4 Summary of results  
o MS can be used to delineate changes in signalling upon drug treatment in 
endometrial cancer cells  
o Approximately 7000 phosphopeptides were identified using MS; of these over 
500 were significantly up- or down-regulated in PD173074-treated samples 
compared to the control  
o A change in the phosphoproteome was induced after seven days FGFR 
inhibition; approximately 400 phosphopeptides were significantly down-
regulated compared to the control. These returned to basal levels at 14 days; 
direct substrates of AKT or pathways associated with AKT were enriched in 
this subset of phosphopeptides  
o Nine phosphopeptides were significantly up-regulated after 14 days FGFR 
inhibition. Four of these were implicated in AKT signalling   
o AKT was identified as having a potential role in FGFR inhibitor resistance 
acquisition  
o The 3D organotypic model of endometrial cancer was used to assess the 
effect of AKT inhibition alone and in combination with FGFR inhibition  
o Inhibition of AKT1 and 2 or AKT1, 2 and 3 resulted in generation of an 
inhibitor resistant population  
o Drug combination treatment targeting FGFR and AKT1, 2 and 3 led to cell 
death in FGFR2 mutant endometrial cancer cells  
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4.5 Discussion  
Using an MS phosphoproteomic approach, we have demonstrated the changes in 
signalling networks upon acquisition of FGFR inhibitor resistance in MFE-296 cells, a 
FGFR2 mutant cell line. By investigating this, using an unbiased and quantitative 
approach, we have provided evidence of the importance of AKT signalling in 
acquisition of FGFR inhibitor resistance. Importantly, the effects of small molecule 
inhibition outlined in these data are FGFR2 mutation status dependent, as shown by 
the absence of growth inhibition in the FGFR2 wild-type Ishikawa cell line, in the 
presence of FGFR inhibitor. Thus, we provide evidence of the utility of 
phosphoproteomics in elucidating inhibitor resistance mechanisms and identifying 
viable therapeutic targets. In addition, we have also demonstrated the successful 
use of 2D and 3D cell culture to complement each other in the delineation of cell 
signalling changes upon perturbation of a given pathway.  
 
FGFR inhibition induces a distinct change in the global phosphoproteome of 
MFE-296 cells  
Having established that MFE-296 cells acquire resistance to PD173074 treatment, 
we aimed to identify the underlying changes in cell signalling induced by receptor 
inhibition. To do this, we used MS, comparing the global phosphoproteome of 
PD173074 treated MFE-296 cells to control cells. Utilising this technique, we were 
able to assess differences in the levels of phosphopeptides induced by drug 
treatment in an unbiased manner and investigate the mechanisms that underlie 
resistance to targeted compounds (Casado et al., 2013a, Casado et al., 2013b, 
Cutillas and Vanhaesebroeck, 2007, Alcolea et al., 2012). This highlights the use of 
MS as a tool to elucidate signalling pathways that play a role in adaptation to small-
molecule inhibitor treatment and underscores how this information can be used to 
identify druggable targets to overcome resistance.  
 
Of the 6706 phosphopeptides identified across all samples, changes in the 
abundance of 525 were statistically significant in PD173074 treated samples, 
compared to the DMSO control. Analysis of this subset of phosphopeptides showed 
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the predominant pattern of phosphorylation across the time points in PD173074 
treated cells to be the same as DMSO samples at one day treatment, significant 
down-regulation at seven days drug exposure, and a return to baseline levels at 14 
days. The absence of a significant change in phosphorylation of PD173074-treated 
cells at one day was surprising, given our initial western blot analysis showing 
abrogation of P-ERK and decreased P-AKT after two hours PD173074 treatment of 
MFE-296 cells. However, it was apparent from the MS data that signalling was 
recovered after 24 hours, while constant exposure to PD173074 for seven days 
resulted in changes in the phosphoproteome. This was supported by our 3D 
organotypic analysis, which showed no change in cell number or proliferation of 
MFE-296 cells treated with PD173074 for one day and a significant decrease in both 
of these parameters at seven days of inhibitor treatment.  
 
To better understand the signalling pathways identified by the differentially 
phosphorylated sites, their upstream kinases were inferred using KSEA. 
Interestingly, a number of phosphorylation sites known to be downstream of AKT 
followed the baseline – down-regulation – baseline pattern over the three time points 
in PD173074 treated cells. Phosphorylation sites known to be substrates of kinases 
downstream of AKT, including mTOR, were also found to follow this pattern, further 
supporting the findings that the change in AKT signalling identified in the MS data 
was transmitted downstream. The potential role of AKT signalling in overcoming 
FGFR inhibitor resistance in MFE-296 cells was further highlighted by up-regulation 
of four phosphopeptides, each implicated in AKT signalling, after 14 days of drug 
exposure (Chaudhury et al., 2010, Hussey et al., 2011, Ma et al., 2014, Morita et al., 
2013, Roux and Topisirovic, 2012, Song et al., 2014, Zhang and Dou, 2014). 
 
The exact phosphorylation sites of a small number of phosphopeptides could not be 
determined definitively, due to inadequate fragmentation of the peptide. Furthermore, 
these peptides possessed multiple potential phosphorylation sites and so the specific 
phosphorylated residues remained elusive. Whilst the fragmentation method 
employed in our work (CID-MSA) is routinely used in phosphopeptide analysis 
(Boersema et al., 2009), more sensitive methods do exist, for example ECD and 
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HCD, which could be used in future to determine the exact phosphorylated residues 
in these peptides (Olsen et al., 2007, Syka et al., 2004, Zubarev, 2004). Notably, 
total protein levels were not assessed in this study. Our work has focused primarily 
on changes in signalling peptides upon drug exposure, of which phosphopeptides 
are the most important (Cohen, 2000, Manning et al., 2002). We do, however, 
acknowledge that analysis of total protein levels adds an additional layer of 
information to changes within the cell upon drug treatment, and so repetition of this 
experiment to elucidate such changes may be of interest in the future.  
 
Another potential shortcoming of this study is the number of repeats of the 
experiment. Due to time constraints, only two biological replicates of each condition 
were performed. Although these were analysed on the MS twice, producing an n of 
four for each sample, a more robust experiment would include more biological and 
technical replicates. Repetition of this experiment using the Ishikawa cell line should 
also be considered in future work. This would assess the specificity of signalling 
changes seen in MFE-296 cells upon FGFR inhibition with regards to the FGFR2 
mutation status of the cell line.  
 
MS generates a large quantity of data, and validation of all potential pathways 
highlighted in this analysis is outside of the scope of this study. Whilst the AKT 
pathway was associated with the most de-regulated phosphopeptides identified in 
our study, we are nevertheless mindful that pathways other than AKT could have 
been selected to target alongside FGFR2. Rather than this diminishing the validity of 
this work, we believe it: (i) reinforces the known complexity of cell signalling; (ii) 
validates the use of MS as a tool in drug target discovery and (iii) provides evidence 
of how prior knowledge of the importance of certain proteins in signalling networks 
can be used to aid selection of potentially important phosphopeptides from MS data.  
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Inhibition of FGFR in combination with AKT1, 2 and 3 overcomes FGFR 
inhibitor resistance in MFE-296 cells  
To investigate the significance of AKT1, 2 and 3 in this FGFR inhibitor resistance 
mechanism, two small molecule inhibitors were used; AKTVIII, targeting AKT1 and 2 
(Lindsley et al., 2005), and MK2206, which blocks AKT1, 2 and 3 (Hirai et al., 2010). 
As MK2206 has a more marked effect on cell number and proliferation on MFE-296 
cells than AKTVIII, both alone and in combination with PD173074, our data suggest 
a specific role for AKT3 in the compensatory mechanism. While in vivo studies 
investigating the role of AKT in development and disease have shown different 
phenotypes for individual knockout of AKT1, 2 and 3, little is known about the 
specific functions of these isoforms and how they are regulated (Madhunapantula 
and Robertson, 2011). However, increased AKT3 activity has been shown to play an 
important role in the development of melanoma (Stahl et al., 2004). AKT1 and 3 
have also been shown to be involved in regulation of splicing of FGFR2 in lung 
cancer (Sanidas et al., 2014). As such, the role of the individual isoforms of AKT in 
the resistance mechanism outlined in this chapter warrants further investigation.  
 
Dual drug therapy in FGFR2 mutant cancer  
The prospect of treating endometrial cancer with a combination of chemotherapeutic 
drugs or small molecule inhibitors and chemotherapeutics has been outlined 
previously (Gozgit et al., 2013, Byron et al., 2012). Although these studies 
investigated the synergistic effects of dual drug therapy, we present the first study to 
investigate potential resistance mechanisms upon FGFR inhibition and use these 
data as the rationale for choosing an additional therapeutic target.  
 
FGFR2 mutations are known to be putative oncogenic drivers in other cancers (Su et 
al., 2014, Hong et al., 2013). It remains to be investigated whether FGFR2 mutant 
cell lines derived from such cancers undergo similar reorganisation of their signalling 
pathways upon FGFR inhibition as that seen in MFE-296 cells. However, we have 
identified the importance of AKT signalling in overcoming FGFR inhibition, a 
relationship that may also be important in other FGFR2 mutant cancers. The 
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relevance of AKT in relation to FGFR signalling has already been demonstrated in 
lung and gastric cancers (Sanidas et al., 2014, Hu et al., 2013), yet the implications 
of AKT signalling in relation to, but not necessarily downstream of, FGFR signalling 
remain to be fully understood. As such, it is possible that the dual drug treatment 
identified in this study is applicable to a range of FGFR2 mutant cancers.  
 
Since we have shown that AKT inhibition can overcome FGFR inhibitor resistance in 
MFE-296 cells, further in vivo investigations should be undertaken to establish the 
potential viability of this FGFR/AKT drug combination in the treatment of endometrial 
cancer. Although combination trials are not currently underway, initial investigations 
into neuroblastoma and glioma, amongst others, suggest use of MK2206 alongside 
other small molecule inhibitors and chemotherapeutics provides an advantage in 
inducing cancer cell death (Cheng et al., 2012, Li et al., 2012, Agarwal et al., 2013). 
It is also promising that use of MK2206 alone is currently in clinical trials (Molife et 
al., 2014), as is the AZD4547 FGFR inhibitor (Xie et al., 2013, Zamora et al., 2014). 
The combinatorial use of both drugs represents an exciting line of clinical 
investigation, with the potential to overcome chemoresistance in FGFR2-driven 
cancers.  
 
While we have established the importance of AKT in acquiring inhibitor resistance in 
MFE-296 cells, it is important to delineate the mechanism of this compensatory 
response. As such, further investigation was undertaken to establish the inducer/s of 
this AKT-mediated recovery in FGFR inhibitor resistance in MFE-296 cells (Chapter 
5).  
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Chapter 5 
Results: Investigation of FGFR inhibitor 
resistance mechanisms in MFE-296 cells   
 
 
 
 
 
 
 
 
157 
 
5.1 Introduction  
Initial data assessing the effect of FGFR inhibition in FGFR2 mutant endometrial 
cancer showed the MFE-296 cell line acquired resistance to drug treatment, over 14 
days exposure to an FGFR-targeted small molecule inhibitor. To investigate the 
effect of resistance acquisition on intracellular signalling pathways, MS was 
employed. From these data, the importance of AKT signalling recovery in drug 
resistant cells was established and validated using a 3D organotypic model of 
endometrial cancer. Dual drug therapy targeting FGFR and AKT signalling overcame 
drug resistance and, importantly, this effect was FGFR2 mutation status dependent. 
 
To fully understand the cellular changes responsible for AKT pathway recovery in 
FGFR inhibitor resistant cells, microarray gene expression analysis was employed. 
These data, coupled with the knowledge garnered from MS analysis, were used to 
delineate the FGFR inhibitor resistance mechanism of FGFR2 mutant endometrial 
cancer cells.  
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5.2 Generation and characterisation of an FGFR inhibitor resistant cell line  
To investigate the phenotypic and mechanistic consequences of sustained FGFR 
inhibitor resistance, an FGFR inhibitor resistant population of cells was generated by 
continuous treatment of MFE-296 cells with 5 µM PD173074. This inhibitor 
concentration was decided upon based on initial data showing over 50% reduction in 
MFE-296 cell number relative to DMSO control treated cells after seven days of 5 
µM PD173074 (Figure 3.3). It was therefore assumed that the resulting population 
was resistant to PD173074 treatment. This population was named MFE-296PDR. The 
standard medium for these cells was supplemented with 5 µM PD173074 from this 
point onwards.  
 
The FGFR2 mutation status of MFE-296PDR cells was assessed at approximately 
passage 15. The resistant cell line harboured the same N550K and K310R mutations 
as its MFE-296 parental cell line (Appendix Figure 1.9).  
 
At approximately the same passage, the effect of increasing PD173074 
concentration on MFE-296PDR cells after seven days in 2D culture was assessed. 
The same PD173074 concentrations as those used to treat parental cells in our 
initial investigations were used (Figure 3.3). PD173074 treatment of MFE-296PDR 
cells from 10–10000 nM did not decrease cell number (Figure 5.1).  
 
 
 
 
 
159 
 
 
Figure 5.1. Effect of PD173074 treatment on MFE-296
PDR 
cells in 2D culture.   
MFE-296
PDR
 cells were treated with the same concentrations of PD173074 as the parental 
MFE-296 cell line had been treated previously (Figure 3.3). After seven days, cells were 
counted using a haemocytometer and the values displayed as a percentage of DMSO 
control treated cell number. FGFR inhibition did not induce cell death in MFE-296
PDR 
cells. 
Arrow indicates concentration of PD173074 supplemented in MFE-296
PDR
 cell medium in all 
subsequent experiments (5 µM PD173074). Error bars show means ± SEM of three 
replicates. 
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Changes in the signalling capacity of MFE-296 parental cells, upon 5 µM PD173074 
treatment, and MFE-296PDR cells, upon removal of the drug, were investigated. ERK 
phosphorylation was decreased upon PD173074 treatment in MFE-296 cells after 
both seven and 14 days (Figure 5.2 A, left panel). Interestingly, removal of 
PD173074 from the medium of MFE-296PDR cells significantly increased P-ERK 
levels (Figure 5.2 A and B, right panel). Indeed, ERK phosphorylation in MFE-296PDR 
cells in the absence of PD173074 was increased compared to the MFE-296 parental 
cell line. AKT phosphorylation remained unchanged in both MFE-296 and MFE-
296PDR cells regardless of PD173074 treatment (Figure 5.2 A and B).  
 
The consequences of drug removal from the established MFE-296PDR cell line were 
investigated further in 3D culture. There was no significant difference in cell number, 
or the percentage of cells able to proliferate, between cultures grown in 5 µM 
PD173074 or DMSO vehicle control (Figure 5.3). 
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Figure 5.2. Changes in signalling upon PD173074 treatment in MFE-296 parental and 
MFE-296
PDR
 cells.  
MFE-296 and MFE-296
PDR
 cells were cultured in the presence or absence of 5 µM 
PD173074 for seven and 14 days, after which western blot analysis was performed to 
investigate changes in key signalling pathways. (A) ERK phosphorylation was inhibited upon 
PD173074 treatment in MFE-296 cells. Removal of PD173074 from MFE-296
PDR
 cell 
medium resulted in a significant increase in ERK phosphorylation. AKT phosphorylation was 
unchanged regardless of the presence or absence of PD173074 after seven or 14 days. (B) 
Densitometric analysis of P-ERK and P-AKT levels compared to their total protein 
counterparts. **, P ≤0.01 (Student’s t test). 20 µg protein was used for each lane. Error bars 
show means ± SEM of three replicates. 
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Figure 5.3. Effect of drug removal on MFE-296
PDR 
cell number and proliferation in a 3D 
physiomimetic model.  
Organotypic cultures of MFE-296
PDR
 cells were prepared as detailed in Figure 1.9 B. MFE-
296
PDR 
cells were grown in the presence or absence of 5 µM PD173074 for seven days. 
There was no significant difference in cell number, or the percentage of proliferative cells 
(Ki67, green), between cultures in the presence or absence of PD173074. n.s., not 
significant, P >0.05 (Student’s t test). Nuclei were stained with DAPI (blue). Original 
magnification of H&E images, 10X objective; bar, 100 µm. Original magnification of confocal 
images, 40X objective; bar, 25 µm. Error bars show means ± SEM. Data points represent 
the average cell number/percentage Ki67 positive cells of three fields of view of two to three 
technical replicates of three biological replicates. Cell number and percent Ki67 positive cells 
represent average values per field of view.  
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Analysis of changes in the phosphoproteome of MFE-296 cells upon inhibition of 
FGFR signalling, via exposure to PD173074, indicated a potential role for AKT 
signalling in acquiring this resistance (Figures 4.2 and 4.3). Subsequent 3D 
organotypic modelling showed that dual drug treatment, targeting the AKT1, 2, 3 and 
FGFR pathways, could overcome this resistance in MFE-296 cells (Figure 4.6). The 
effect of these drug combinations on cells with established PD173074 resistance 
was investigated.  
 
MFE-296PDR cells were cultured for seven days in the presence of two AKT inhibitors 
alone or in the presence of PD173074. Control culture medium was supplemented 
with 5 µM PD173074.  
 
MFE-296PDR cells were resistant to inhibition of AKT1 and 2 using 1 µM AKTVIII 
(Figure 5.4. A). However, dual drug treatment using AKTVIII in combination with 
PD173074 significantly decreased both cell growth and the percentage of cells 
capable of proliferation (Figure 5.4 B). Inhibition of AKT1, 2 and 3 for seven days 
with 1 µM MK2206 significantly decreased both cell number and proliferation of 
MFE-296PDR cells (Figure 5.4 C), as did MK2206 and PD173074 dual drug treatment 
(Figure 5.4 D).  
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Figure 5.4. Effect of AKT inhibition, in the presence or absence of PD173074, in MFE-
296
PDR
 cells in a 3D organotypic model.   
3D cultures of MFE-296
PDR 
cells were prepared as detailed in Figure 1.9 B. Cultures were 
treated with 5 µM PD173074 as a control. (A) There was no significant difference in cell 
number or percentage of proliferative cells (Ki67, green), between cells treated with 
PD173074 and those treated with 1 µM AKTVIII for seven days. (B) Both cell number and 
percentage of Ki67 positive cells decreased in cultures treated with both PD173074 and 
AKTVIII for seven days. (C) Cell number and the percentage of cells that stained positive for 
Ki67 significantly decreased upon 1 µM MK2206 treatment. (D) Both cell number and 
percentage of Ki67 positive cells decreased in cultures treated with both PD173074 and 
MK2206 for seven days. n.s., not significant, P >0.05; **, P ≤0.01; ***, P ≤0.001 (Student’s t 
test). Nuclei were stained with DAPI (blue). Original magnification of H&E images, 10X 
objective; bar, 100 µm. Original magnification of confocal images, 40X objective; bar, 25 µm. 
Error bars show means ± SEM. Data points represent the average cell number/percentage 
of Ki67 positive cells of three fields of view of two to three technical replicates of three 
biological replicates. Cell number and percent Ki67 positive cells represents average values 
per field of view.  
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MK2206 treatment, both alone and in combination with PD173074, had a significant 
effect on both cell number and the proliferative capacity of MFE-296PDR cells. The 
effect of MK2206 alone, as well as PD173074 removal, PD173074 alone and 
MK2206/PD173074 combination treatment, on a mixed population of parental MFE-
296 and MFE-296PDR cells was investigated.  
 
Both cell lines were labelled with distinct fluorescent dyes. An equal number of MFE-
296 (red) and MFE-296PDR (green) cells were seeded and images taken using a 
confocal microscope every day for four days (Figure 5.5). The dyes used were cell 
permeable. However, their intracellular reaction products were retained within the 
cell and passed to their progeny, enabling efficient tracing of cells over several 
generations. Importantly, these dyes could not be passed to adjacent cells, enabling 
reliable analysis of a mixed cell population.  
 
Culture of the mixed population in a DMSO control showed growth of both cell lines, 
with MFE-296PDR cell number significantly higher than the parental cell line at both 
one and three days (Figure 5.5 A). MFE-296 cell number was decreased compared 
to the control upon treatment with 5 µM PD173074; MFE-296PDR cell number was 
significantly higher than that of MFE-296 in the presence of PD173074 (Figure 5.5 
B). The number of cells in both populations was decreased upon MK2206 treatment 
(Figure 5.5 C). However, the effect of MK2206 in combination with PD173074 
blocked any increase in cell number of both MFE-296 parental and MFE-296PDR cells 
over the course of the four days experiment (Figure 5.5 D).  
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Figure 5.5. Effect of FGFR and AKT inhibition, alone and in combination, on a mixed 
population of MFE-296 and MFE-296
PDR
 cells.  
MFE-296 and MFE-296
PDR
 cells were labelled with a cell permeable fluorescent dye (red 
and green, respectively). The intracellular reaction products of these dyes were cell 
impermeable, therefore preventing passage of the dye to adjacent cells. The tag was, 
however, passed on to daughter cells. (A) Cell number increased over four days in both 
MFE-296 and MFE-296
PDR 
cells in the presence of a DMSO vehicle control. (B) MFE-296 
cell number was significantly lower than MFE-296
PDR
 cells at one, three and four days upon 
5 µM PD173074 treatment. (C) Cell number of both cell populations was decreased 
compared to the DMSO and PD173074 treated cells upon 1 µM MK2206 treatment. MFE-
296
PDR 
cell number was significantly higher than that of parental cells at four days treatment. 
(D) Both MFE-296 and MFE-296
PDR 
cells failed to increased in number upon PD173074 and 
MK2206 dual drug treatment. Lines through ‘FGFR’ and ‘AKT’ signify which pathways were 
targeted using small molecule inhibitors under each condition. *, P ≤0.05; **, P ≤0.01, 
(Student’s t test). Original magnification of confocal images, 40X objective; bar, 25 µm. Error 
bars show means ± SEM. Data points represent the average cell number of six fields of view 
of three technical replicates of three biological replicates. Cell number and percent Ki67 
positive cells represents average values per field of view.  
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MFE-296 cell line sequencing showed that this cell line was heterozygous for an 
activating PIK3CA mutation (Table 3.1). As this mutation leads to activation of PI3Ka 
(Gymnopoulos et al., 2007, Konstantinova et al., 2010, Weigelt et al., 2013), the 
effect of inhibition of PI3K signalling in MFE-296 and MFE-296PDR cells was 
assessed using the ZSTK474 class I PI3K inhibitor.  
 
Cells were treated with increasing concentrations of ZSTK474 for seven days, after 
which cell number was counted using a haemocytometer. MFE-296PDR cell medium 
was also supplemented with 5 µM PD173074 throughout the investigation. A similar 
decrease in cell number with increasing drug concentration was seen in both MFE-
296 and MFE-296PDR cells (Figure 5.6 A and B, respectively), indicating that 
sensitivity to PI3K inhibition was independent of FGFR inhibitor resistance. 
Interestingly, both MFE-296 and MFE-296PDR cells showed PI3K inhibitor sensitivity 
comparable to that seen in MFE-296 cells upon FGFR inhibitor treatment (Figure 
3.3). These data suggested that MFE-296 cells relied on both FGFR2 and PI3K 
mutant pathways for optimal cell survival in contrast to AN3CA cells, which were 
FGFR2 oncogene addicted (Figure 3.7 B).  
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Figure 5.6. Effect of PI3K inhibition on MFE-296 and MFE-296
PDR
 cells in 2D culture.   
Increasing concentration of ZSTK474 pan PI3K inhibitor reduced cell number of both 
parental and PD173074 inhibitor resistant cells in 2D culture after 7 days (A and B 
respectively). (A) Data displayed as average of three replicates and values normalised to 
DMSO control treated cells. (B) Data displayed as average of two replicates and values 
normalised to control cells treated with 5 µM PD173074. MFE-296
PDR 
cells were treated with 
5 µM PD173074 in addition to various ZSTK474 concentrations throughout the experiments. 
Error bars show means ± SEM. 
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5.3 Investigation of the MFE-296PDR FGFR inhibitor resistance pathway 
After establishing the importance of AKT signalling in FGFR inhibitor resistance, 
further analysis was employed to dissect this mechanism. The phosphoproteomics 
method outlined in Chapter 4 primarily detected peptides phosphorylated on serine 
and threonine residues. Whilst this gives great insight into the activity of intracellular 
signalling cascades, changes in phosphotyrosine residues can go unnoticed, since 
they are much less abundant than serine and threonine phosphorylations (Delom 
and Chevet, 2006). As up-regulation of alternative receptor tyrosine kinase (RTK) 
pathways is a common mechanism of resistance in RTK mutant cancers (Niederst 
and Engelman, 2013), a fluorescence-based assay allowing for detection of a range 
of phosphorylated RTKs, as well as other important signalling nodes, was performed. 
In the PathScan array used, antibodies specific to each protein of interest were 
spotted on to a chip, to which cell lysates were added (Figure 5.7, left and middle 
panels). A pan-phosphoprotein detection antibody was applied, followed by 
Streptavidin-conjugated DyLight 680, to visualise the bound detection antibody 
(Figure 5.7, right panel). The fluorescent image produced was then used to quantify 
each spot, and therefore phosphoprotein, intensities.  
 
MFE-296 and MFE-296PDR cells were analysed using the PathScan assay. A down-
regulation of ERK phosphorylation of almost two-fold was seen in MFE-296PDR cells 
compared to the parental cell line (Figure 5.8 A and B). The array also showed an 
approximately one-fold decrease in AKT phosphorylation on both serine 473 
(ser473) and threonine 308 (thr308). None of the RTKs investigated in this assay 
showed increased phosphorylation levels in MFE-296PDR cells, relative to the 
parental cell line. Four phosphoproteins were more abundant in the MFE-296PDR cell 
line relative to MFE-296 parental cells, however, this was a small increase of 
approximately one-fold.   
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Figure 5.7. Schematic representation of the PathScan array.  
The PathScan array used to analyse phosphoprotein levels in MFE-296 and MFE-296PDR 
cells was based on sandwich immunoassay technology. Each nitrocellulose-coated glass 
slide contained eight pads, spotted with antibodies for a range of signalling proteins, as well 
as a biotinylated positive control and a nonspecific IgG negative control (left and middle 
panels). Samples were incubated on each pad, followed by a biotinylated detection antibody 
specific to phosphoproteins. A Streptavidin-conjugated DyLight 680 was then used to 
visualise the bound detection antibody (right panel). The resulting fluorescent image was 
used to quantify spot, and therefore phosphoprotein, intensities.  
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Figure 5.8. Changes in signalling node phosphorylation in MFE-296
PDR
 vs MFE-296 
parental cells.  
The PathScan assay was employed to determine changes in a range of RTKs and 
downstream effectors in MFE-296
PDR 
vs MFE-296 parental cells. (A and B) Phosphorylation 
of all RTKs investigated decreased upon FGFR inhibitor resistance. A 1-fold increase in 
phosphorylation of four downstream signalling nodes was exhibited upon acquisition of 
resistance. Values represent fold change in signal intensity of each phosphoprotein in MFE-
296
PDR
 cells vs MFE-296 cells. The average of two technical replicates from one PathScan 
slide pad was used to calculate the fold change.  
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To further dissect changes induced upon FGFR inhibitor resistance acquisition in 
MFE-296 cells, transcriptomic analysis was employed. RNA from MFE-296 and 
MFE-296PDR cells was isolated and sent to Barts Genome Centre. Following reverse 
transcription and labelling, it was run on an Illumina microarray gene expression 
chip, containing approximately 45000 probes specific to various gene transcripts. 
Relative expression levels for each of these transcripts was then analysed using 
Genome Studio, Microsoft Excel and Prism software.  
 
An additional inhibitor resistant cell line, termed MFE-296AZR, was generated by 
continuous exposure to 2.5 µM AZD4547. cDNA from this cell line was run on the 
Illumina microarray chip in tandem with the MFE-296 and MFE-296PDR cell lines. Two 
biological replicates of each cell line were run on the chip in duplicate, giving a total 
of four data points per gene transcript for each cell line.  
 
MFE-296 and MFE-296PDR cell replicates one to four were clustered according to 
their transcriptomic profile (Figure 5.9 A). MFE-296 and MFE-296PDR cells formed 
two distinct clusters, indicating distinct transcriptomes. The four replicates of each 
experiment also clustered together, indicative of the reproducibility of these data.   
 
We identified 1129 transcripts that were significantly up- or down-regulated in MFE-
296PDR cells compared to the parental cell line, of which 586 were up-regulated and 
543 were down-regulated (Figure 5.9 B and C, respectively). The top 10 up-
regulated genes included IGFBP5, the expression of which is known to be elevated 
in the absence of FGFR2 in keratinocytes in vivo (Grose et al., 2007, Schlake, 2005) 
(Figure 5.9 B, bottom panel). Moreover, DUSP6 and SPRY4 were down-regulated in 
both resistant populations compared to the parental controls, both of which are 
transcriptional targets of FGFR and play an important role in negative feedback of 
FGFR signalling (Furthauer et al., 2001, Li et al., 2007).  
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The most significantly down-regulated gene was PHLDA1 (Figure 5.9 C, bottom 
panel), a negative regulator of AKT signalling (Murata et al., 2014). Interestingly, 
levels of many of the top 10 up- and down-regulated transcripts identified in MFE-
296PDR cells were similarly regulated in MFE-296AZR cells (Figure 5.9 D and E, 
respectively). Indeed, PHLDA1 was down-regulated by equivalent levels in this 
inhibitor resistant cell line as in MFE-296PDR cells.   
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Figure 5.9. Transcriptomic changes induced upon FGFR inhibitor resistance 
acquisition in MFE-296 cells.  
RNA was extracted from MFE-296, MFE-296PDR and MFE-296AZR cells and gene expression 
analysis performed using the Illumina microarray platform. (A) Hierarchical clustering of the 
four MFE-296 and MFE-296PDR
 
cells resulted in generation of two distinct clusters, indicative 
of discrete transcriptome signatures in the two cell populations. (B) 586 gene transcripts 
were up-regulated in MFE-296
PDR
 cells compared to the MFE-296 parental cell line (top 
panel). The 10 transcripts with the highest fold change relative to the parental cells included 
IGFBP5, previously shown to increase in response to FGFR2 inhibition in vivo (Schlake, 
2005) (bottom panel). (C) Of the 543 transcripts that were significantly down-regulated in 
MFE-296
PDR
 cells compared to the parental cell line (top panel), PHLDA1, a negative 
regulator of AKT signalling, showed the largest fold decrease. (D) Comparison of an 
additional FGFR inhibitor resistant cell line generated via exposure to the AZD4547 
compound, MFE-296
AZR
, showed a similar number of up-regulated transcripts, as well as 
overlap of five genes in the top 10 highest fold up-regulation with that seen in figure B (top 
and bottom panels respectively). (E) Of the 547 significantly down-regulated transcripts 
identified in MFE-296
AZR
 cells relative to the parental cell line, six of the top 10 with the 
highest fold decrease in the resistant cell line were also seen in figure C (top and bottom 
panels respectively). Of note, PHLDA1 was down-regulated by equivalent amounts 
compared to the parental cells in both FGFR inhibitor resistant populations. Two technical 
replicates of two biological replicates of each cell line were run on the Illumina microarray 
assay. The average signal intensity of each transcript probe in each sample was quantile 
normalised, to adjust sample signals in order to minimise the effects of variation arising from 
non-biological factors. The average signal of the four replicates was taken for each gene 
transcript in each cell line examined. Values in MFE-296
PDR
 and MFE-296
AZR
 cells were 
then compared to those obtained in the parental cell line. Gene transcripts with values 
significantly higher or lower than the parental cells were identified (diff score >65). The fold 
change between the resistant populations compared to the parental cells, in these 
significantly up- or down-regulated transcripts, was then calculated. Circle sizes in figures B-
E are proportional to each other.  
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Upon PI3K activation, PIP2 is converted to PIP3, to which PH domain containing 
proteins can bind. In the case of AKT, recruitment to the membrane via PIP3 binding 
leads to phosphorylation of the thr308 residue by PDK1 and subsequent activation of 
AKT (Alessi et al., 1997, Franke et al., 1995). This in turn leads to mTORC2 
activation, which can further phosphorylate AKT, resulting in its compete activation 
and subsequent pro-survival signalling (Facchinetti et al., 2008, Sarbassov et al., 
2005) (Figure 5.10 A).  
 
PHLDA1, another PH domain containing protein, is also a known binding partner of 
PIP3 (Murata et al., 2014). In this way, it competes with AKT, as well as many other 
PH domain-containing proteins (Varnai et al., 2005), for PIP3 binding. Upon PIP3-
PHLDA1 interaction, AKT phosphorylation and subsequent activation is prevented, 
leading to inhibition of AKT signalling (Figure 5.10 B). Therefore, a balance between 
AKT and PHLDA1 exists, whereby an increase in AKT displaces PHLDA1-PIP3 
binding and leads to anti-apoptotic signalling, while up-regulation of PHLDA1 protein 
levels inhibits pro-survival activity (Figure 5.10 C).  
 
The dramatic decrease in PHLDA1 in drug resistant cell lines, identified via 
microarray gene expression analysis, was particularly interesting given our previous 
data implicating the importance of AKT signalling in FGFR inhibitor resistance 
(Figures 4.2, 4.3 and 4.6). Previous studies have shown down-regulation of PHLDA1 
correlated with poor prognosis in breast cancer tissue samples and has also been 
reported in melanoma (Nagai et al., 2007, Neef et al., 2002). However, this was the 
first potential demonstration of the down-regulation of PHLDA1 in an apparent 
compensatory capacity in response to inhibition of a mutant RTK pathway. 
Therefore, the validity of these transcriptomics data and their importance in the 
FGFR inhibitor resistance mechanism were investigated further.  
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Figure 5.10. Schematic representation of the opposing cellular effects of the PIP3 
binding proteins AKT and PHLDA1.   
(A) PI3K activation leads to conversion of membrane-bound PIP2 to PIP3. AKT binds to PIP3 
via its PH domain, upon which it is phosphorylated by PDK1 (Alessi et al., 1997, Franke et 
al., 1995). This, in turn, leads to activation of mTORC2, which further phosphorylates AKT, 
leading to full activation of the protein and subsequent activation of pro-survival signals 
(Facchinetti et al., 2008, Sarbassov et al., 2005). (B) PHLDA1 is also able to bind to PIP3, 
therefore preventing AKT recruitment to the membrane and subsequently inhibiting AKT-
induced anti-apoptotic signalling (Murata et al., 2014). (C) AKT and PHLDA1 levels exist in a 
state of balance, whereby a higher ratio of AKT:PHLDA1 favours pro-survival signalling and 
vice versa.  
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5.4 Investigation of the role of PHLDA1 in FGFR inhibitor resistance  
To establish the validity of microarray gene expression data at the protein level, 
PHLDA1 levels in MFE-296 and MFE-296PDR cells were assessed via western blot 
(Figure 5.11). MFE-296 cells expressed PHLDA1 in the basal state. PHLDA1 levels 
in MFE-296 cells were significantly decreased upon treatment with 5 µM PD173074 
for seven days (Figure 5.11, left). Preliminary data showed that, whilst PHLDA1 
levels decreased after one and three days PD173074 treatment, the down-regulation 
of this protein was significant after seven days (Appendix Figure 1.10). PHLDA1 was 
not expressed in MFE-296PDR cells. Expression of PHLDA1 was not recovered when 
resistant cells were cultured in PD173074-free medium (Figure 5.11, right).  
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Figure 5.11. PHLDA1 expression in the basal state and after PD173074 treatment of 
MFE-296 and MFE-296
PDR
 cells.  
MFE-296 and MFE-296
PDR
 cells were cultured in medium supplemented with 5 µM 
PD173074 or a DMSO vehicle control for seven days. MFE-296 cells expressed PHLDA1 in 
the basal state; this expression was significantly decreased upon PD173074 treatment (left 
panel). MFE-296
PDR
 cells did not express PHLDA1 in either the presence or the absence of 
PD173074. *, P ≤0.05 (Student’s t test). 40 µg protein was used for each lane. Error bars 
show means ± SEM of three replicates. 
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As detailed in Figure 5.10, PHLDA1 negatively regulates AKT signalling via direct 
competition with AKT for PIP3 binding at the membrane. As such, an indicator of the 
importance of the balance between PHLDA1 and AKT in MFE-296 cells is the 
cellular localisation of both proteins. We assessed cellular localisation of PHLDA1, 
P-AKT and total AKT in MFE-296 and MFE-296PDR cells via fractionation of cells, into 
their membrane and cytoplasmic components (Figure 5.12). PHLDA1 was 
predominately localised to the membrane in MFE-296 cells, while MFE-296PDR cells 
did not express PHLDA1 at either the membrane or in the cytoplasm (Figure 5.12 A 
and B, left panel). There was no significant difference in AKT levels at the membrane 
or in the cytoplasm in MFE-296 cells. However, there was significantly more AKT 
localised to the membrane in MFE-296PDR cells (Figure 5.12 A and B, middle panel). 
AKT phosphorylation was significantly higher in the cytoplasm than at the membrane 
in both MFE-296 and MFE-296PDR cells (Figure 5.12 A and B, right panel).  
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Figure 5.12. Cellular localisation of PHLDA1, P-AKT and total AKT in MFE-296 and 
MFE-296
PDR
 cells.  
PHLDA1, P-AKT and total AKT localisation in MFE-296 and MFE-296PDR cells was 
assessed, via fractionation of both cell lines into their cytoplasmic and membrane portions. 
(A and B) PHLDA1 was predominantly expressed at the membrane in MFE-296 cells. MFE-
296PDR cells did not express PHLDA1. Total AKT levels were equivalent in the membrane 
and cytoplasmic portions in MFE-296 cells, whilst AKT was significantly higher at the 
membrane in MFE-296PDR cells. P-AKT was higher in the cytoplasm than at the membrane 
in both cell lines. Calnexin and Cyclophilin A were used as loading controls for membrane 
and cytoplasmic fractions, respectively. *, P ≤0.05; **, P ≤0.01; ***, P ≤0.001 (Student’s t 
test). 40 µg protein was used for each lane. Error bars show means ± SEM of three 
replicates. 
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Having confirmed down-regulation of PHLDA1 in resistant cells, and established that 
PHLDA1 was down regulated in MFE-296 parental cells upon seven days PD173074 
treatment, we aimed to assess the effect PHLDA1 on sensitivity to FGFR inhibitor 
treatment in MFE-296 cells. To investigate this, siRNA knockdown of PHLDA1 was 
utilised. Initial investigations showed significantly decreased protein levels of 
PHLDA1 in MFE-296 cells upon two days exposure to siRNA (Figure 5.13, A, left). 
This returned to levels equivalent to cells treated with a non-targeting siRNA control 
after five days (Figure 5.13 A, right). MFE-296PDR cells did not express PHLDA1. The 
effect of PHLDA1 knockdown on cell number was assessed, after two days siRNA 
treatment. This showed no significant difference in cell number between non-
targeting scrambled control and PHLDA1 siRNA treated MFE-296 cells (Figure 5.13 
B).  
 
As MFE-296 cell number was significantly decreased compared to a DMSO control 
after three days 5 µM PD173074 treatment (Figure 5.13 C), the effect of loss of 
PHLDA1 on MFE-296 cell line sensitivity to PD173074 was investigated. Cells were 
treated with PHLDA1-targeting siRNA for two days, followed by incubation with 5 µM 
PD173074 for three days, after which cell number was determined. There was no 
difference in cell number between siRNA/drug treated cells compared to those 
treated with non-targeting siRNA/DMSO vehicle control (Figure 5.13 D). The same 
treatment did not affect MFE-296PDR cells (Appendix Figure 1.11). Therefore, loss of 
PHLDA1 expression in MFE-296 cells induced FGFR-inhibitor resistance.  
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Figure 5.13. Induction of FGFR inhibitor resistance in MFE-296 cells upon PHLDA1 
knockdown.    
(A) MFE-296 and MFE-296PDR cells were treated with PHLDA1 targeted siRNA or a non-
targeting control for two or five days. PHLDA1 expression was significantly decreased in 
MFE-296 cells upon two day siRNA treatment. However, this returned to near control levels 
after five days exposure to PHLDA1 targeted siRNA. PHLDA1 was not expressed in MFE-
296PDR cells. (B) MFE-296 cells were treated with PHLDA1 targeted siRNA or a non-
targeting control for two days, after which cell number was counted using a 
haemocytometer. There was no significant difference in cell number upon PHLDA1 
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knockdown. (C) MFE-296 cells were treated with 5 µM PD173074 or a DMSO control for 
three days, after which cell number was assessed as previously described. Cell number was 
significantly decreased after three days exposure to PD173074. (D) MFE-296 cells were 
treated with PHLDA1 targeting siRNA for two days and treated subsequently with PD173074 
for three days, after which cell number was assessed. Control cells were treated with non-
targeting siRNA, followed by DMSO for three days. There was no significant difference in 
cell number between control and PHLDA1 knockdown/PD173074 treated cells. Therefore, 
knockdown of PHLDA1 induced inhibition to FGFR inhibition in MFE-296 cells. *, P ≤0.05 
(Student’s t test). 40 µg protein was used for each lane. Error bars show means ± SEM of 
three replicates. Cell number data displayed as average of three replicates and values 
expressed as percentage of number of cells seeded. Error bars show means ± SEM. 
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5.5 Summary of results  
o Two FGFR inhibitor resistant populations of MFE-296 cells were generated by 
continuous treatment with PD173074 or AZD4547  
o ERK phosphorylation was inhibited in MFE-296PDR cells whilst P-AKT levels in 
resistant and parental cells were equivalent  
o Seven day treatment of MFE-296 and MFE-296PDR cells with MK2206 or 
MK2206 in combination with PD173074 significantly reduced cell number and 
proliferation  
o Compensatory signalling via an alternative RTK was not induced in MFE-
296PDR cells  
o Comparison of MFE-296PDR transcriptomic data with that of MFE-296 cells 
showed PHLDA1, a negative regulator of AKT signalling, was down-regulated 
by approximately 15-fold; this was recapitulated in MFE-296AZR cells  
o A lack of PHLDA1 expression in MFE-296PDR cells was confirmed at the 
protein level  
o MFE-296 cells expressed PHLDA1; this was significantly decreased upon 
seven day PD173074 treatment  
o PHLDA1 was located predominantly at the membrane in MFE-296 cells  
o AKT was located predominantly at the membrane in MFE-296PDR cells, 
however, P-AKT was higher in the cytoplasm  
o PHLDA1 siRNA knockdown in MFE-296 cells induced PD173074 inhibitor 
resistance  
o First evidence of PHLDA1 down-regulation in response to small molecule 
inhibitor treatment leading to drug resistance  
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5.6 Discussion  
Initial work showed generation of a drug resistant population of MFE-296 cells upon 
FGFR inhibition, in which the importance of AKT signalling recovery and 
maintenance was implicated via phosphoproteomic analysis. To dissect this drug 
resistance mechanism further, an inhibitor resistant population of MFE-296 cells was 
produced, by continuous exposure to PD173074, and named MFE-296PDR. 
Comparison of this cell line to its parental counterpart facilitated discovery of a 
PHLDA1 down-regulation mediated compensatory mechanism of signalling in FGFR 
inhibitor resistant endometrial cancer cells.  
 
Differential signalling in MFE-296 and MFE-296PDR cells  
Changes in the signalling capacity of MFE-296PDR cells were shown via western blot 
analysis. ERK phosphorylation was inhibited in MFE-296PDR cells, but P-ERK 
returned to levels equivalent to that of parental cells upon removal of the drug. This 
reversible inhibition of ERK phosphorylation in resistant cells implies that FGFR2 
signalling was indeed blocked by PD173074 in MFE-296PDR cells and that drug 
resistance was acquired by an alternative signalling method, rather than resulting 
from mutation of the receptor so as to overcome small molecule inhibition.  
 
The validity of the drug combinations detailed in Chapter 4 were further shown in 
MFE-296PDR cells, whereby AKTVIII treatment alone resulted in an inhibitor resistant 
population, while dual drug treatment with MK2206 and PD173074 induced cell 
death. Interestingly, FGFR inhibitor resistance in MFE-296PDR cells was also 
overcome by MK2206 inhibition alone, suggesting a key role for AKT signalling in 
this resistant population, as inferred from the phosphoproteomic data.  
 
To probe this AKT related mechanism further, we addressed the question of possible 
up-regulation of an alternative RTK pathway to compensate for loss of FGFR 
signalling, as has been noted elsewhere in the literature (Niederst and Engelman, 
2013). As tyrosine phosphorylation events occur at a reduced rate compared to that 
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of serine and threonine (Delom and Chevet, 2006), it was possible that our MS 
investigations failed to highlight increased phosphorylation of an alternative RTK. 
However, PathScan analysis revealed low level down-regulation of alternative RTKs 
in MFE-296PDR cells, implying the resistance mechanism was acquired via alternative 
means.  
 
The MFE-296 cell line also harboured a mutant copy of PIK3CA, leading to activation 
of PI3Ka. Although treatment of MFE-296 cells with AKT inhibitors alone generated a 
resistant population, we investigated the effects of PI3K inhibition in MFE-296 and 
MFE-296PDR cells. The growth curve resulting from increasing concentration of 
ZSTK474, a PI3Ka inhibitor (Dan et al., 2002, Kong et al., 2009), was similar to that 
seen when MFE-296 cells were exposed to PD173074 and AZD4547. This 
suggested both of these mutations are important in maintaining full signalling 
capacity in MFE-296 cells, whereas the AN3CA cell line was oncogene addicted to 
mutant FGFR2. Interestingly, MFE-296PDR cells showed a similar dose response to 
ZSTK474 treatment to their MFE-296 parental cell line, indicating the significance of 
this pathway to their survival. With the potential importance of AKT signalling in 
mind, we used transcriptomic analysis of parental and drug resistant cells to further 
delineate the mechanism of FGFR inhibitor resistance.  
 
Changes in the global transcriptome of MFE-296 drug resistant cells  
Use of microarray gene expression analysis of transcriptomic changes in drug 
resistant cells allowed insight into events in a global, unbiased fashion. 
Transcriptomic analysis of MFE-296PDR cells and MFE-296AZR cells, an additional 
inhibitor resistant cell line, showed a distinct gene expression signature common to 
drug resistant cells compared to their parental counterparts.  
 
1129 transcripts were significantly up- or down-regulated in MFE-296PDR cells, 
compared to the parental cell line. The top 10 up-regulated genes included IGFBP5, 
the expression of which is known to be elevated in the absence of FGFR2 in 
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keratinocytes in vivo (Grose et al., 2007, Schlake, 2005), therefore potentially 
validating our data. The most significantly down-regulated gene was PHLDA1, a 
negative regulator of AKT signalling. MFE-296AZR cells produced similar results in 
terms of significantly up- and down-regulated genes. Of note, PHLDA1 was also 
down-regulated by approximately 15 fold in the MFE-296AZR cell line, recapitulating 
the data obtained from MFE-296PDR cells.  
 
In light of our data identifying a role for AKT in maintaining FGFR inhibitor resistance 
in MFE-296 cells, it was of particular interest that a negative regulator of AKT 
signalling was the most significantly down-regulated of all genes analysed on the 
microarray. Published work has noted the down-regulation of this gene in patient 
samples of melanoma and has postulated its use as a biomarker of disease 
progression (Nagai et al., 2007, Neef et al., 2002). However, this was the first 
demonstration of a potential role for PHLDA1 in the acquisition and maintenance of 
drug resistance in cancer cells.  
 
We sought to validate the importance of this protein in our parental and resistant 
cells at the protein level and found expression was down regulated in MFE-296 cells, 
upon seven days exposure to PD173074. PHLDA1 was not expressed in MFE-
296PDR cells. The importance of down-regulation of this protein was shown upon 
siRNA knockdown of PHLDA1 in the parental MFE-296 cell line, which induced 
PD173074 inhibitor resistance after just three days of drug exposure.  
 
Interestingly, PHLDA1 expression was not recovered upon removal of PD173074 
from the medium of resistant cells, suggesting this down regulation may be of a 
permanent nature, potentially induced by epigenetic modulation of the gene. Whilst 
this mechanism of PHLDA1 down-regulation is speculative, future work will aim to 
validate the means by which PHLDA1 is modulated. Another intriguing line of enquiry 
is the potential feedback loop between AKT and p53 resulting in down-regulation of 
PHLDA1, as has been noted in signalling of its protein family member, PHLDA3 
(Kawase et al., 2009, Liao and Hung, 2010).  
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In an alternative approach, the effect of PHLDA1 over-expression on MFE-296 and 
MFE-296PDR cells will be assessed. Initial experiments validated the efficiency of 
transfection with a GFP-tagged PHLDA1 plasmid or GFP alone as a control 
(Appendix Figure 1.12). GFP expression and PHLDA1 protein levels were assessed 
one day post transfection, which showed PHLDA1 expression in both MFE-296 and 
MFE-296PDR cell lines (Appendix Figure 1.12 A and B). PHLDA1 over-expressing 
cells, alongside GFP transfected controls, will undergo DAPI stained cell cycle 
analysis, as well as annexin V staining, as a marker of apoptosis, using flow 
cytometry.  
 
As with MS, transcriptomic analysis generates a large amount of data, the 
interrogation of all aspects of which was beyond the scope of this work. However, 
while we are mindful that other genes, just as other phosphoproteins, could have 
been selected for investigation from these data sets, we believe the current thesis (i) 
validates the known complexity of signalling networks and their changes upon 
perturbation of a single pathway and (ii) demonstrates the compatibility of MS and 
gene microarray to complement each other in large scale studies.  
 
PHLDA1 down-regulation led to FGFR inhibitor resistance in MFE-296 cells  
Based on these data, we propose the following model (Figure 5.14): Inhibition of 
mutant FGFR signalling in MFE-296 cells decreased cell growth and proliferation 
over seven days. Although FGFR2 signalling was blocked, the cells were able to 
continue signalling at a reduced level. This most likely occurred via the mutant copy 
of PI3Ka harboured in this cell line. As FGFR2 also induces PI3K signalling, 
decreased downstream effects of PI3K were observed via MS analysis following 
seven days exposure to PD173074. This decreased PI3K signalling subsequently 
led to a decrease in PIP3 at the membrane. To compensate for the decrease in PI3K 
signalling upon FGFR2 inhibition, PHLDA1 expression was decreased. Therefore, 
whilst there was reduced PI3K signalling, the AKT available in the cells was able to 
bind to PIP3 free of competition with PHLDA1. In this way, AKT signalling could be 
sustained, even in the absence of mutant FGFR2 signalling.  
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Important to this mechanism is the cellular localisation of PHLDA1 and AKT in 
parental and resistant cells. Via cellular fractionation, we were able to determine that 
PHLDA1 was expressed predominantly at the membrane of MFE-296 cells, whilst it 
was not expressed in the resistant cell line. Therefore AKT could bind to the 
membrane unhindered in the MFE-296PDR cells. Another important aspect of this 
mechanism is the differential level of PIP2 and PIP3 in MFE-296 and MFE-296
PDR 
cells. Whilst we postulate PIP3 levels are lower in the resistant cell line, requiring 
PHLDA1 down-regulation in order to maintain AKT signalling, we aim to validate this 
using a PIP3 competition assay in future work.  
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Figure 5.14. Proposed mechanism of FGFR inhibitor drug resistance in MFE-296 
endometrial cancer cells.  
(A) In the basal state, FGFR2 mutant MFE-296 cells signal via mutant FGFR2. This induces 
activation of downstream signalling pathways, including PI3K. Signalling via the PI3K 
pathway is further enriched due to the presence of mutant PI3Ka in MFE-296 cells. This 
leads to an abundance of PIP3 at the cell membrane, to which AKT can bind and induce its 
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pro-survival downstream signalling cascades. MFE-296 cells also express PHLDA1, which 
competes with AKT for PIP3 binding. However, due to the dual activation of PI3K signalling 
via mutant FGFR2 and mutant PI3Ka, PIP3 is abundant and freely available for both AKT 
and PHLDA1 to bind. (B) Upon continuous treatment of MFE-296 cells with an FGFR 
inhibitor, PI3K signalling is reduced; therefore the cells now rely on only the mutant version 
of PI3Ka. Overall, membrane bound PIP3 levels are decreased due to less PIP2 to PIP3 
conversion as a result of diminished total PI3K signalling. In response, PHLDA1 is down-
regulated in these FGFR inhibitor exposed cells. Therefore, AKT can bind to PIP3 
unhindered and continue to signal at the same rate as in non-inhibitor treated cells. In this 
way, an FGFR inhibitor resistant population is generated.  
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Chapter 6 
General discussion  
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6.1 Overview  
FGFs and their receptors mediate a variety of processes, from embryonic 
development to cellular growth and proliferation (Bottcher and Niehrs, 2005, Dubrulle 
and Pourquie, 2004, Feldman et al., 1995, Ghabrial et al., 2003, Huang and Stern, 
2005, Polanska et al., 2009, Sun et al., 1999). It is therefore unsurprising that these 
receptors are often co-opted by cancer cells to drive cell growth and tumour 
progression. With the advent of small molecule inhibitor treatment of cancers 
harbouring mutations in a range of RTKs, the therapeutic viability of targeting mutant 
FGFR with such inhibitors has been much discussed in the literature (Byron et al., 
2008, Carter et al., 2014, Pollock et al., 2007). Indeed, a wide range of RTK 
inhibitors are showing success in the clinical setting (Clinicaltrials.gov, 2014, Gavine 
et al., 2012). However, drug resistance is a major issue (Holohan et al., 2013). As 
such, alternative regimens must be investigated based upon the cellular alterations 
acquired in response to small molecule inhibition.  
 
The most common gynaecological malignancy in the western world is that of the 
endometrium, with approximately 8500 women diagnosed with endometrial cancer in 
2011 in the UK alone (CRUK, 2014). At present, the most common treatment is a full 
hysterectomy. However, whilst curative in the majority of cases, an alternative 
approach to surgery would be of great benefit to patients. Up to 16% of endometrial 
cancers harbour FGFR2 mutations analogous to those found in a range of 
developmental disorders (Pollock et al., 2007). As such, tumours harbouring these 
mutations have been postulated to be reliant on aberrant FGFR2 signalling and so 
inhibition of this RTK is of therapeutic interest.  
 
Whilst initial studies of the role of these mutations in endometrial cancer has shown 
targeting FGFR2 reduced cell number in vitro, effects of prolonged exposure to 
FGFR inhibitors, particularly AZD4547 which is currently in clinical trials in the 
treatment of FGFR2 mutant solid tumours, have not been investigated. Signalling de-
regulation upon small molecule inhibitor treatment of a dominant pathway often leads 
to induction of compensatory signalling (Holohan et al., 2013). Therefore, 
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investigation of the effect of such treatment in endometrial cancer is of paramount 
importance, prior to commencement of clinical trials.  
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6.2. Generation of a 3D model of endometrial cancer and its use in 
investigation of small molecule inhibition of FGFR signalling  
In order to fully assess the effect of a compound in vitro, a viable cell model is 
required. Organotypic cultures, such as those used in the study of breast and 
pancreatic cancers (Chioni and Grose, 2012, Coleman et al., 2014), provide a tool 
capable of assessing the effects of small molecule inhibition in the context of a 3D 
environment, comprising an ECM-like stromal cell-containing component. Since such 
tools are not currently available for the study of endometrial cancer, we developed 
and validated a novel 3D organotypic model.  
 
This model facilitated the identification of differential effects of FGFR inhibition in two 
FGFR2 mutant endometrial cell lines, consistent with our previous 2D culture data. 
The importance of mutant FGFR2 in the AN3CA cell line was demonstrated by 
induction of cell death upon FGFR inhibition after seven days.  
 
Both 2D and 3D models showed reduced sensitivity of the MFE-296 cell line to 
FGFR2 inhibition, compared to AN3CA cells. Most interestingly, while cell number 
was decreased upon treatment with two FGFR inhibitors, PD173074 and AZD4547, 
compared to the DMSO control, an inhibitor resistant population remained after 14 
days and retained its ability to proliferate. The absence of cell growth and 
proliferation inhibition in FGFR2 wild type Ishikawa cells suggested the effects 
observed in both FGFR2 mutant cell lines were due to blockade of aberrant FGFR2 
signalling rather than off target effects of the inhibitor.   
 
Our model was further modified to simulate endometrial cancer cell metastasis, via 
retrograde menstruation, and the effect of FGFR2 inhibition on the viability of 
migrating cells. Full submersion of the organotypic cultures in medium showed the 
ability of MFE-296 cells to bud from the organotypic culture and either remain free in 
the medium or re-adhere to the culture plate. After 14 days of FGFR inhibition, the 
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viability of these cells was demonstrated and showed the establishment of an FGFR 
inhibitor resistant population.  
 
Future directions  
Ideally, the effects of tumourigenic mutations would be compared to non-malignant 
cells arising from the same tissue of origin. While such epithelial cells of endometrial 
origin are not commercially available, we attempted to generate our own 
immortalised non-malignant endometrial cell lines. However, epithelial cells 
underwent EMT and so could not be used, and stromal cells did not survive the 
culture conditions. Future attempts at stromal cell immortalisation should assess the 
effect of coating culture plates with collagen prior to cell culture, to increase 
efficiency of cell attachment and proliferation. Successful generation of these 
immortalised stromal cells would be of great benefit for use in the ECM component 
of the organotypic model, in place of the HFF2 cells used in our investigations, so as 
to provide a more physiomimetic model. Culture of endometrial cancer cells in the 
presence of cancer-related stromal endometrial cells would also be of benefit in 
delineating the possible effects of paracrine signalling between the two populations. 
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6.3 Identification of changes in the phosphoproteome upon drug resistance 
acquisition using MS  
Having established that MFE-296 cells acquire resistance to FGFR inhibition, we 
used MS-based phosphoproteomics to identify underlying changes in cell signalling 
induced by receptor inhibition. Assessment of differences in the phosphoproteome 
induced by drug treatment guided investigations of the mechanisms underlying 
resistance to an FGFR targeted compound.  
 
The MS method employed identified 6706 phosphopeptides across all samples, with 
the abundance of 525 of these changed significantly in PD173074 treated samples. 
Analysis of this subset of phosphopeptides showed the predominant pattern of 
phosphorylation across the time points in PD173074 treated cells to be the same as 
DMSO samples at one day treatment, significant down-regulation at seven days drug 
exposure, and a return to baseline levels at 14 days. Inference of the upstream 
kinases of these phosphopeptides, garnered from KSEA analysis, revealed that a 
number of phosphorylation sites known to be downstream of AKT followed the 
baseline – down-regulation – baseline pattern, over the three time points in 
PD173074 treated cells. Phosphorylation sites known to be substrates of kinases 
downstream of AKT, including mTOR, were also found to follow this pattern, further 
supporting the findings that the change in AKT signalling identified in the MS data 
was transmitted downstream. The potential role of AKT signalling in overcoming 
FGFR inhibitor resistance in MFE-296 cells was further highlighted by up-regulation 
of four phosphopeptides, each implicated in AKT signalling, after 14 days of drug 
exposure (Chaudhury et al., 2010, Hussey et al., 2011, Ma et al., 2014, Morita et al., 
2013, Roux and Topisirovic, 2012, Song et al., 2014, Zhang and Dou, 2014). 
 
The significance of AKT signalling in FGFR inhibitor resistant MFE-296 cells was 
investigated in our 3D organotypic model, to assess the effects of AKT-targeted 
small molecule inhibition. MK2206, an inhibitor of AKT 1, 2 and 3 (Hirai et al., 2010), 
had a more marked effect on cell number and proliferation in MFE-296 cells than 
AKTVIII, which inhibits AKT 1 and 2 (Lindsley et al., 2005), both alone and in 
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combination with PD173074, suggesting AKT3 may be particularly important in the 
compensatory mechanism of MFE-296 cells.  
 
The dramatic reduction in cell number and proliferation exhibited upon dual drug 
treatment targeting FGFR and AKT1-3 suggested a possible therapeutic regimen for 
overcoming FGFR inhibitor resistant acquisition. The prospect of treating 
endometrial cancer with a combination of chemotherapeutic drugs, or small molecule 
inhibitors and chemotherapeutics, has been outlined previously (Gozgit et al., 2013, 
Byron et al., 2012). Although these studies investigated the synergistic effects of 
dual drug therapy, we present the first study to investigate potential resistance 
mechanisms upon FGFR inhibition in endometrial cancer, and use these data as the 
rationale for choosing an additional therapeutic target.  
 
Using an MS phosphoproteomic approach, we have demonstrated the changes in 
signalling networks upon acquisition of FGFR inhibitor resistance in MFE-296 cells. 
By investigating this, using an unbiased and quantitative approach, we have 
provided evidence of the importance of AKT signalling in acquisition of FGFR 
inhibitor resistance. Importantly, the effects of small molecule inhibition outlined in 
these data are FGFR2 mutation status dependent, as shown by the absence of 
growth inhibition in the FGFR2 wild-type Ishikawa cell line, in the presence of FGFR 
inhibitor. The lack of effect of the AKT inhibitors in Ishikawa cells was interesting, 
given that this cell line was PTEN and PIK3R1 mutant. However, these mutations 
occur in the context of additional genetic aberrations in this cell line, of which 
deregulation of the PI3K pathway may not be of critical importance.  
 
Future Directions  
The exact phosphorylation sites of the nine of the phosphopeptides identified using 
MS could not be determined definitively, due to inadequate fragmentation of the 
peptide. Furthermore, these peptides possessed multiple potential phosphorylation 
sites and so the specific phosphorylated residues remained elusive. Whilst the 
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fragmentation method employed in our work (CID-MSA) is used routinely in 
phosphopeptide analysis (Boersema et al., 2009), more sensitive methods do exist, 
for example ECD and HCD, which could be used in future to determine the exact 
phosphorylated residues in these peptides (Olsen et al., 2007, Syka et al., 2004, 
Zubarev, 2004).  
 
Notably, total protein levels were not assessed in this study. Our work has focused 
primarily on changes in signalling peptides upon drug exposure, of which 
phosphopeptides are the most important (Cohen, 2000, Manning et al., 2002). We 
do, however, acknowledge that analysis of total protein levels adds an additional 
layer of information to changes within the cell upon drug treatment, and so repetition 
of this experiment to elucidate such changes may be of interest in the future.  
 
MS generates a large quantity of data, and validation of all potential pathways 
highlighted in this analysis is outside of the scope of this thesis. Whilst the AKT 
pathway was associated with the most de-regulated phosphopeptides identified in 
our study, we are nevertheless mindful that pathways other than AKT could have 
been selected to target alongside FGFR2. 
 
While in vivo studies investigating the role of AKT in development and disease have 
shown different phenotypes for individual knockout of AKT1, 2 and 3, little is known 
about the specific functions of these isoforms and how they are regulated 
(Madhunapantula and Robertson, 2011). However, increased AKT3 activity has 
been shown to play an important role in the development of melanoma (Stahl et al., 
2004). AKT1 and 3 have also been shown to be involved in regulation of splicing of 
FGFR2 in lung cancer (Sanidas et al., 2014). As such, the role of the individual 
isoforms of AKT in the FGFR inhibitor resistance mechanism warrants further 
investigation. One method of analysis would be siRNA-mediated knockdown of 
AKT3 in MFE-296 cells and subsequent treatment with PD173074, to assess the 
propensity of this cell line to acquire FGFR inhibitor resistance without AKT3 
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expression. However, such investigations may prove difficult given the ability of the 
various AKT isoforms to compensate for one another (Dummler et al., 2006).  
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6.4 Dissection of drug resistance mechanisms using transcriptomic analysis  
To dissect the AKT-related drug resistance mechanism further, an inhibitor resistant 
population of MFE-296 cells was produced, by continuous exposure to PD173074, 
and named MFE-296PDR. We addressed the question of possible up-regulation of an 
alternative RTK pathway to compensate for loss of FGFR signalling, as has been 
noted elsewhere in the literature (Niederst and Engelman, 2013). As tyrosine 
phosphorylation events occur at a reduced rate compared to that of serine and 
threonine (Delom and Chevet, 2006), it was possible that our MS investigations 
failed to highlight increased phosphorylation of an alternative RTK. However, 
PathScan analysis showed there to be low level down-regulation of alternative RTKs 
in MFE-296PDR cells, implying the resistance mechanism was acquired via alternative 
means.  
 
To gain insight into the differences in the transcriptomes of parental and resistant 
cells in a global, unbiased manner, microarray gene expression analysis was 
employed. Transcriptomic analysis of MFE-296PDR cells, along with analysis of an 
additional inhibitor resistant cell line, MFE-296AZR, showed a distinct gene expression 
signature common to drug resistant cells, compared to their parental counterparts.  
 
IGFBP5 was significantly up-regulated in both resistant cell lines compared to the 
parental cells. Expression of this gene is known to be elevated in the absence of 
FGFR2 in keratinocytes in in vivo models (Schlake, 2005) and therefore potentially 
validating our data. The most significantly down-regulated gene in both resistant cell 
lines was PHLDA1, a negative regulator of AKT signalling.  
 
In light of our data identifying a role for AKT in maintaining FGFR inhibitor resistance 
in MFE-296 cells, it was of particular interest that a negative regulator of AKT 
signalling was the most significantly down-regulated of all genes analysed on the 
microarray. Published work has noted the down-regulation of this gene in patient 
samples of melanoma and has postulated its use as a biomarker of disease 
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progression (Nagai et al., 2007, Neef et al., 2002). However, this was the first 
demonstration of a potential role for PHLDA1 in the acquisition and maintenance of 
drug resistance in cancers cells.  
 
PHLDA1 expression was validated at the protein level, showing high expression in 
MFE-296 cells, localised to the membrane, and inhibition of this upon seven days 
PD173074 treatment. PHLDA1 was not expressed in MFE-296PDR cells.  The 
importance of down-regulation of this protein was shown upon siRNA knockdown of 
PHLDA1 in the parental MFE-296 cell line, which induced PD173074 inhibitor 
resistance after just three days of exposure to the drug.  
 
In summary, our work has shown that inhibition of mutant FGFR signalling in the 
MFE-296 cell line decreased cell growth and proliferation over seven days. Although 
FGFR2 signalling was blocked, the cells were able to continue signalling at a 
reduced rate. This most likely occurred via the mutant copy of PIK3CA harboured in 
this cell line. As FGFR2 also induces PI3K signalling, decreased downstream effects 
of PI3K were observed via MS analysis over seven days exposure to PD173074. 
This decreased PI3K signalling led subsequently to a decrease in PIP3 at the 
membrane. To compensate for the decreased PI3K signalling upon FGFR2 
inhibition, PHLDA1 expression was decreased. Therefore, whilst there was reduced 
PI3K signalling, the AKT available in the cells was able to bind to PIP3 free of 
competition with PHLDA1. In this way, AKT signalling could be sustained, even in 
the absence of mutant FGFR2 signalling.  
 
Future Directions  
Future work should focus on identification of the mechanism of PHLDA1 down-
regulation in response to FGFR2 signalling inhibition. As PHLDA1 expression was 
not recovered upon removal of PD173074 from the medium of resistant cells, the 
down-regulation may be of a permanent nature, potentially induced by epigenetic 
modulation of the gene. Another intriguing line of enquiry is the potential feedback 
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loop between AKT and p53 resulting in down-regulation of PHLDA1, as has been 
noted in signalling of its protein family member, PHLDA3 (Kawase et al., 2009, Liao 
and Hung, 2010).  
 
Crucial to the proposed mechanism outlined in this work are the differential levels of 
PIP2 and PIP3 levels in MFE-296 and MFE-296
PDR cells. Whilst we postulate these 
are lower in the resistant cell line, requiring PHLDA1 down-regulation in order to 
maintain AKT signalling, we aim to validate this using a PIP3 competition assay in 
our future work.  
 
In an alternative approach, the effect of PHLDA1 over-expression on MFE-296 and 
MFE-296PDR cells will be assessed. Here we aim to assess whether MFE-296PDR 
cells can be re-sensitised to PD173074 treatment by reintroduction of PHLDA1 into 
cells. We also aim to further validate the importance of PHLDA1 in FGFR inhibitor 
resistance by assessing basal levels in AN3CA cells and, if expressed, knocking 
down this protein in this cell line to investigate whether drug resistance can be 
induced.  
 
Whilst this work focuses on endometrial cancer, activating FGFR2 mutations are 
found in a range of malignancies. As such, an interesting line of enquiry is whether 
the PHLDA1-associated drug resistance mechanism highlighted in this work is 
induced in other cancer types, in response to FGFR perturbation – or indeed when 
other RTKs are inhibited. The validity of the drug combinations highlighted in this 
work should also be investigated further in in vivo models.  
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6.5 Concluding remarks   
Using a combination of MS-based phosphoproteomics, transcriptomics and 
biochemical methods, we have identified differential signalling in FGFR2 mutant 
endometrial cancer cells and successfully elucidated a mechanism of its acquisition. 
We show the first evidence of PHLDA1 down-regulation in response to targeted 
inhibition of a mutant RTK, and establish its role in maintaining drug resistance. 
Whether this phenomenon is specific to endometrial cancer cells or is a more global 
method of acquiring drug resistance remains to be elucidated. Nevertheless, further 
in vivo investigations should be undertaken to establish the potential viability of the 
FGFR/AKT drug combination outlined in this work in the treatment of endometrial 
cancer. Although combination trials are not currently underway, initial investigations 
into neuroblastoma and glioma, amongst others, suggest use of MK2206 alongside 
other small molecule inhibitors and chemotherapeutics provides an advantage in 
inducing cancer cell death (Cheng et al., 2012, Li et al., 2012, Agarwal et al., 2013). 
It is also promising that use of MK2206 alone is currently in clinical trials (Molife et 
al., 2014), as is the AZD4547 FGFR inhibitor (Xie et al., 2013, Zamora et al., 2014). 
The combinatorial use of both drugs represents an exciting line of clinical 
investigation, with the potential to overcome chemoresistance in FGFR2-driven 
cancers.  
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Appendix Figure 1.1. FGFR2 mutation sequencing of endometrial cancer cell lines.  
PCR was performed on cDNA from each cell line using primers designed to amplify the 
region containing the two FGFR2 mutations of interest. Cycle sequencing was then 
performed on the PCR products and the resulting sequences compared to wild type FGFR2 
cDNA using CLC Sequence Viewer (v6). (A) Substitution of a thymine residue to guanine at 
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FGFR2 cDNA position 1647 results in the N550K amino acid mutation. The MFE-296 cell 
line contains this mutation, as shown by the mismatch between wild type and MFE-296 
cDNA in the alignment (top panel). Conversion of residue 929 from adenosine to guanine 
results in the K310R FGFR2 mutation. The MFE-296 cell line contains this mismatch, as 
shown by the mismatch in sequence alignment with wild type FGFR2 cDNA (bottom panel). 
There are also many additional mismatches between MFE-296 and wild type cDNA in this 
region. These are not noted in the literature. (B) The AN3CA cell line harbours both the 
N550K and K310R FGFR2 mutations (top and bottom panels, respectively). (C) The 
Ishikawa cell line is wild type for both the N550K and K310R mutations.  
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Appendix Figure 1.2. PTEN and PIK3CA mutation sequencing of MFE-296 cells.  
MFE-296 cells were sequenced for the PTEN R130Q and R130fs*1 mutations, as well as 
the PIK3CA P539R mutations using cycle sequencing; resulting sequences were analysed 
using BioEdit and CLC Sequence Viewer (v6). (A) MFE-296 cells are PTEN R130Q mutant 
(top panel). The R130fs*1 frame shift is not present in the MFE-296 cell line. The PI3Ka 
P539R sequencing data gave an ‘S’ in the 1616 residue position, indicating that the software 
could not distinguish between cytosine or guanine (bottom panel). (B) BioEdit visualisation of 
the sequencing trace revealed two peaks at the 1616 position of cytosine and guanine, 
indicating the cell line harbours copies of both of these residues. The MFE-296 cell line is 
therefore heterozygous for this mutation, as noted in the literature.  
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Appendix Figure 1.3. PTEN and PIK3CA mutation sequencing of AN3CA cells.  
AN3CA cells were sequenced for the PTEN R130Q and R130fs*1 mutations, as well as the 
PIK3CA P539R mutation using cycle sequencing; resulting sequences were analysed using 
BioEdit and CLC Sequence Viewer (v6). (A) AN3CA cells are R130fs*1 PTEN mutant (top 
panel). Sequencing for P539R shows AN3CA cells are PIK3CA wild type (bottom panel). (B) 
BioEdit analysis of the missing base at position 1635 shows the residue is most likely 
guanine (listed as ‘S’ in the trace) but is shown as the trace around the base is not clear and 
so the base can not be definitively assigned. (C) The missing base at position 1586 is most 
likely adenine, as shown in the BioEdit trace where the adenine triplicate appears as an 
indefinable smear in the BioEdit trace.  
 
 
251 
 
 
Appendix Figure 1.4. PTEN and PIK3CA mutation sequencing of Ishikawa cells.  
Ishikawa cells were sequenced for both R130Q and R130fs*1 PTEN mutations, as well as 
P539R PIK3CA mutations using cycle sequencing; the resulting data were analysed using 
BioEdit and CLC Sequence Viewer (v6). (A) Ishikawa cells are PTEN R130fs*1 and R130Q 
wild type (top panel). BioEdit analysis of the missing thymine residue at position 331 shows 
this base is present, however, owing to a poor sequencing trace at this base, the software 
was not able to definitively assign thymine to this position (middle panel). Thymine appears 
as adenine in the trace as the sequence has been reversed. The ‘W’ residue at position 399 
is most likely an adenine, as shown in the BioEdit trace (bottom panel). (B) Ishikawa cells 
are PIK3CA wild type (top panel). The missing base at position 1596 is most likely adenine, 
as shown in the BioEdit trace (bottom panel). 
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Appendix Figure 1.5. FGFR isoform expression in MFE-296 and AN3CA.  
PCR was performed on MFE-296 and AN3CA cell lines to establish expression of each of 
the FGFR1-4 isoforms. MFE-296 and AN3CA cells expressed FGFR1IIIa, b and c, 
FGFR2IIIa and c and FGFR4. Neither cell line expressed FGFR3. III represents the isoform 
produced as a result of alternative splicing of the third Ig loop. There are three potential 
isoforms of FGFR1 and 2 (IIIa, b and c), two of FGFR3 (IIIb and c) and one of FGFR4.  
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Appendix Figure 1.6. FGFR2 antibody validation.  
Specificity and efficiency of the FGFR2 antibody used throughout this work was validated via 
siRNA knockdown of FGFR2 for 48 hours in MFE-296 cells. 15 µg protein was used for each 
blot. Error bars show means ± SEM of three replicates.  
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Appendix Figure 1.7. Effect of varying HFF2:MFE-296 ratio in a 3D organotypic model 
of endometrial cancer.  
An endometrial cancer cell model was designed using a collagen/Matrigel mix containing 
human foreskin fibroblasts (HFF2) cells as a stromal equivalent, overlaid with MFE-296 cells 
in a Transwell insert, respecting the cell ratios previously outlined. Cells were cultured at an 
air-liquid interface for seven days in the presence of an FGFR inhibitor or DMSO control. 
Ratios refer to HFF2:MFE-296 cell ratios. (A) Cell number was decreased significantly after 
seven days FGFR inhibition using PD173074, when cells were cultured in the absence of 
fibroblasts. However, there was no change in the percentage of cells capable of proliferation, 
as shown by Ki67 staining (green). (B and C) Both cell number and proliferation was 
decreased significantly upon inclusion of HFF2 cells in the organotypic model. Original 
magnification of H&E images, 10X objective; bar, 100 µm. Original magnification of confocal 
images, 40X objective; bar, 25 µm. Error bars show means ± SEM. Data points represent 
the average cell number/Ki67 positive cells of six fields of view of one to three technical 
replicates of three biological replicates. Cell number and percent Ki67 positive cells 
represents average values per field of view. 
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Appendix Figure 1.8. False discovery rate (FDR) and quantile normalisation of 
phosphopeptide ions.  
Statistical normalisation of MS data. (A) The false discovery rate (FDR) of phosphopeptides 
was <1% for 95% of identifications and <5% for the remainder. (B) Log2 peak intensity of 
phosphopeptides in each sample. (C) Quantile normalized Log2 peak intensity of 
phosphopeptides (Bolstad et al., 2003).  
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Appendix Figure 1.9. FGFR2 mutation sequencing of MFE-296PDR cells.  
PCR was performed on cDNA from each cell line using primers designed to amplify the 
region containing the two FGFR2 mutations of interest. Cycle sequencing was then 
performed on the PCR products and the resulting sequences compared to wild type FGFR2 
cDNA using CLC Sequence Viewer (v6). Substitution of a thymine residue to guanine at 
FGFR2 cDNA position 1647 results in the N550K amino acid mutation. The MFE-296 cell 
line contains this mutation, as shown by the mismatch between wild type and MFE-296 
cDNA in the alignment (top panel). Conversion of residue 929 from adenine to guanine 
results in the K310R FGFR2 mutation. The MFE-296 cell line contains this mismatch, as 
shown by the mismatch in sequence alignment with wild type FGFR2 cDNA (bottom panel). 
MFE-296
PDR cells contain the same FGFR2 mutations as the parental MFE-296 cell line. 
The resulting sequences were analysed in BioEdit Sequence Alignment Editor and CLC 
Sequence Viewer (v.6).  
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Appendix Figure 1.10. Effect of PD173074 on PHLDA1 levels in MFE-296 cells.  
MFE-296 cells were treated with 2 µM PD173074 or DMSO as a vehicle control for one and 
three days and PHLDA1 levels assessed. There was no significant difference in PHLDA1 
levels after 1 or 3 days PD173074 treatment in MFE-296 cells (Student’s t test, P >0.05). 40 
µg protein was used for each blot. Error bars show means ± SEM of two replicates.  
 
 
 
 
 
 
 
 
 
 
 
 
259 
 
                 
Appendix Figure 1.11. PHLDA1 knockdown does not affect MFE-296PDR cell number.   
The effect of PHLDA1 knockdown (KD) on MFE-296PDR cells in the presence and 
absence of PD173074 was assessed in 2D culture. (A) MFE-296PDR cells were 
treated with PHLDA1 siRNA (PHDLA1 KD) or a non-targeting control (scrambled) for 
two days, after which cell number was counted using a haemocytometer. There was 
no significant difference in cell number when MFE-296PDR cells were treated with 
PHLDA1 siRNA. (B) Cells were treated with PHLDA1 siRNA or a scrambled control 
for two days. PHLDA1 siRNA treated cells were subsequently treated with 5 µM 
PD173074 for three days, while scrambled siRNA treated cells were treated with 
DMSO as a control. The number of cells remaining after each treatment was 
calculated by counting cells using a haemocytometer. sIRNA knockdown of PHLDA1 
followed by treatment with PD173074 did not affect cell number compared to the 
control. Cell number is displayed as the percentage of cells seeded. Error bars show 
means ± SEM of three replicates. 
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Appendix Figure 1.12. PHLDA1 over-expression in MFE-296 and MFE-296PDR cells.  
MFE-296 and MFE-296PDR cells were transfected with a GFP-tagged PHLDA1 plasmid or a 
GFP only plasmid as a control. (A) After one day, cells were visualised under a light 
microscope as well as under UV light. Transfection of both plasmids was successful in both 
cell lines. (B) Western blot analysis of control and PHLDA1 transfected cells showed 
PHLDA1 expression in both MFE-296 and MFE-296PDR cell lines. Brightfield and UV light 
images of each transfection are of the same field of view. Original magnification of bright 
field and UV images, 10X objective; bar 100 µm. Images are representative of three 
biological replicates. **, P ≤0.01; ***, P ≤0.001 (Student’s t test). 40 µg protein was used for 
each lane. Error bars show means ± SEM of three replicates. 
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Appendix 2 
Genomic editing of FGFR2 mutation status 
using ZFN technology   
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Appendix 2.1 Introduction  
Advances in high throughput screening have greatly increased our knowledge of 
potentially important genes of interest in the initiation and progression of cancer. 
While our ability to identify these targets has advanced, our capacity to assess their 
function in a physiologically relevant context has been lacking. Historically, use of 
RNA interference (RNAi) and pharmacological inhibitors have been used to assess 
genes and proteins of interest (McManus and Sharp, 2002). Whilst this has produced 
relevant and important results, such methods often have off-target effects, 
occasionally making phenotypic consequences hard to decipher. To combat this, a 
variety of genomic editing tools have been developed, allowing for more precise 
targeting of the gene of interest. Whilst these tools, for example zinc finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and 
clustered regulatory interspaced short palindromic repeats (CRISPRs), are still 
relatively novel, their potential to aid understanding of cell behaviour is profound.  
 
ZFNs and TALENs allow targeted genome editing via introduction of double strand 
breaks (DSBs) and subsequent DNA repair (Capecchi, 2005). These tools comprise 
a nuclease component, engineered to target and bind to a specific DNA sequence, 
and a non-specific DNA cleavage domain, most commonly derived from the FokI 
endonuclease (Carroll, 2011, Cheng and Alper, 2014, Urnov et al., 2010) (Appendix 
Figure 2.1 A). Importantly, these chimeric nucleases act in pairs, forming precise 
molecular scissors. This enables site-specific localisation of the FokI dimer and 
subsequent editing of the endogenous gene sequence by induction of the cellular 
DNA repair mechanisms; non-homologous end joining (NHEJ) and homologous 
repair (HR) (Gaj et al., 2013). The pioneering work on these tools was performed 
using ZFNs, while the recent discovery of TALE proteins has led to the expansion of 
these genome editing technologies (Boch et al., 2009, Moscou and Bogdanove, 
2009). As the latest agent in this repertoire, CRISPR technology is still in relative 
infancy. However, recent work has shown how this RNA-guided DNA endonuclease 
system affords excellent specificity to its targets and can allow for complex 
manipulation of multiple genes in a pathway (Zalatan et al., 2014).  
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ZFN technology  
The DNA recognition portion of ZFNs consists of Cys2-His2 zinc finger domains, the 
most common DNA-binding motif in eukaryotes (Gaj et al., 2013). Each zinc finger 
protein exists in an highly conserved β-sheet, β-sheet, α-helix conformation with a 
single zinc atom; the α portion is able to engage three base pairs of DNA (Beerli and 
Barbas, 2002, Kim et al., 1993). Chains of zinc finger proteins can be produced 
utilising a conserved linker sequence, forming a synthetic protein engineered to 
target a specific DNA motif (Liu et al., 1997). Zinc finger modules recognising nearly 
all 64 nucleotide triplets have been developed, allowing production of assemblies up 
to 18 base pairs long, engineered to the gene of interest (Beerli et al., 1998, Beerli 
and Barbas, 2002, Bhakta et al., 2013, Gonzalez et al., 2010, Kim et al., 2011). 
Therefore, ZFN technology allows for targeting of virtually any DNA sequence.  
 
These ZFN assemblies are bound to the catalytic domain of the FokI endonuclease 
(Bibikova et al., 2001, Mani et al., 2005, Smith et al., 2000). Type IIS FokI consists of 
two domains with separable DNA recognition and cleavage functions (Li et al., 
1992). This protein is utilised in ZFN technology by replacing the DNA recognition 
domain with the zinc finger chain (Kim et al., 1996). Since DNA cleavage is only 
achieved upon FokI dimerisation, the action of each ZFN can only be achieved when 
acting in a pair, therefore increasing target specificity (Mani et al., 2005, Miller et al., 
2007).  
 
The range of uses of ZFN technology is broad, from gene knockout, tagging of an 
endogenous gene or site-directed mutagenesis with an alternative repair construct 
(Beerli et al., 2000). For example, manipulation of gene expression can be achieved 
by flooding cells with an engineered repair construct in combination with ZFN 
transfection (Appendix Figure 2.1 B). In a proportion of cells, this construct will be 
incorporated into the genome, during the DSB repair process induced by the ZFN, 
resulting in transcription of the construct under the endogenous promoter. This 
technology is particularly useful in assessing the effect of specific mutations in, for 
example, a wild type background, by incorporation of a mutant construct at the ZFN 
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cut site. The validity of this technology for use in FGFR2 has been shown in breast 
cancer cells (Robbez-Masson et al., 2013). Constructs with varying small nucleotide 
polymorphisms (SNPs) in intron 2 of FGFR2, shown in genome wide association 
studies (GWAS) to associate with increased breast cancer risk (Easton et al., 2007, 
Hunter et al., 2007), were introduced into cells. While this did not produce any 
obvious phenotype, proof of concept of this genome editing tool was confirmed.  
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Appendix Figure 2.1. ZFN-mediated genome editing.  
(A) Organisation of the ZFN pair at the FGFR2 target site. Each ZFN consists of two 
functional domains: a DNA-binding domain, comprised of a chain of four zinc finger subunits 
(red), and a DNA-cleaving domain, consisting of two FokI endonuclease domains (blue), 
which act as a specific pair of ‘genomic scissors’ The DNA sequence shown is specific to 
intron 2 of FGFR2. (B) Schematic representation of ZFN-mediated insertion of the FGFR2 
gene into cells. The ZFN pair is targeted to intron 2 of the FGFR2 gene, inducing a double 
strand break. Transfection of an alternative repair construct results in its incorporation in 
place of the normal cellular homologous recombination DNA repair, aided by inclusion of 1 
kb homologous arms at either end of the construct. Inclusion of a poly-adenylation sequence 
ensures transcription terminates at the end of the construct, preventing transcription of the 
endogenous FGFR2 locus downstream of the ZFN cut site. The GFP tag and neomycin 
resistance cassette allow effective screening of transfected cells for successful targeting. 
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The neomycin resistance box is flanked by two LoxP sites, allowing for removal of the 
neomycin cassette upon expression of Cre recombinase.  
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Appendix 2.2 Materials and Methods  
2.2.1 Custom-made FGFR2 ZFN  
The CompoZr custom made FGFR2 ZFNs were purchased from Sigma-Alrich 
(Sequence shown in Appendix Figure 2.1 A). Vials of ZFN mRNA sufficient for 10 
transfections were also supplied by Sigma-Aldrich, as were the two ZFN plasmids 
from which additional mRNA was generated.  
 
2.2.2 Bacterial transformation  
1-10 ng ZFN plasmid DNA was added to 50 μL chemically competent bacteria 
(Bioline) and placed on ice for 15 min, followed by heat shock for 30 s at 42oC and 
returned to ice for a further 2 min. Bacteria were re-suspended in 500 μL antibiotic-
free Luria Broth (LB) and incubated at 37oC with constant agitation at 225 rpm for 1 
h. 100 μL cells were plated on LB agar plates containing 100 μg/mL kanamycin for 
antibiotic selection and incubated overnight at 37oC. Small scale and large scale 
plasmid DNA preparations were carried out using QIAprep Spin Miniprep (QIAGEN) 
and QIAfilter Maxiprep (QIAGEN) kits, respectively. DNA concentrations were 
measured using a Nanodrop spectrophotometer.  
 
2.2.3 ZFN mRNA synthesis  
ZFN mRNA was prepared using the MessageMax T7 mRNA transcription kit 
(Cellscript Inc.) according to the manufacturer’s instructions. A polyA tail was then 
added to the mRNA using the A-Plus poly(A) polymerase tailing kit (Epicentre) 
according to the manufacturer’s instructions.  
 
2.2.4 Alternative repair construct  
The FGFR2IIIb-GFP construct with 1 kb homologous regions in the pJET1.2 
ampicillin resistant plasmid was a gift from John Ladbury (University of Leeds). Cells 
transfected with the construct were screened for GFP expression under UV light to 
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confirm successful transfection. As an additional selection method, a neomycin 
resistance cassette was inserted (FGFR2IIIb-GFP-neo). This cassette was flanked 
by LoxP sites to enable removal of the cassette from selected cells via expression of 
Cre recombinase.  
 
2.2.5 Site directed mutagenesis  
FGFR2IIIb-GFP constructs containing two common FGFR2 mutations found in 
endometrial cancer were generated via site directed mutagenesis (SDM). Two 
mutant constructs were generated: N550K and K310R. SDM can be used to 
introduce point mutations into double stranded plasmid DNA.  Using complimentary 
primers that contain the mutation of interest, KOD DNA Polymerase (Novagen) was 
used according to the manufacturer’s instructions. Briefly, PCR was performed to 
introduce the mutation and amplify the PCR product. DpnI endonuclease was then 
used to digest the methylated, wild type DNA, leaving the newly synthesised mutant 
DNA intact. The final product was cloned into competent bacteria to be re-
circularised and amplified. Plasmid DNA was amplified as outline in section 2.2.2. 
Primers for SDM were generated using the QuikChange Primer Design Programme 
(Agilent Technologies) (Appendix Table 2.1).  
 
To validate the mutation status, HotStarTaq Plus DNA Polymerase (QIAGEN) was 
used, utilising the primers detailed in Appendix Table 2.2 and the PCR cycle in 
Appendix Table 2.3. PCR products were run on an agarose (Life Technologies) gel 
containing Gel Red (Biotium) and visualised under UV light to ensure a single, strong 
band was produced from the PCR. The PCR product was then sent to Barts 
Genome Centre for cycle sequencing. The resulting sequence was analysed using 
BioEdit and CLC Sequence Viewer (v6) software.  
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Appendix Table 2.1. Primers used to produce mutant FGFR2IIIb-GFP constructs via 
SDM 
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Appendix Table 2.2. Primers used to sequence endometrial cancer cells for point 
mutations 
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Appendix Table 2.3. HotStarTaq Plus DNA polymerase PCR programme 
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2.2.6 ZFN transfection – lipofection  
Cells were seeded in a six well plate at 40% confluency in standard medium. The 
following day, medium was removed and cells were washed with PBS. OptiMEM 
(Life Technologies) was warmed to 37oC and 1 mL added to each well. For ZFN 
transfection control wells, 2 μg/μL ZFN mRNA was added to 250 μL OptiMEM in an 
eppendorf tube. A second eppendorf tube containing 5 μL Lipofectamine 2000 
(Invitrogen) with 250 μL OptiMEM was prepared and both solutions incubated at 
room temperature for 5 min. The contents of both tubes were then mixed and 
incubated at room temperature for 20 min. The total volume was then added to 
control wells and incubated at 30oC for 4 hours. Medium was then removed and 
replaced with standard culture medium and cells incubated for three days at 30oC.  
 
For pmaxGFP (pGFP) (Lonza) control wells, 2 μg/μL pGFP was added to 250 μL 
OptiMEM in an eppendorf tube and the method above followed.  
 
For FGFR2IIIb-GFP-neo construct transfection, 2 μg/μL of construct, in addition to 2 
μg/μL ZFN mRNA, was added to 250 μL OptiMEM and mixed with the Lipofectamine 
2000 preparation as above and added to the cells.  
 
Wells were inspected under UV light for GFP expression over the three days 
incubation period. Genomic DNA (gDNA) was then extracted from the cells using 
GenElute Mammalian Genomic DNA miniprep kit (Sigma-Aldrich) according to the 
manufacturer’s instructions. FGFR2IIIb-GFP-neo construct transfected samples were 
cultured in six well plates and transferred to T75 tissue culture flasks when 
approximately 80% confluent.  
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2.2.7 ZFN transfection – nucleofection  
Cells were seeded in a 75 cm2 tissue culture flask. When cells were approximately 
80% confluent, medium was removed and cells were incubated with trypsin/EDTA 
(Sigma-Aldrich) at 37oC to detach cells from the surface of the flask. Trypsin was 
inactivated by adding standard medium. The cell suspension was centrifuged at 
1500 x g for 3 min. The supernatant was removed and cells were resuspended in 10 
mL of fresh culture medium. Cells were counted using a haemocytometer under a 
light microscope. The required number of cells for the total number of experiments (2 
x 106 cells per experiment) was then centrifuged at 90 x g for 10 min at room 
temperature in a 1.5 mL eppendorf. The supernatant was removed and the cell pellet 
resuspended in the required volume of Nucleofector solution and supplement 
(Lonza) for the total number of experiments (100 μL per experiment).  
 
For ZFN controls, 2 μg/μL ZFN mRNA was added to 100 μL of cell suspension in a 
cuvette (supplied in Nucleofector kit). For GFP controls, 2 μg/μL pGFP was added to 
100 μL of cell suspension in a cuvette.  
 
Each cuvette was then inserted into the Nucleofector (Lonza) and the selected 
programme, specified per kit, applied. The cuvette was then removed and 500 μL of 
pre-equilibrated culture medium added to the cuvette. The total sample suspension 
was added to a T75 flask in 12 mL standard medium. Cells were incubated at 30oC 
for three days, after which gDNA was isolated from control samples. Flasks were 
inspected under UV light for GFP expression over the three day incubation period.  
 
2.2.8 ZFN-induced mutation detection PCR   
To establish the efficiency of the ZFN, an assay was performed using the 
SURVEYOR Mutation Detection Kit (Transgenomic) on ZFN and pGFP control 
samples, according to the manufacturer’s instructions. Extracted genomic DNA was 
amplified using ZFN forward and reverse primers in Appendix Table 2.4 and the 
PCR programme detailed in Appendix Table 2.5. PCR products were denatured and 
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re-annealed to create mismatch duplexes using the cycler conditions in Appendix 
Table 2.6.   
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Appendix Table 2.4. Sequencing and ZFN-induced mutation detection PCR primers 
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Appendix Table 2.5. ZFN-induced mutation detection PCR 
primers
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Appendix Table 2.6. Cycler conditions for re-annealing of PCR products in ZFN-
induced mutation detection PCR  
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2.2.9 Single cell cloning  
To establish monoclonal cell lines of FGFR2IIIb-GFP-neo construct transfected cells, 
a single cell cloning approach was used (Appendix Figure 2.2). 100 μL of standard 
medium supplemented with 100 ng/mL G418 was added to each well of a 96 well 
plate except well A1. A 200 μL cell suspension containing 4 x 104 cells/mL was 
plated in well A1. A serial dilution of this suspension was then achieved by 
sequentially adding 100 μL of cell suspension from well A1 to H1. 100 μL of standard 
medium was added to each well of column 1 and a serial dilution of each well across 
the plate achieved in a final volume of 200 μL/well.  
 
G418-containing medium was changed every two to three days and wells inspected 
under a light microscope. Wells with single cell colonies were noted and expanded 
as necessary. Monoclonal cell lines were plated in 25 cm2 flasks and six well plates 
and gDNA extracted, as detailed in section 2.2.6.  
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Appendix Figure 2.2. Schematic representation of single cell cloning by serial dilution.  
Well A1 of a 96 well plate was seeded with 4 x 104 cells, after which 1:1 serial dilution were 
performed from well A1 to H1 (vertical arrow). Serial dilutions of 1:1 of A1-H1 were then 
performed across the plate (horizontal arrow), leaving well H12 with the lowest seeding cell 
number.  
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2.2.10 FGFR2 N550K mutation sequencing  
To establish the mutation status of cells transfected with the FGFR2IIIb-GFP-neo 
wild type construct, HotStarTaq Plus DNA Polymerase (QIAGEN) was used, utilising 
the N550K primers detailed in Appendix Table 2.2 and the PCR cycle in Appendix 
Table 2.3. PCR products were run on an agarose gel containing Gel Red and 
visualised under UV light to ensure a single, strong band was produced from the 
PCR. The PCR product was then sent to Barts Genome Centre for cycle sequencing 
and the resulting data analysed using BioEdit and CLC Sequence Viewer software.  
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2.2.11 Amplification of the neomycin resistance gene   
To assess whether the alternative repair template containing a neomycin resistance 
cassette was incorporated into the genome after transfection, PCR using primers 
which recognise this cassette (Appendix Table 2.7) was performed. The PCR cycle 
outlined in Appendix Table 2.8 was performed and the resulting products were run 
on an agarose gel containing gel red and visualised under UV light.  
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Appendix Table 2.7. Neomycin resistance gene primers 
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Appendix Table 2.8. PCR conditions for amplification of neomycin resistance gene 
product 
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Appendix 2.3 ZFN cleavage in endometrial cancer cell lines    
The specificity of the FGFR2 targeted ZFN was assessed using the ZFN-site 
database (Cradick et al., 2011). This resource identifies any possible off target 
cleavage sites of a given ZFN. This algorithm did not identify any other perfect match 
than FGFR2. The other potential non-specific DNA binding regions were two 
intergenic regions of the genome, four non-coding regions (introns and promoters) 
and tetraspanin 11 (TSPAN11), a membrane scaffolding protein. All of the DNA 
regions identified only allow for a five nucleotide long spacer region, compared to the 
six nucleotides in the FGFR2 site. This makes binding and subsequent cutting of the 
ZFN at these sites unlikely. All of these potential off target sites also had mismatches 
with the ZFN in the ZFN binding region, further reducing the likelihood of off target 
effects.  
 
The efficiency of the ZFN activity in the endometrial cancer cell lines was determined 
using the surveyor nuclease assay (Appendix Figure 2.3). Cells were transfected 
using either the ZFN or pGFP as a control. Upon transfection of the ZFN into cells, a 
proportion of the DNA is cut at the target site. In the absence of a user introduced 
alternative repair construct, the cellular machinery resolves the double strand break, 
usually resulting in loss of a few base pairs. After transfection, gDNA was extracted 
and PCR performed, using primers to amplify the region surrounding the ZFN 
binding domain. This subsequently generated a combination of PCR products 
containing the uncut amplicon and the ZFN-cut DNA. A further round of PCR was 
performed on these PCR products, whereby the DNA was denatured and re-
annealed, resulting in the formation of homoduplexes, where two strands of uncut or 
cut DNA re-annealed, and heteroduplexes, where one strand of each cut and uncut 
DNA annealed together (Appendix Figure 2.3 A, left and right respectively). In the 
case of the latter, a mismatch repair bubble is formed. The PCR products were 
treated with CelI, an endonuclease which cuts the mismatch repair bubble, resulting 
in two fragments of 194 base pairs (bp) and 141 bp. When resolved on a 
polyacrylamide gel, the homoduplexes run as a single 335 bp band. The presence of 
the two 194 bp and 141 bp bands on a gel were indicative of successful ZFN DNA 
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cleavage. The intensity of the three bands was proportional to the ZFN DNA 
cleavage efficiency. 
 
Lipid-based transfection of the ZFN and subsequent incubation at 37oC for three 
days before gDNA extraction was unsuccessful, as indicated by a lack of 194 bp and 
141 bp bands upon UV visualisation of the surveyor assay PCR products (Appendix 
Figure 2.3 B). The lipofection method was attempted again, this time followed by 
cold shock treatment of cells at 30oC. Transient incubation of ZFN transfected cells 
at this temperature has been shown to increase the genomic editing capabilities of 
ZFNs (Doyon et al., 2010). This resulted in successful transfection and subsequent 
DNA modification by the ZFN in MFE-296 cells (Appendix Figure 2.3 C).  
 
However, lipid-based transfection was insufficient to introduce the ZFN into AN3CA 
cells. Because of this, nucleofection was attempted. The Lonza nucleofection 
optimisation kit was used, therefore a range of nucleofection solutions and 
Nucelofector programmes were utilised (Appendix Figure 2.3 D, 1-6). Nucleofection 
condition 1, followed by incubation of transfected cells at 30oC for three days, 
resulted in successful transfection of the ZFN (Appendix Figure 2.3 D).  
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Appendix Figure 2.3. Utilisation of the surveyor nuclease assay to assess the 
efficiency of ZFN genomic DNA editing.  
287 
 
(A) Schematic representation of the surveyor nuclease assay. Upon transfection of the ZFN 
into cells, a proportion of the DNA is cut at the target site. In the absence of a user 
introduced alternative repair construct, the cellular machinery resolves the double strand 
break, usually resulting in the loss of a few base pairs. PCR is performed to amplify the 
region around the ZFN target site, generating a combination of PCR products containing the 
uncut amplicon and the ZFN-cut DNA. A further round of PCR is performed to denature and 
re-anneal the DNA, resulting in formation of homoduplexes (left), whereby two strands of 
uncut DNA or cut DNA are annealed together, and heteroduplexes (right), where one cut 
and one uncut strand of DNA is re-annealed. In the case of the latter, a mismatch repair 
bubble is formed. This is cut upon introduction of the CelI endonuclease, resulting in 
generation of two fragments of 194 bp and 141 bp in size. When resolved on a 
polyacrylamide gel, the homoduplexes run as a single 335 bp band. The presence of the two 
194 bp and 141 bp bands on a gel are indicative of successful ZFN DNA cleavage. The 
intensity of the three bands is proportional to the ZFN DNA cleavage efficiency. (B) 
Transfection of ZFN followed by the three days incubation at 37oC did not result in genomic 
modification by the ZFN as exhibited by only one 335 bp band on the gel. (C) Lipid-based 
transfection followed by incubation at 30oC for three days prior to gDNA extraction led to 
successful integration of the ZFN into the MFE-296 cell line and resulted in DNA 
modification, as indicated by the presence of 194 bp and 141 bp bands on the 
polyacrylamide gel. Lipofection of the ZFN mRNA followed by cold shock did was 
unsuccessful in the AN2CA cell line. (D) Nucleofection of ZFN mRNA was trialled on AN3CA 
cells as an alternative to lipofection. A nucleofection optimisation kit was used. 1-6 refers to 
sample number as detailed in the nucleofection optimisation kit; each sample used a 
different Nucleofector programme. Use of programme 1 followed by incubation at 30oC for 
three days resulted in successful transfection of the ZFN into the AN3CA cell line. PCR 
products from a successful transfection of the ZFN into MCF-7 cells was used as a positive 
control. Samples were resolved on 10% non-denaturing polyacrylamide gels. 
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Appendix 2.4 Generation of FGFR2 mutant alternative repair templates    
Upon ZFN transfection and subsequent introduction of a double strand break into the 
user-defined target site, HR machinery is directed to the ZFN cut site (Urnov et al., 
2005). ZFN technology can be utilised to introduce a change in the genome at the 
specified locus by flooding the cells with an alternative repair construct alongside 
ZFN transfection (Appendix Figure 2.1 B). In this case, the alternative repair 
template can be used in the DNA repair process, replacing the sister chromatid 
routinely used in HR. The inclusion of 1 kb lengths of DNA, which are homologous to 
the 1 kb regions either side of the ZFN cut site, allows for the cellular machinery to 
use this construct in place of the sister chromatid. This results in a genomic change 
in the proportion of the cells which are cut by the ZFN and subsequently use the 
alternative repair template. Indeed, as the concentration of the alternative repair 
construct transfected into cells is increased, the DNA HR machinery is more likely to 
use this in place of the sister chromatid, therefore increasing the proportion of cells 
with altered gene expression.  
 
As the ZFN used in this study cuts in intron 2 of FGFR2, an alternative repair 
construct consisting of wild type FGFR2 cDNA from exon 3 onwards was designed, 
with the aim of converting the FGFR2 mutation status of endometrial cancer cells 
from mutant to wild type. This cDNA was tagged with a GFP construct, for selection 
of transfected cells, as well as a polyA sequence. Inclusion of this polyA sequence 
ensured transcription ended at this point; therefore the endogenous gene 
downstream of intron 2 was not transcribed (Appendix Figure 2.1 B). A neomycin 
resistance cassette was added to the construct to act as an additional selectable 
marker. This box was flanked by loxP sites to enable removal of the cassette upon 
expression of Cre recombinase.  
 
As well as reverting the mutation status of endometrial cancer cells back to the wild 
type version of FGFR2, we generated mutant versions of the construct for use in 
FGFR2 wild type cells (Appendix Figure 2.4). Using SDM, two constructs were 
generated, each containing the two FGFR2 mutations harboured in the endometrial 
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cancer cell lines under investigation: N550K and K310R. Cycle sequencing and 
subsequent analysis of the resulting data using CLC sequence Viewer of the 
constructs showed the SDM was successful (Appendix Figure 2.4).  
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Appendix Figure 2.4. Sequence alignment of FGFR2 wild type and mutant constructs 
generated via SDM.  
Using complimentary primers that contain the mutation of interest, PCR was performed to 
introduce the mutation and amplify the PCR product. DpnI endonuclease was then used to 
digest the methylated, wild type DNA, leaving the newly synthesised mutant DNA intact. The 
final product was cloned into competent bacteria to be re-circularised and amplified. Cycle 
sequencing on the resulting construct was performed and compared to wild type FGFR2 
cDNA using CLC Sequence Viewer (v6). (A) The conversion of a thymine residue to guanine 
at FGFR2 cDNA position 1647 results in the N550K amino acid mutation. SDM performed on 
the FGFR2 alternative repair construct was successful, as shown by the mismatch between 
wild type and SDM cDNA in the alignment. (B) Conversion of residue 929 from adenosine to 
guanine, resulting in the K310R mutation, in the FGFR2 alternative repair construct was 
successful.  
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Appendix 2.5 Transfection and screening of MFE-296 cells following ZFN and 
FGFR2IIIb-GFP-neo construct transfection  
MFE-296 cells were transfected with the ZFN mRNA and simultaneously flooded 
with the FGFR2IIIb-GFP-neo alternative repair construct. An additional transfection 
was also performed using pGFP as a positive control. Cells were incubated at 30oC 
for three days, after which they were cultured at 37oC. From this point onwards, cells 
transfected with the FGFR2IIIb-GFP-neo construct were grown in medium 
supplemented with 100 ng/mL G418. Inspection under UV light after three days 
showed both positive GFP expression in polyclonal population of cells transfected 
with the pGFP alone as well as in ZFN and FGFR2IIIb-GFP-neo construct 
transfected cells (Appendix Figure 2.5). This was indicative of integration of the 
transfected plasmids into the cellular genome.  
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Appendix Figure 2.5. GFP expression in a polyclonal population of MFE-296 cells 
transfected with pGFP or ZFN in combination with the FGFR2IIIb-GFP-neo construct.  
MFE-296 cells were transfected with pGFP or ZFN in combination with the FGFR2IIIb-GFP-
neo construct via lipofection and were incubated at 30oC for three days, after which cells 
were returned to 37oC and cultured. FGFR2IIIb-GFP-neo transfected cells were grown in 
G418-supplemented medium. Cells were assessed for GFP expression using UV light  after 
the initial three day cold shock treatment. Both the pGFP and ZFN/FGFR2IIIb-GFP-neo 
MFE-296 transfected cells showed a proportion of cells positive for GFP expression, 
indicative of plasmid uptake. Original magnification of images, 20X objective; bar, 50 µm. 
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Upon reaching confluence, single cell cloning of the polyclonal population of the 
FGFR2IIIb-GFP-neo transfected cells was employed to generate a monoclonal cell 
line (Appendix Figure 2.2). One monoclonal population was established and labelled 
MC1. MC1 cells were cultured in G418-supplemented medium. PCR using primers 
designed to recognise the neomycin resistance cassette was subsequently 
performed on MC1 cells, as well as un-transfected MFE-296 cells and a neomycin 
plasmid as negative and positive controls, respectively (Appendix Figure 2.6). UV 
visualisation of the PCR products run on a polyacrylamide gel show the MC1 cell line 
was positive for neomycin, implying integration of the FGFR2IIIb-GFP-neo construct 
into the genome.  
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Appendix Figure 2.6. Neomycin gene amplification in MC1 cells after ZFN and 
FGFR2IIIb-GFP-neo transfection.  
ZFN and FGFR2IIIb-GFP-neo transfected cells were subject to single cell cloning, resulting 
in establishment of a monoclonal cell line (MC1). The MC1 cell line was cultured and gDNA 
extracted for PCR with primers specific to the neomycin resistance cassette. MC1 cells 
expressed the neomycin resistance cassette. Samples were run in duplicate. Un-transfected 
MFE-296 cells and a neomycin-containing plasmid were used as negative and positive 
controls, respectively.  
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To definitively establish whether ZFN-mediated genome editing of the FGFR2 locus 
was successful, cycle sequencing was employed to assess the N550K FGFR2 
mutation status (Appendix Figure 2.7). Both untransfected MFE-296 and MC1 cell 
lines were sequenced, using primers designed to amplify the region surrounding the 
N550K mutation site. This sequencing revealed the MC1 cell line was N550K 
mutant, indicating the FGFR2IIIb-GFP-neo construct had not been integrated into the 
genome of MC1 cells.  
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Appendix Figure 2.7. MC1 cells are N550K FGFR2 mutant.     
Cycle sequencing of un-transfected MFE-296 and MC1 cells was performed to assess the 
N550K mutation status. (A) MFE-296 cells are N550K mutant, as shown by the T-G 
mismatch with wild type FGFR2 cDNA at position 1647. (B) MC1 cells are also N550K 
mutant. The MC1 cell line did not express the wild type FGFR2IIIb-GFP-neo construct.  
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Appendix 2.6 Summary of results  
o The FGFR2-directed ZFN successfully cuts gDNA in the MFE-296 and 
AN3CA cell line  
o Further work is required to increase transfection efficiency and establish a 
viable monoclonal cell line in an efficient manner  
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Appendix 2.7 Discussion  
Targeted editing of a genomic locus using ZFN technology enables investigation of 
the functional significance of a plethora of genes and their mutations (Beerli and 
Barbas, 2002, Robbez-Masson et al., 2013). In this project, we aimed to utilise a 
custom made FGFR2-targeted ZFN to investigate the functional significance of 
FGFR2 mutations in endometrial cancer.  
 
After optimisation of the transfection conditions, we were able to establish that the 
FGFR2 ZFN successfully introduced a double strand break in two endometrial 
cancer cell lines, MFE-296  and AN3CA. We proceeded to transfect MFE-296 cells 
with the ZFN in combination with an FGFR2IIIb-GFP-neo construct, aiming to revert 
the mutation status from mutant to wild type. Previous studies have speculated that 
FGFR2 mutations may drive the subset of endometrial cancers they are found in 
(Byron et al., 2013, Greulich and Pollock, 2011b, Pollock et al., 2007). As such, use 
of the FGFR2 ZFN is particularly interesting, as it offers a method of investigating the 
phenotypic consequences of FGFR2 mutations in endometrial cancer by expression 
of the wild type receptor under the control of the endogenous promoter, in the 
context of other mutations present in these cells. This therefore has the potential to 
answer the question of the nature of mutant FGFR2 as a driver in endometrial 
cancer.  
 
Upon transfection of these cells with the construct, the polyclonal population was 
assessed for GFP expression by visualisation under UV light. A subset of cells was 
GFP positive, implying integration of the construct into the genome. To fully 
understand the consequences of the FGFR2 mutation reversion, single cell cloning 
was employed with the aim of establishing a monoclonal cell line. This would 
therefore remove the effects of mutant cells that may prevent the phenotypic 
consequences of the mutation status reversion being evident. It is also probable that 
the mutant cells would out-compete the FGFR2 wild type population, further 
increasing the need for establishment of a monoclonal cell line.  
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The single cell cloning technique employed has enjoyed success in some studies 
(Hombrink et al., 2015). However, the effectiveness of this technique is cell type 
specific. For example, cells which rely heavily on paracrine signalling do not survive 
well when cultured on their own. Also, monoclonal cell lines were identified by eye 
following daily inspection of the wells of a 96 well plate under a light microscope. 
This method has the potential for errors, whereby a polyclonal population may be 
incorrectly labelled monoclonal. Nevertheless, this method of selection was trialled in 
FGFR2IIIb-GFP-neo transfected MFE-296 cells and the MC1 monoclonal cell line 
generated.  
 
Transfected cells were also grown in G418-supplemented medium as an additional 
selective marker. This neomycin resistance cassette included in the construct was 
also used as a PCR target; gDNA amplification was evident in MC1 cells. While this 
indicated that the FGFR2IIIb-GFP-neo construct had been taken up by the cells and 
integrated into the genome, cycle sequencing revealed the MC1 cells did in fact 
harbour the N550K FGFR2 mutation.  
 
As PCR analysis indicated integration of the neomycin resistance cassette into the 
genome, it is possible that the MC1 cell line was not in fact a true monoclonal cell 
line. A mixed population would result in some neomycin expression but these cells 
would likely be out-competed by the mutant cells over further culture. Alternative 
methods, such as ring cloning (Mathupala and Sloan, 2009), could be employed in 
future attempts of FGFR2-targeted genome editing of endometrial cancer cells which 
may increase the effectiveness of this technique in yielding results. While MC1 cells 
were grown in G418-supplemented medium, it is possible a subpopulation of FGFR2 
mutant MFE-296 cells in the polyclonal population acquired resistance to neomycin 
treatment and were therefore able to grow in the supplemented medium. In addition, 
while the chances are low, it is also possible that the construct was integrated into 
the genome via random insertion and was expressed at low levels under the control 
of a weak promoter (Phang et al., 2013).  
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This attempt at reversion of the FGFR2 mutation status of MFE-296 cells using ZFN 
technology was unsuccessful. However, the modifications of various elements of the 
procedure discussed could be employed to increase the chances of successfully 
integrating the FGFR2IIIb-GFP-neo construct into endometrial cancer cells. We have 
established the ability of the ZFN to cut in the AN3CA cells and so this cell line could 
also be utilised for investigation in the future.  
 
Since purchasing the FGFR2 targeted ZFN, TALEN and CRISPR technology has 
been optimised and now represent a better alternative to ZFNs for genomic editing 
(Cerbini et al., 2015, Jiang et al., 2015, Kaulich et al., 2015, Matsubara et al., 2015). 
Use of these alternatives should be considered in future work.  
 
During the course of this project, we have successfully generated N550K and K310R 
mutant FGFR2 constructs and so these could be used to investigate the importance 
of these mutations on cell transformation by transfection into an FGFR2 wild type cell 
line.  
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Appendix 4 
Nature Structural and Molecular Biology 
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Grb-ing receptor activation by the tail  
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Appendix 5 
Trends in Cell Biology review:  
Careless talks costs lives: fibroblast 
growth factor receptor signalling and the 
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